The role of citrulline in patients following hematopoietic stem cell transplantation by Herbers, A.H.E.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/142570
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
THE RO
LE O
F CITRULLIN
E IN
 PATIEN
TS FO
LLO
W
IN
G HEM
ATO
PO
IETIC STEM
 CELL TRAN
SPLAN
TATIO
N
         A.H.E. HERBERS
Hematopoietic stem cell transplantation (HSCT) provides effective treat-
ment of hematological malignancies and other disorders. However, the 
procedure temporarily compromises the immune system resulting in 
damage to the gastrointestinal (GI) tract, called mucosal barrier injury 
(MBI), and neutropenia. The GI tract is host to billions of micro-organisms 
that not only share our body space but are essential for health. These 
micro-organisms constitute the microbiome and seldom cause us harm. 
However infection can, and does, occur when the mucosal barrier of the 
gut is injured. Fortunately antimicrobial agents are employed to prevent 
and treat infectious complications.
Never the less, as this thesis shows, almost all HSCT recipients develop 
fever that is the result of inflammation induced by certain drugs employed 
to prepare for the transplant. Furthermore, measuring the blood concen-
trations of the amino acid citrulline provides a means of assessing MBI and 
indicates that MBI, rather than neutropenia, defines the period of risk of 
fever and bacteraemia following transplant. With the ready availability 
of blood, this simple and reliable test can help to explore ways of amelio-
rating MBI to reduce inflammation and fever which, in turn, would lead 
to a more tailored approach to antibiotic treatment. This can only be 
a good thing as it will help reduce the risk of antimicrobial resistance. 
Knowing the citrulline level could also help decide whether a patient 
needs to be admitted to hospital or can be treated safely at home.
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Chapter 1
GENERAL INTRODUCTION
For many patients intensive treatment with high-dose chemotherapy alone or combined with 
radiotherapy followed by a hematopoietic stem cell transplantation (HSCT) is the only way to 
cure hematological malignancies. The supportive care afforded by the transfusion of blood, 
platelets and stem cell products, treatment with antimicrobial agents and recombinant 
growth factors, has permitted the use of more intensive regimens, but fever and infection 
remain the most prominent complications of cytotoxic therapy.1 Approximately four of every 
five patients experience fever. Microbiologically documented infections, usually bacteraemia 
accounts for about one third to half of fevers, clinically documented infections for a further 
one in five with no infectious aetiology being identified for the remainder.2,3 Bacteraemia 
can result in fulminant sepsis and death and is reported as the primary cause of death of 7% 
of autologous stem cell transplant recipients and 13-17% of allogeneic stem cell transplant 
 recipients.1,4 Damage to the host defences induced by the intensive treatment to prepare for 
a HSCT is the primary cause of fever and breaches to the innate immunity allow infection and 
translocation of bacteria into the blood stream leading to infection. The patient’s vulnerable 
condition warrants prompt administration of empirical antibiotic treatment directed primarily 
against the gram-negative bacilli that inhabit the gastro-intestinal (GI) tract e.g. Escherichia	
coli and other enteric bacteria as well as Pseudomonas	aeruginosa at the first occurrence of 
fever, even if there is no obvious cause for the fever. Nowadays protocols advise treatment with 
broad-spectrum antibiotics of the third or fourth generation cephalosporins e.g. ceftazidime, 
carbapenems e.g. meropenem or ureidopenicillins combined with a beta-lactamase inhibitor e.g. 
piperacillin-tazobactam.5-10 Fever persisting for more than 3-4 days is often a reason for adding 
further antimicrobial agents even when no infectious focus is found.11 (However our practice 
is that this should only be done when there is an objectively verifiable reason for doing so).
This means that fever and infections bring about the use of increased supportive care, including 
antimicrobials, prolonged hospitalization and increased costs. Antibiotic treatment leads to 
selective resistance of the patient’s microflora also called its microbiome. The emergence of 
antimicrobial resistance with at the same time a decline in the development of new antimicro-
bial agents can increase the global burden of infectious disease that can threaten the care for 
hematology patients in the future.12,13 
 
MAN AND HIS MICROBES: A DELICATE BALANCE
The surfaces of the human body internally and externally are covered in billions of individual 
micro-organisms. There being 10 times the number of normal bacterial cells that live on the 
body, i.e. approximately 1014, than cells that make up the human body (Figure 1).14 
11
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Figure 1. Man and his microbes
 
 
Figure courtesy of J. P. Donnelly.41
Under normal circumstances these resident microbiota do little harm and, in fact, help protect 
the human body from becoming infected with harmful microbes. Together with the anatomic 
barrier (such as skin or GI tract) they prevent the entrance of pathogens into the body. Should 
bacteria invade, they will be met by neutrophils that gather at the entry side in order to clear 
the invasion. If these phagocytes fail, other blood cells of the innate and adaptive immune 
system are ready to come into action.  
When cytotoxic therapy damages the host defences, the skin and alimentary tract mucosa 
become a reservoir of potential opportunistic pathogens. Furthermore, the intensive treat-
ment will also disrupt the balance between the host and microbial residents. Not surprisingly, 
infections of HSCT recipients are typically due to those opportunistic pathogens that normally 
inhabit the surfaces of the human body, rather than professional pathogens such as Streptococcus	
pneumonia.15-17 Indeed, the common causes of infection during neutropenia following HSCT 
are due to bacteria including Gram-negative bacilli e.g. Escherichia	coli, and less frequently 
Pseudomonas	aeruginosa as well as gram-positive cocci especially the so-called coagulase-
negative staphylococci e.g. Staphylococcus	 epidermidis, and oral viridans streptococci e.g. 
Streptococcus	mitis. Fungal infections occur at a rate of < 10% and involve mainly yeasts, e.g. 
Candida	albicans and moulds e.g. Aspergillus	fumigatus. Viral infections, especially Herpes simplex 
virus are also common. Never the less, mortality is mainly associated with severe bacterial 
sepsis, pneumonia and invasive fungal infections.18 
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CYTOTOXIC TREATMENT INDUCED DAMAGE TO 
HOST DEFENCE MECHANISMS IN HSCT 
RECIPIENTS
1. NEUTROPENIA
Historically the focus has been on neutropenia as main risk factor for the occurrence of fever 
and infections in patients with cancer. The myeloablative nature of chemotherapy results in 
bone marrow suppression shortly after cytotoxic treatment is given leading to a precipitous 
decrease in circulating blood cells. Neutrophils are particularly affected because of their short 
life span, resulting in neutropenia which is typically defined by an absolute neutrophil count of 
≤ 0.5 x 109 granulocytes/L. Hence, measures to prevent infectious complications are determined 
on the onset, depth and course of neutropenia. Fever is often the first and only sign of infection 
in HSCT recipients19 and when this develops during neutropenia, it is called “febrile neutropenia” 
and represents a signal to start empirical antibiotic therapy promptly in order to prevent the 
progression of the putative infection to sepsis and even death.20 Moreover, nursing personnel 
undertake extra controls and monitoring based on the duration of neutropenia and, in many 
centres, antibiotic therapy is often continued until neutropenia resolves.10,21
 
2. DAMAGED MUCOCUTANEOUS BARRIERS
The high rate of division and turnover of cells of the skin and alimentary tract renders them 
particularly vulnerable to damage induced by the intensive chemotherapy given prior to a 
HSCT.22 Since the gut is the largest reservoir of the commensal flora, damage there will play 
an important role in the occurrence of infection and fever in HSCT recipients.23 Surprisingly 
cytotoxic therapy-induced damage to the GI tract has attracted little attention until recently.  
2.1	 Mucositis	or	mucosal	barrier	injury
Cytotoxic therapy-induced damage to the mucosal barrier of the alimentary tract is called muco-
sal barrier injury (MBI) and mucositis refers to the attributable clinical manifestations. MBI affects 
the entire alimentary tract and is often separated into oral MBI and intestinal MBI based on 
anatomical and functional differences. MBI is seen as one of the most debilitating side-effects of 
the myeloablative treatment employed for a HSCT though it eventually resolves spontaneously.24 
Most knowledge regarding MBI has been garnered from oral MBI since the manifestations can 
be easily observed. 
2.2	 Pathogenesis	of	MBI
The development of MBI depends on the type of cytotoxic treatment, the agents employed, and 
the dose and duration of the regimen.25 Virtually every patient who receives a myeloablative 
regimen for a HSCT develops MBI to some extent and the incidence for reduced intensity regi-
mens for MBI is approximately 40-50%.26,27  
13
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According to the model introduced by Sonis, five overlapping phases are important in the 
pathobiology of MBI.28 (1) Initiation phase, in this phase the intensive treatment given prior to 
a HSCT induces both DNA and non DNA damage and injury in cells of mucosa as well as submu-
cosa occurs. Generation of reactive oxygen species leads to the activation of nuclear factor-kappa 
B (NFkB).29 In the (2) upregulation and message generation phase, DNA- and non DNA-damage 
triggers a cascade of biological events. Several transduction factors are upregulated, including 
NFkB leading to the release of cytokines and chemokines (IL-1β, IL-6, IL-8, TNFα, IL-23, interferon-
gamma (IFNγ)) by tissue macrophages, dendritic cells, and release of danger-associated molecular 
patterns (DAMPS). Furthermore the secretion of matrix metalloproteinases is stimulated. The 
result is mucosal injury and death.30,31 In the (3) amplification and signalling phase, tissue injury 
is accelerated and amplified through feedback loops.32 This leads to the (4) ulcerative phase 
where breeches in the mucosal epithelium may provide a portal of entry for bacteria, viruses and 
fungi that reside on the surface. Microbes and pathogen-associated molecular patterns (PAMPS) 
activate immune cells, stimulate the production of pro-inflammatory cytokines, leading to 
further inflammation and apoptosis.33-35 Finally, (5) healing occurs, under the influence of 
several extracellular matrix signals that affect the rate of epithelial cell migration, proliferation 
and differentiation. Recent research also suggests that the deregulation of the microbial homeo-
stasis by cytotoxic treatment could influence each one of the phases of this model.36 
Although developed for oral MBI this model is also likely to be applicable to intestinal MBI 
though the events that take place in the intestine are almost certainly more complicated than 
those occurring in the oral cavity not least because of the plethora of microbial species that 
inhabit the human gut.28,37-40 These bacteria can influence the course of MBI as can gut function 
in terms of nutrient digestion and absorption of food after ingestion.41,42 The gut also has an 
enormous surface area with the small intestine alone having an estimated surface area 20 
times that of the skin.43 
2.3	 Structure	of	the	small	intestine
The small intestine comprises three functionally distinct segments: the duodenum, jejunum 
and ileum. The structure of the mucous membrane lining the intestine is similar in all three parts. 
The small intestine wall is composed of four layers: the mucosa, submucosa, muscularis externa 
and serosa. The inner surface of the small intestine is covered with circular folds or valves of 
Kerckring which are composed of the mucosa and submucosa (Figure 2). The valves of 
Kerckring are positioned perpendicular to the long axis of the intestine and project into the 
intestinal lumen. These structures increase the absorptive surface area 2-3 fold and are most 
prominent in the distal duodenum and jejunum.
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Figure 2. Valves of Kerckring
 
1. Epithelium, 2. lamina propria mucosae, 3. muscularis mucosae
The mucosa of the small intestine consists of three layers: epithelium (innermost layer, facing 
the intestinal lumen), lamina propria mucosae (connective tissue) and muscularis mucosae 
(smooth muscle). The epithelium is made of a monolayer of numerous invaginations (crypts of 
Lieberkühn) and finger-like protrusions (villi).44 Their role is to further increase the absorptive sur-
face of the intestine, by a factor of approximately 10 (yielding 30- fold increase in total) (Figure 2). 
Almost 90% of the cells comprising the epithelium are enterocytes which are responsible for the 
degradation and absorption of food after ingestion. Their luminal surface area is covered with 
microvilli. The presence of microvilli increases the mucosal surface area of the intestine still further 
by a factor of approximately 20-30 fold resulting in 400-900 fold increase in total (Figure 3).45 
Mucosa	of	the	small	intestine		
The mucosa of the small intestine forms one of hierarchical tissues. There are three types of 
cells: stem cells of high proliferative activity, incompletely differentiated daughter cells and 
mature fully differentiated cells. Complete renewal in the small intestine requires 4 to 6 days. 
15
1
General introduction and outline of the thesis
The stem cells in the lower half of the crypts give rise to daughter cells, thereby producing all the 
cells of the epithelium. Newly produced cells migrate and differentiate into four principal cell types. 
Most cells differentiate into functional enterocytes, goblet cells (± 4%, production of mucus) 
and enteroendocrine cells (± 0.5%, production of hormones) and migrate up along the villi to 
the surface of the intestinal lumen. The migration of these new cells continues until they 
reach the tips of the villi, where they undergo apoptosis and are shed into the lumen.39 The 
fourth cell type, Paneth cells (± 7.5%, production of defensins that are important for immunity) 
migrate downward and reside at the bottom of the crypt (Figure 3).46
Figure 3. Crypts and villi
Due to their high turnover rate, the mucosal cells of the intestine are particularly vulnerable 
to cytotoxic therapy. The proliferative stem cells are very sensitive to DNA damage and are often 
killed by the intensive treatment used for HSCT.47 The daughter cells are less vulnerable to cyto-
toxic therapy- induced damage and are able to repair this damage, retain stem cell properties 
and can repopulate the crypt.48
16
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2.4	 MBI,	inflammation	and	infection	
Cytotoxic therapy- induced damage to the intestinal mucosa induces mucosal inflammation, 
as explained in the Sonis’s model.28,39 The onset of mucosal inflammation is determined by 
the life-span of mature epithelial cells. Once the cytotoxicity ceases, repopulation of stem 
cells and daughter cells ensues resulting in complete recovery and cessation of inflammation.49 
The duration and intensity of mucosal inflammation is determined by the direct toxic effect of 
the intensive treatment on the mucosa together with the inflammation resulting from the 
imbalance between the microbiome and the immunocompromised host.24 MBI can induce 
infection due to the disruption of the body’s natural anatomic barrier allowing opportunistic 
pathogens to translocate to the bloodstream, especially when also the immune system is severely 
compromised.49,50 
To examine the role of mucosal inflammation and translocation of pathogens due to MBI in the 
occurrence of fever and infections, it is first necessary to gain an impression of the severity of 
the mucosal damage that occurs after the intensive treatment is given. 
2.4.1 Scoring	methods	for	MBI
Several assessment methods are applied. 
A.	Based	on	signs	and	symptoms:	
Oral MBI is visible in the oropharynx as red, inflamed, easily bleeding tissue with or without 
the presence of ulcers. Symptoms include pain, oedema, excessive mucus production, reduced 
saliva and haemorhage all which reduces the patient’s ability to eat and drink.51,52 Assessment 
scorings systems, including the World Health Organization and the National Cancer Institute- 
Common Terminology Criteria for Adverse Event (NCI-CTCAE), combine objective signs (erythema 
and ulcer formation) with subjective and functional outcome (pain and the ability to eat) to 
gauge the severity of oral MBI.53,54
Intestinal MBI presents a challenge as it cannot be seen directly or readily detected. The 
intestinal symptoms that can be associated with gastrointestinal MBI include nausea, vomiting, 
abdominal pain, cramping and watery diarrhoea occasionally accompanied by macroscopic blood 
loss.24 These symptoms are clearly non-specific as they can also be caused or influenced by 
the conditioning chemotherapy, infection, as well as by medications such as opioids, making 
assessment scores based on signs and symptoms much less reliable. Intestinal MBI can only be 
seen by endoscopy and biopsy but these are usually precluded because of the high likelihood 
for bleeding complications due to the profound thrombocytopenia that develops contempora-
neously with bone marrow aplasia.54  
B.	Absorption	and	permeability	tests
The pathological alterations in the intestine due to cytotoxic damage start with crypt loss. This 
is followed by villous atrophy and blunting, enterocyte damage, infiltration of inflammatory 
17
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cells and accumulation of goblet cells at tops of the villi.32,55-57 The end result is gut dysfunction 
so functional tests have been employed to determine the severity and course of the mucosal 
damage. Since the principal features of intestinal MBI are loss of epithelial surface and change in 
permeability several permeability and absorption tests were assessed.58 The permeability of 
51Cr-labeled ethylenediaminetetracetic acid (51Cr-EDTA) will increase shortly after the start of 
cytotoxic treatment prior to a HSCT.59 However, 51Cr-EDTA is radioactive and therefore not 
suitable for routine use. Sugar permeability and absorption tests have been shown to be able to 
determine the onset of disruption and dysfunction of the mucosal barrier of the small intestine.60 
The peak of gut permeability has been shown to occur 10-14 days after starting intensive chemo-
therapy.60,61 However, no real difference could be found in the overall pattern of perturbed 
gut integrity and the absorptive capacity of patients given various myeloablative regimens. 
Furthermore, both 51Cr-EDTA and sugar permeability tests are influenced by extraneous factors 
such as bowel transit time, gastric emptying and renal function. They are also cumbersome 
and wholly dependent on compliance, which means that patients are reluctant or not fit 
enough to undergo these tests when they are feeling particularly unwell or are ill.
A test to measure the intestinal MBI that could be performed in blood would therefore be much 
better.62 This would prove less of a burden to the patient especially if the blood has already 
been taken for other purposes, often via an intravascular catheter.
C.	Citrulline
In 2000, Crenn et	al. reported that the amino acid citrulline was a reliable biochemical marker 
of the small bowel enterocyte mass of patients.63 The name citrulline comes from Citrullus, 
the Latin word for water melon. In 1914 Koga and Odake detected it in water melon juice.64 
In 1930 Wada defined the chemical formula of the amino acid and named it citrulline.65 
Diet is a poor source of citrulline and most citrulline is produced by endogenous synthesis 
predominately in the gut enterocytes of the small intestine, most likely from the middle and 
upper parts of the villi.66 
The substrates for citrulline in the small intestine are dietary glutamine, glutamate and proline, 
and also glutamine found in the serum.67 In fact, 80% of the circulating citrulline is derived 
from the conversion of glutamine extracted from the blood.68
Five mitochondrial enzymes are involved in the synthesis of citrulline from glutamine in the 
enterocyte (Figure 4).69-71 Glutaminase (GLNase) converts glutamine to glutamate and ammonia. 
Glutamate is then converted to pyrolline-5-carboxylate by pyrroline-5-carboxylate synthase 
(P5Cs). P5Cs is converted to ornithine by ornithine aminotranferase (OAT). Glutamine derived 
ammonia plus bicarbonate (HCO3) are converted to carbamoyl phosphate by carbamoyl phos-
phate synthetase 1 (CPS1). Carbamoyl phosphate and ornithine are finally converted to citrulline 
by ornithine carbamoyltransferase (OCT).
Proline is another precursor for pyrolline-5-carboxylate. Via proline oxidase (PO) proline is 
converted into pyrolline-5-carboxylate.66,72-74 The subsequent metabolic steps are identical as 
for the citrulline synthesis from glutamine and involve OAT, CPS1 and OCT. 
18
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Although small intestinal enterocytes contain a complete urea cycle, there is a very low level of 
argininosuccinate synthetase (ASS) in the enterocyte so, as a result, citrulline is released in 
the bloodstream.66,74   
Figure 4. Citrulline synthesis in small intestinal enterocyte
Abbreviations: GLNase= glutaminase, P5Cs= pyrroline-5-carboxylate synthase, PO= proline oxidase, 
OAT= ornithine aminotransferase, OCT= ornithine carbamoyl transferase, CPS1= carbamoyl phosphate 
synthetase 1, ASS= argininosuccinate synthetase, ASL= argininosuccinate lyase, Arg-ase= arginase.
The availability of substrate and the activity of the intestinal citrulline synthesizing enzymes can 
influence the citrulline concentration in plasma but it has been shown in preclinical experiments 
and confirmed by clinical data that the number of functional enterocytes is the major determi-
nant for the release of citrulline into the circulation.63,74-78  
After citrulline is released into the bloodstream it passes through the liver nearly unchanged 
and is not influenced by systemic inflammation. It is removed from the blood by the kidney, 
where it is converted to arginine. Hence the concentration of citrulline depends only on the 
production and release of citrulline by the enterocytes mass and on renal excretion.79 Individuals 
with normal intestinal mucosal function and normal renal function given a Western diet have 
citrulline levels between 30 and 50 μmol/L with a median of 40 μmol/L, as determined by ion-
exchange chromatography.66 The citrulline concentration in blood will decrease when there is 
19
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injury to the intestine, but has no intrinsic diagnostic value. Regular assessment of citrulline 
allows monitoring of small intestinal function the only limitation being marked renal failure 
(creatinine clearance < 30 ml/L).66
In patients with villous atrophy disease, the plasma level of citrulline has been shown to be 
discriminative for the degree of villous atrophy: < 10 μmol/L corresponding with total villous 
atrophy, levels ranging between 10 and 20 μmol/L corresponding with subtotal villous atrophy 
and > 20 μmol/L indicating partial atrophy.80 Furthermore citrulline can be used for monitoring 
treatment response. Citrulline concentrations have also proved a reliable marker of the remaining 
length of the small bowel of patients with short bowel syndrome and are consistent with small 
bowel absorption capacity.63,81,82 Plasma concentrations of citrulline remain low for up to a 
year after treatment underlining the strict dependence of circulating citrulline on epithelial 
mass. Furthermore citrulline concentrations are also proposed as marker for patients with 
small bowel transplants being indicative of the functional epithelial mass or the dependence 
on total parental nutrition.83,84 
In our own hospital citrulline has also been evaluated in HSCT recipients and proved more 
sensitive and more specific for measuring small bowel enterocyte loss than did sugar permea-
bility tests.25,85  
In this thesis the questions of whether citrulline is really able to fulfil its role as valuable and 
reliable marker for intestinal MBI in HSCT recipients will be explored. Furthermore the relation 
between intestinal MBI, fever and infection will be examined. Finally, an attempt will be made 
to see whether knowledge about MBI can lead to changes and improvements in the care of 
the HSCT recipient.
  
 
OUTLINE OF THE THESIS
This thesis consists of four parts: 
PART I: BACKGROUND OF MANAGING FEBRILE NEUTROPENIA IN  
HEMATOLOGY PATIENTS
In this first part we illustrate the management of febrile episodes in neutropenic hematological 
patients and show that there is very little interest in the role of MBI in common practice 
(chapter	2). 
PART II: INTRODUCTION OF CITRULLINE AS BIOMARKER FOR MUCOSAL 
BARRIER INJURY 
Citrulline is introduced as a marker of MBI that results from the cytotoxic treatment to prepare 
for hematopoietic stem cell transplants. 
In a clinical review we describe various means of measuring MBI and show that citrulline is an 
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objective, sensitive, precise, validated, reproducible and reliable marker of intestinal MBI in HSCT 
recipients. We review the history, biochemistry and measurement of citrulline and describe 
its use and potential utility for managing the intestinal complications arising from treating 
HSCT recipients (chapter	3). 
We examine two different citrulline-based assessment scores for intestinal MBI in a cohort of 
94 HSCT recipients (chapter	4).  
Next we test whether citrulline is really a more valuable marker of intestinal MBI than serum 
albumin that clinicians often rely on as indicator (chapter	5).
PART III: FEBRILE NEUTROPENIA OR FEBRILE MUCOSITIS?  
In this third part we investigate the relationship of MBI, neutropenia and the incidence of 
post- transplant complications, especially fever and bacteraemia. Our hypothesis is that MBI, 
rather than neutropenia, determines the onset and extent of inflammation and influences the 
incidence of post-transplant complications.
We start by examining the occurrence of bacteraemia in relation to neutropenia and MBI in 
one regimen (chapter	6).  
This is followed by a retrospective study in a cohort of 163 HSCT recipients given five different 
conditioning regimens, in which the kinetics of citrulline, the relationship of intestinal MBI, 
and the occurrence of fever and bacteraemia are studied in greater detail (chapter	7). 
We further unravel the relationship between intestinal MBI, neutropenia and the occurrence 
of inflammation, fever and bacteraemia in a study in which a non-myeloablative regimen is 
compared to myeloablative regimen and blood cultures are taken from admission onwards as 
well as at the onset of fever (chapter	8). 
PART IV: CONSEQUENCES OF USING CITRULLINE IN CLINICAL PRACTICE   
In this last part we examine how we might use the knowledge gained from studying MBI and 
the kinetics of citrulline to improve the management of febrile episodes of patients who received 
intensive cytotoxic treatment to treat cancer.  
Since permeability tests suggest a protective effect of the keratinocyte growth factor palifermin, 
on the intestinal MBI of HSCT recipients who had received BEAM conditioning, we investigate 
whether the drug is able to reduce intestinal MBI by monitoring citrulline and evaluate its effect, 
if any, on the inflammatory response and occurrence of bacteraemia (chapter	9).   
Furthermore we examine whether better planning of the start of the intensive treatment before 
HSCT can prevent recipients from developing inflammatory and infectious complications during 
the weekend, as this is often accompanied with less than optimal care (chapter	10).
To conclude, we gather together all recent information concerning MBI and show how the 
inflammatory response and fever occurring in HSCT recipients can be the direct consequence 
of MBI alone, with neutropenia playing a minor role, if at all. We postulate a new paradigm in 
the management of febrile episodes in neutropenic cancer patients, namely “febrile mucositis” 
(chapter	11).  
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These insights should provide a new impetus for developing drugs that ameliorate MBI, but 
also should lead to a more targeted use of antimicrobials for the treatment of the febrile HSCT 
recipient. 
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ABSTRACT
Aggressive chemotherapy has a deleterious effect on all components of the defense system of 
the human body. The resulting neutropenia as well as mucosal barrier injury allow pathogenic 
micro-organisms easy access to the body. The symptoms of an incipient infection are usually 
subtle and limited to unexplained fever due to the absence of granulocytes. This is the reason 
why prompt administration of antimicrobial agents while waiting for the results of the blood 
cultures, the so-called empirical approach, became an undisputed standard of care. Gram-
negative pathogens remain the principal concern because their virulence accounts for serious 
morbidity and a high early mortality rate. Three basic intravenous antibiotic regimens have 
evolved: initial therapy with a single antipseudomonal β-lactam, the so-called monotherapy; 
a combination of two drugs: a β-lactam with an aminoglycoside, a second β-lactam or a 
quinolone; and, thirdly, a glycopeptide in addition to β-lactam monotherapy or combination. 
As there is no single consistently superior empirical regimen, one should consider the local 
antibiotic susceptibility of bacterial isolates in the selection of the initial antibiotic regimen. 
Not all febrile neutropenic patients carry the same risk as those with fever only generally 
respond rapidly, whereas those with a clinically or microbiologically documented infection 
show a much slower reaction and less favorable response rate.
Once an empirical antibiotic therapy has been started, the patient must be monitored con-
tinuously for nonresponse, emergence of secondary infections, adverse effects, and the 
development of drug-resistant organisms. The average duration of fever in serious infections 
in eventually successfully treated neutropenic patients is 4-5 days. Adaptations of an anti-
biotic regimen in a patient who is clearly not responding is relatively straightforward when a 
micro-organism has been isolated; the results of the cultures, supplemented by susceptibility 
testing, will assist in selecting the proper antibiotics. The management of febrile patients with 
pulmonary infiltrates is complex. Broncho scopy and a high resolution computer-assisted 
tomographic scan represent the cornerstones of all diagnostic procedures, supplemented by 
serological tests for relevant viral pathogens and for aspergillosis. Fungi have been found to 
be responsible for two thirds of all superinfections that may surface during broad-spectrum 
antibiotic treatment of neutropenic patients. Antibiotic treatment is usually continued for a 
minimum of 7 days or until culture results indicate that the causative organism has been eradi-
cated and the patient is free of major signs and symptoms. If a persistently neutropenic patient 
has no complaints and displays no evidence of infection, early watchful cessation of antibiotic 
therapy or a change to the oral regimen should be considered.
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INTRODUCTION
Only 50 years ago, dealing with a patient with a disseminated malignant disease was relatively 
simple. There were no curative options and information on the inevitable dismal prognosis 
was often not shared with the patient or his family. The mid sixties of the 20th century witnessed 
the first successes of chemotherapeutic agents. This encouraged investigators to explore this 
route further thereby escalating the dosage of the cytostatic drugs in the expectation of better 
results. It became rapidly clear that the destructive effects of cytotoxic compounds were not 
limited to malignant cells. Infection has emerged as a prominent complication of chemotherapy, 
which was particularly worrisome in the sixties, a decade without powerful broad-spectrum 
antimicrobial agents. Since a possible cure of the cancer was seen as the primary goal, compli-
cations of rigid cytotoxic regimens were taken for granted and when they occurred, treatment 
was more or less improvised. This situation remained actual until Bodey1 pointed out that 
patients in remission of their underlying disease could die suddenly of an overwhelming 
infection during cytotoxic therapy-induced neutropenia. Neutropenia was and remains defined 
as an absolute neutrophil count of ≤ 0.5 x 109/l (500/ mm3) or a count ≤ 1.0 x 109/l (1000/ 
mm3) expected to fall below 0.5 x 109/l (500/ mm3).1 He even showed a positive correlation 
between the severity and duration of neutropenia and the risk of acquiring a life-threatening 
bacterial infection. This risk appeared even more outspoken in individuals who were treated for 
an acute leukaemia or lymphoma as these disorders interfere directly with vital components 
of the immune system. Next to gram-negative bacilli, notably Staphylococcus aureus earned a 
bad reputation.2 A few years later, Schimpff and coworkers demonstrated convincingly that 
early administration of antimicrobial agents covering the above mentioned pathogens without 
waiting for the results of the blood cultures saved lives. His so-called empirical approach became 
an undisputed standard of care.3 However, better options to manage infections stimulated 
the haematologists to intensify their antileukemic regimens further in an attempt to improve 
the remission rates in refractory cases. Moreover, in the meantime allogeneic bone marrow 
transplantations have become a fully accepted treatment modality. These intensifications, in 
turn, inspired a more thorough clinical research of potentially more effective antimicrobial 
regimens, which was facilitated by the booming development of new antimicrobial agents such 
as the broad-spectrum penicillins, third and fourth generation cephalosporins, fluoroquinolones, 
and carbapenems in conjunction with a keen eagerness of the respective pharmaceutical 
companies to put their compounds to the test in large clinical trials that were usually conducted 
by cooperative groups.4,5 A spiral of several subsequent rounds of improved antibiotic cover 
and further escalation of chemotherapeutic regimens has eventually downgraded neutropenia 
to only one of many problems in today’s clinical practice. Modern anti-leukemic therapy is 
almost inherently associated with ulceration of the mucosa (called mucosal barrier injury 
(MBI)) allowing micro-organisms originating from the damaged gastrointestinal (GI) tract easy 
access to the body.6,7 These pathogens may be part of the original indigenous flora but are, 
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more commonly, acquired during hospitalization.8 It was, therefore, logic that attempts to 
prevent invasion of the body by indigenous flora by prophylactic administration of anti-infective 
agents became quite popular. Since such prophylactic agents were mainly targeted against 
the gram-negative enterobacteriaceae a shift from gram-negative to gram-positive micro- 
organisms, including coagulase-negative staphylococci, viridans streptococci, and enterococci, 
as the primary cause of fever in neutropenic patients was seen.9-15 In the meantime, therapeutic 
regimens in the treatment of hematological malignancies have become so complex that usage 
of surgically implanted venous access devices appears inevitable in spite of the apparent risk of 
infections and/or thrombosis.16,17 An epidemiological survey among hospitalized patients treat-
ed for a hematological malignancy between 1995 and 2001 in the United States showed that 
approximately 70 percent (64% in 1995 and 76% in 2001) of all microbiologically confirmed 
febrile episodes were due to gram-positive bacteria and 18 percent (22% in 1995 and 14% in 
2001) to gram-negative bacilli.18 This change in causative pathogens was enhanced by an 
increased use of central venous catheters and other medical devices. Finally, introduction of 
immuno-manipulative monoclonal antibodies into the therapeutic arena has extended the 
treatment-related immunodeficiency to the T-cell functions and innate immunity, which brought 
viral and fungal infections, including Pneumocystis	 jerovecii, into play, particularly when an 
impaired cellular community coincided with a prolonged, severe neutropenia.19,20 The 
modern chemotherapeutic regimens designed to treat acute lymphoblastic leukaemia incor-
porate high doses of corticosteroids. As a result, patients treated with such regimens are at 
increased risk of infections typically related to an impaired cellular immunity. Nowadays, in-
fections are still accountable for substantial morbidity and mortality among patients who undergo 
myeloablative therapy for a hematological malignancy. In spite of all changes in the spectrum 
of infectious agents, gram-negative pathogens remain a principal consideration because of 
their virulence that accounts for serious morbidity and a high early mortality rate.21,22
MANAGEMENT OF NEW FEVER AND 
INFECTIONS
PRINCIPLES 
Administration of potentially curative chemotherapy is the starting point; cytotoxic drugs are 
given without too much consideration since internationally accepted antitumor protocols 
dictate the dosages. Once the chemical compounds are in the body, the haematologist can 
relax and wait for the outcome a few weeks later. However, where the scientist in the haema-
tologist has completed his first task, the general clinician in him or her has to step forward 
when the natural defence system gradually disintegrates. Indeed, during this episode close 
surveillance of the patients with attention for the emergence of infectious complications is 
mandatory. It is work on an individual basis, where fixed protocols hardly help.23,24 It is here 
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that the science and art of medicine meet; listening to the patient’s complaints and meticulous 
physical examinations constitute the crucial factors for timely therapeutic interventions and 
eventual success. This applies to both patients who are treated with intensive chemotherapeutic 
regimens and recipients of a stem cell transplant. During this episode appropriate coordination 
of the information coming from different sources is important, since, next to the patient, family 
members, nurses, microbiologists, pulmonologists, radiologist and pathologists can assist in 
the timely discovery of an emerging complication. Different centers acquit themselves from this 
task in different ways but it occurs to us that the physician who is responsible for treatment 
of the underlying disease should also act as the captain of the ship. This coordinating role 
obliges him or her to have at least some basic knowledge of the likely problems and, perhaps 
even more importantly, to have fine communication skills to keep all parties on board as well 
as on the same course. Since the symptoms of an incipient infection are usually rather subtle 
due to the absence of granulocytes, teamwork is crucial to ensure that antibiotics are admin-
istered within hours of the first signs or symptoms of infection.25 In most cases fever, defined 
as a single oral temperature of more than 38,3° Celsius (101° F) or a temperature of more 
than 38.0° Celsius (100,5° F) for more than 1 hour, will serve as a trigger for action. At the 
onset of fever, attempts to identify the cause of fever deserve absolute priority (see Table 1), 
together with immediate institution of appropriate broad-spectrum antibiotic therapy.22 
Fever in a neutropenic patient is a warning sign that should be taken very seriously because 
self-limiting infection is virtually nonexistent in neutropenic patients irrespective whether they 
have been treated for acute leukemia or lymphoma or did receive a stem cell transplantation. 
In anticipation of the results of the diagnostic procedures, fever denotes infection until proven 
otherwise. The absence of phagocytic cells in combination with a damaged integument allows 
micro-organisms residing at a superficial site of infection easy access to the bloodstream. Under 
these circumstances, a relatively small inoculum that easily can escape detection when limited 
volumes of blood are sampled for culturing can cause a serious septic syndrome.3 Therefore, 
waiting for a blood culture to become positive is a bad idea, although it should be kept in 
mind that fever can be of non-infectious origin.26 A sudden onset of fever accompanied by 
chills, tachycardia with or without a drop in blood pressure and tachypnea is associated with 
a higher rate of positive blood cultures. Shock at the onset of fever is an ominous clinical sign 
but neither clinical manifestations nor the pattern of fever during neutropenia can serve as an 
indicator of a particular causative agent, not even when the most notorious pathogens such 
as Pseudomonas	aeruginosa	or Staphylococcus	aureus are involved.19,27 Acute fever following 
transfusion is often related to the presence of irregular blood group antigens or to cytotoxic 
antibodies acquired during previous transfusions or a pregnancy.28
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Table 1. Diagnostic procedures at the onset of fever
• Short history of the patient with recent complaints
• Physical examination with special attention for:
1. vital signs
2. gastrointestinal tract: peridontium, abdomen, perineum
3. respiratory tract: oropharyngeal area and lungs 
4. skin, including bone marrow aspiration sites, vascular access sites, and tissue 
around the nails
• Cultures of blood (minimal 15 ml) and any clinical suspicious body site, including urine
• Radiological examination of the chest
• Check: medication list, compliance with prophylaxis, results surveillance cultures, 
course of the leukocyte count
• Consider determination of CRP, galactomannan antigen, viral serology and tests 
for Legionella
A substantial minority of patients will show an insidious onset of fever. Although more frequently 
related to non-infectious causes than acute fever, a slow rise of temperature does not exclude 
an infectious origin, although gram-negative rods, viridans streptococci and Staphylococcus	
aureus	are less prevalent amongst these patients.15 Of note, a relative bradycardia in patients 
who not receive anti-arrhythmic medication suggests either a viral or non-infectious origin of 
the fever.19,25 A possible relation between fever and frequently used drugs such as allopurinol, 
antibiotics, bleomycin, and cytarabine or with the underlying disease process itself should 
always be kept in mind.29,30 A dysfunctional immune system is presumed to be responsible for 
the high rate of drug allergy in patients with active acute leukaemia; the allergy may abate 
when complete remission is achieved.28 This phenomenon is well known in patients with 
infectious mononucleosis or acquired immunodeficiency syndrome.
Until recently, coagulase-negative staphylococcal bacteraemia was thought to be entirely 
related to the use of central venous catheters but recent work points at mucosal sites as an 
even more important portal of entry.31-33 The clinical spectrum of catheter-related infections 
ranges from asymptomatic bacteraemia as a manifestation of intraluminal colonization or a 
process confined to the site of insertion to marked inflammation of the tunnel tract and septi-
cemia with metastatic emboli in the skin and other organs. Suspicion of a tunnel or exit line 
infection should arise when the catheter tract becomes painful, red or swollen or when signs 
of inflammation are visible at the exit site. Malfunction of the catheter, illustrated by problems 
to draw blood through the line, is a common first warning of a possible lumen infection.16,17
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SELECTION OF ANTIMICROBIAL AGENTS FOR 
THE EMPIRIC PHASE
BASIC REGIMENS
In the selection of the initial antibiotic regimen, one should contemplate the type, frequency 
of occurrence, and antibiotic susceptibility of bacterial isolates recovered from other patients 
at the same hospital. In addition, the use of certain antibiotics may be limited by special 
circumstances, such as drug allergy, liver function disturbances or renal insufficiency. Despite 
numerous clinical studies since the 1970s, no single empirical antibiotic regimen has classified 
as superior for the initial treatment of patients who become febrile during a neutropenic 
episode after therapy with cytoreductive drugs for a malignant hematological disease (Table 
2).4,9,34-44 However, there is world-wide consensus that any initial antibiotic regimen should 
include drugs with reliable activity against Escherichia	coli,	Pseudomonas	aeruginosa,	Klebsiella 
species, other enterobacteriaceae, and Staphylococcus	 aureus.22 Three basic intravenous 
antibiotic regimens have evolved: initial therapy with a single drug, so-called monotherapy; a 
combination of two drugs, a β-lactam with an aminoglycoside, a second β-lactam or a quino-
lone but without a glycopeptide; and, thirdly, a glycopeptide as addition to a single β-lactam 
or a combination. Numerous large studies have shown that traditional combinations, consisting 
of an antipseudomonal β-lactam and an aminoglycoside, are not universally more powerful 
than monotherapy in the empiric treatment of uncomplicated episodes of fever in neutropenic 
patients. A third or fourth generation cephalosporin, a carbapenem, as well as piperacillin-
tazobactam have been found to be effective single agents in the majority of cases.43-45  
It appears appropriate to reserve two-drug regimens for complicated cases or if antimicrobial 
resistance is a potential problem. The major disadvantages of an aminoglycoside are nephro-
toxicity and ototoxicity, and the necessity to monitor serum levels.46-48 Combination of drugs 
such as amphotericin B, cyclosporine and cisplatin with an aminoglycoside is best avoided, 
because of their additive renal toxicity, whereas the high sodium contents may limit the 
simultaneous use of two β-lactam antibiotics in elderly patients. A large European Organization 
for Research and Treatment of Cancer – National Cancer Institute of Canada study11 showed 
unambiguously that vancomycin administered empirically for fever persistent despite appro-
priate initial antibiotic treatment can be withheld until the results of the cultures indicate the 
need for this antibiotic. Vancomycin must be included in an initial empiric regimen for patients 
known to be colonized with penicillin- and cephalosporin-resistant pneumococci and viridans 
streptococci or methicillin-resistant Staphylococcus	aureus.
The choice to implement a particular antibiotic regimen is, at least partly, based on the results 
of clinical trials as reported in the literature. Yet, the results of such trials should be interpreted 
with great caution. Definitions for response as well as inclusion and exclusion criteria for clinical 
study protocols are usually very rigid and quite different from common clinical practice.23,24 
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Table 2. Efficacy of antibacterial regimens in the treatment of neutropenic patients with
fever
Study No of evaluable 
episodes 
(patients)
Treatment Responses/ documented 
infections 
Responses/ 
bacteraemia
Wade et al 
1981 34
121(92)
Piperacillin + Amikacin 22/38 (58%) 5/15 (33%)
Ticarcillin + Amikacin 19/34 (56%) 6/11 (55%)
Duprez, Michaux 
1981 35
(118)
Piperacillin + Amikacin 26/34 (76%) 9/14 (64%)
Cefotaxime + Amikacin 27/37 (78%) 15/20 (75%)
Winston et al 
1982 36
297 (244)
Piperacillin + Amikacin 38/53 (72%) 16/25 (64%)
Carbenicillin + Amikacin 48/66 (73%) 20/36 (56%)
Winston et al 
1984 37
272 (219)
Piperacillin + Moxalactam 45/61 (74%) 17/23 (74%)
Moxalactam + Amikacin 41/50 (82%) 13/18 (72%)
EORTC 
1987 9
(872)
Azlocillin + Amikacin full course 75/138 (54%) 12/47 (26%)
Ceftazidime + Amikacin short 69/118 (58%) 12/ 35 (34%)
Ceftazidime + Amikacin full course 95/145 (66%) 19/41(46%)
Winston et al 
1988 38
(187)
Piperacillin + Cefoperozone 39/50 (78%) 22/29 (76%)
Piperacillin + Moxalactam 31/38 (82%) 16/22 (73%)
Sage et al 
1988 39
174 (225)
Piperacillin + Netilmicin 12/15 (80%) 1/ 2 (50%)
Ticarcillin + Netilmicin 11/14 (79%) 1/ 2 (50%)
Mezlocillin + Netilmicin 11/18 (61%) 1/ 5 (20%)
Cefoperozone + Netilmicin 4/10 (40%) 0/ 2 (0%)
Feliu et al 
1992 40
170 (118)
Piperacillin + Amikacin 24/44 (55%) 9/21 (43%)
Ceftazidime + Amikacin 30/ 51 (59%) 14/23 (61%)
De Pauw et al 
1994 4
784 (696)
Ceftazidim 127/367 (35%) 33/118 (28%)
Piperacillin + Tobramycin 117/335 (33%) 25/132 (19%)
Cometta et al 
1995 13
706 (475)
Piperacillin-Tazobactam + Amikacin 210/342 (61%) 40/50 (50%)
Ceftazidim + Amikacin 196/364 (54%) 35/101 (35%)
De Pauw et al 
1995 41
304 (225)
Meropenem 54/110 (44%) 37/79 (47%)
Ceftazidime 35/105 (41%) 24/79 (30%)
Cometta et al 
1996 14
483 (475)
Meropenem 270/483 (56%) 47/113 (42%)
Ceftazidim + Amikacin 245/475 (52%) 34/114 (30%)
Feld et al 
2000 42
409 (471)
Meropenem 33/ 77 (54%) 14/31 (45%)
Ceftazidime 33/82(44%) 22/43 (51%)
Del Favero et al 
2001 43
(733)
Piperacillin-Tazobactam 67/186 (36%) 42/140 (30%)
Piperacillin-Tazobactam + Amikacin 60/176 (34%) 44/137 (32%)
Bow et al 
2006 44
(528)
Piperacillin-Tazobactam 71/265 (27%) 11/81 (14%)
Cefepime 54/263 (21%) 7/86 (8%)
Response is defined as resolution of fever and clinical signs of infection (where present) for four consecutive 
days, no relapse within 1 week of discontinuing therapy, and eradication of the infecting microorganisms 
(when isolated) without modification of treatment.
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SPECIFICALLY TAILORED REGIMENS
Conduct of clinical trials in febrile neutropenic patients was a booming business in the mid-
seventies and eighties when many new broad-spectrum antibiotics became available. The data 
derived from these trials have expanded our knowledge of the possible infectious complications 
tremendously. For instance, analysis of these studies revealed that only half of the patients 
who develop fever during neutropenia will present with a clinically or microbiologically docu-
mented infection, the majority being pulmonary infiltrates and bacteraemias (Table 3).49,50 
Furthermore, it was obvious that neutropenic patients without a documented infection generally 
defervesced within a few days, whereas those with a clinically or microbiologically documented 
infection showed a much slower as well as an inferior response rate.19,27,51 This very consistent 
observation suggests that it might be prudent to select different antibiotic regimens for patients 
with different symptoms. Although there is no statistically valid evidence to support a more 
individually tailored approach, it appears reasonable to assume that patients might benefit from 
timely administration of the antibiotics with the highest intrinsic potency against a given micro-
organism. A focus of infection, if present, could help to select the most suitable additional 
anti-infective agents to compose a case-specific regimen because the location of an infection 
is, at least to a certain extent, indicative of specific infective agents (Table 4).52 Likewise, the 
results of surveillance cultures and knowledge of the common complications associated with 
particular anti-leukemic regimens may offer a valuable key to most appropriate initial treatment 
of a neutropenic patient with fever.
Table 3. Classification of febrile neutropenic episodes
FUO- fever of unknown origin New fever, not accompanied by clinical or microbiological 
evidence of infection
Clinically documented infection Fever accompanied by a clinical infection, but pathogens 
cannot be identified, e.g. cellulitis, pneumonia
Microbiologically documented infection Fever accompanied by a localized infection and  
microbiologically plausible evidence, or 
Fever without a localized infection, but infectious agents 
can be demonstrated in a (blood) culture
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Table 4. Sites of infection and prevalent causative micro-organisms
Site Prevalent pathogens Preferred antimicrobial agents
Upper respiratory 
tract
Streptococci amoxicillin, clindamycin
Lower respiratory 
tract
Gram-negative bacilli combination therapy
Streptococci amoxicillin, clindamycin, macrolides
Moulds consider antifungal agents
Diffuse infiltrates
   (cytomegalo)virus
			Pneumocystis	jeroveci
antiviral agents
trimethoprim-sulfametoxazole
Skin and soft tissue Staphylococci glycopeptides
Streptococci, anaerobes amoxicillin, clindamycin, macrolides, glycopeptides
Abdominal Anaerobes metronidazole, glycopeptides
Perianal abscess Gram-negative bacilli combination therapy
GASTROINTESTINAL TRACT
A damaged integument probably plays a major etiologic role in virtually all infections that occur 
following aggressive cytoreductive therapy for a hematological malignancy but its involvement 
is most obvious in infections of the skin and GI tract. The use of high-dose cytarabine in conjunc-
tion with the occurrence of diarrhoea were found to be independent risk factors for streptococcal 
infections among 513 patients evaluated during the first episode of neutropenic fever.53 It has 
been recognized that bacteraemias due to oral Streptococcus	mitis and Streptococcus	oralis may 
bring serious complications such as a sepsis or an adult respiratory distress syndrome, which 
carry a high mortality.54-56 Similarly, bacteraemias due to Staphylococcus	aureus, Pseudomonas	
aeruginosa, Clostridium species as well as candidemias are more frequently encountered in 
patients with acute leukaemia who suffer from neutropenic enterocolitis or typhlitis, the ultimate 
disturbance of the delicate balance between mucosal barrier and microbial flora in the setting 
of prolonged exposure to antibiotics after cytotoxic therapy comprising intermediate or high-
dose cytarabine chemotherapy.53 The signs and symptoms of chemotherapy-induced entero-
colitis or typhlitis are very inconsistent and include nausea, vomiting, abdominal cramps and 
severe abdominal pain with virtually no bowel movements but accompanied by profuse, watery 
diarrhoea.7 Many patients are in such pain that they only gain relief from narcotic analgesics 
which, in turn, induce constipation by reduction of bowel movements. This may create a very 
alarming situation as the clinical picture of the severe variant resembles that of gut perforation 
or acute pancreatitis very closely. Because unnecessary surgical interventions in patients during 
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a hypoplastic bone marrow phase after treatment for an acute leukaemia can be detrimental, it 
is essential for physicians to be aware of the existence of this entity with the according symptoms.7 
Ultrasonography or computer-assisted tomographic (CT)-scan, showing pathological thickening 
of the bowel walls, might be useful to establish the diagnosis of typhlitis. Patients treated for 
acute myeloid leukemia with a bowel wall thickness of more than 10 mm had a significantly 
higher mortality rate than did those with a bowel thickness of less than 10 mm.57 Dispropor-
tional bacterial overgrowth in the gastrointestinal tracts of patients with MBI can serve as a source 
of bacteraemia by the well-known gastrointestinal flora as well as by otherwise exclusively 
enteric pathogens such as Clostridium	 septicum and Bacteroides	 fragilis.58,59 In contrast, 
Salmonella species are rarely found in the stool or blood of granulocytopenic patients; these 
organisms are obviously not major players in this field; this is also true for pathogens like 
Campylobacter and Shigella species. Therefore, an adequate antibiotic regimen for patients 
with abdominal symptoms should cover for gram-negative rods but due consideration should 
be given to the use of compounds with activity against anaerobes. Next to glycopeptides and 
carbapenems, metronidazole appears an attractive adjunct to a standard regimen under these 
circumstances. Pseudomembranous colitis caused by Clostridium	 difficile60-64 constitutes a 
related but totally different entity that can be severe and even fatal. Stool should be tested 
immediately for Clostridium	 difficile toxin if the diagnosis is suspected. Enteric Clostridia 
infections necessitate oral antibiotic therapy with either vancomycin or metronidazole. 
Relapses are frequent and may follow cancer chemotherapy or courses with antibiotics such 
as clindamycin. Relapse is harder to document because toxin may persist in the stool of 
successfully treated patients.62 
Diagnostic problems are held accountable for underestimating enteric viruses as causative 
agents in gastrointestinal infections. Although a compromised cell-mediated immunity is 
known to predispose for parasitic and protozoan infections, their incidence is surprisingly low 
in patients who are treated for a hematological malignancy.65,66
SKIN
Folliculitis and cellulitis are the most common manifestations of infectious processes in the 
skin. Sometimes it is difficult to differentiate infectious lesions from drug-induced toxic skin 
eruptions. Infection-associated erythema and swelling are usually mild but, if left untreated, 
infiltration and abscess formation will involve extensive areas of the skin with necrosis and 
gangrene. Since the lesions associated with the various organisms are rather alike, a simple 
needle aspiration or biopsy should be performed to establish an accurate diagnosis as early as 
possible in the course of the disease. The causative micro-organisms include streptococci, 
staphylococci, and, less commonly, gram-negative bacilli and fungi.67-70 Localized infections of 
the skin, particularly in the face, are usually caused by gram-positive bacteria that preferably 
arise in carriers of organisms like Staphylococcus	 aureus. None of the standard empiric 
regimens is the optimal choice for treating infections by the prevalent but usually indolent 
40
Chapter 2
non- Staphylococcus	aureus gram-positive cocci that are often methicillin-resistant, but the 
morbidity from these infections should not be underestimated either. Pseudomonas	aeruginosa 
acquired in a hot Jacuzzi may cause a folliculitis that occasionally progresses to a destructive 
ecthyma gangrenosum.71 This characteristic entity should be distinguished from similar lesions 
caused by other rare pathogens, such as actinomyces, Stenotrophomonas	maltophilia68 and 
fungi69,70 as well as from pyoderma gangrenosum, a noninfectious cutaneous process in patients 
with a myeloid malignancy.72,73 Sweet’s syndrome, a dense, tender infiltration by neutrophils 
of the dermis on the head, neck, and upper extremities is associated with a leukocytosis.74 
Varicella zoster is the leading dermatologic complication in patients with an impaired cell- 
mediated immunity.75-77 If skin or mucous membrane lesions due to Herpes	simplex	or Varicella 
zoster viruses are present, even if they are not the cause of fever, treatment with valaciclovir 
is indicated in the intention to enhance the healing of lesions that could become potential 
portals of entry for bacteria and fungi.22 The results of several prospective studies do not 
indicate a general need for a glycopeptide as part of the front-line therapeutic regimen unless 
one has a particular reason to suspect the presence of methicillin-resistant Staphylococcus	
aureus on the basis of local patterns of resistance. Nevertheless, most physicians intuitively 
prefer an up-front glycopeptide-containing regimen for apparently catheter-related infections 
as these are frequently due to coagulase-negative staphylococci (CoNS), although early glyco-
peptides barely contribute to the chance of survival from these usually indolent infections. 
Hence, when CoNS are involved, a few days of watchful waiting for a possible clinical response 
and the results of the cultures will have no detrimental impact. Most catheter-associated 
infections will respond to antibiotic therapy without removal of the catheter. Rotation of anti-
biotics through each lumen of multilumen catheters to avoid microbial sequestration in one 
of the lines and the use of antibiotic-containing heparin lock solutions to supplement systemic 
therapy have been proposed by some investigators but such practices remain controversial.22 
Pulling the catheter is most likely to be required for cure if a concurrent venous thrombosis is 
found, the tunnel tract appears involved or if the infection, regardless of the etiology, is recurrent 
or if after several days of therapy the response to antibiotics appears doubtful.78
UPPER RESPIRATORY TRACT 
Gingivostomatitis and periodontal lesions occur frequently in patients with acute leukaemia.79 
Oral MBI is characterized by pain, edema, erythema, superficial lesions, pseudomembranous 
formation in conjunction with excessive mucous production, reduced saliva secretion and 
bleeding. A wide array of pathogens can be found and include Herpes	simplex, gram-negative 
bacilli, streptococci, anaerobes, and Candida species.80 With the introduction of aggressive 
chemotherapeutic regimens, hitherto unusual pathogens such as Stomatococcus and Aerococcus 
are increasingly seen in patients with oral MBI. Mixed and polymicrobial infections are more 
or less standard.80,81 Given the range of prevalent pathogens there is little need to deviate from 
one of the standard regimens, although on theoretical grounds one might prefer to select a 
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carbapenem or extended-spectrum penicillin given their superior intrinsic activity against 
viridans streptococci and pneumococci. The course of Herpes	 simplex stomatitis is usually 
protracted in patients treated for leukaemia or lymphoma, and relapses are common.82 Herpes	
simplex lesions are most commonly white painful plaques on the gums, tongue, buccal mucosa, 
or oropharynx and may be difficult to discriminate from oropharyngeal candidiasis and, indeed, 
co-infections do occur. Swallowing can be so painful that saliva is expectorated and intake of 
food and fluids drastically reduced.7 It is not uncommon for oropharyngeal Herpes	simplex and 
Candida infection to extend to the oesophagus.82 Although neither herpes nor candidiasis do 
belong to the category of diseases that requires an empiric approach, it is generally contended 
that early treatment with valaciclovir and fluconazole, respectively, is important to prevent 
extension into the oesophagus and further dissemination, particularly among bone marrow 
transplant recipients. When the paranasal sinuses are involved in the infectious process, 
moulds have to be considered as possible causes. As the clinical picture has typical features, 
direct inspection of the nasal turbinates and a CT-scan of the sinuses can be helpful to establish 
or reject the diagnosis.79,80
LOWER RESPIRATORY TRACT
Management of pulmonary infiltrates that are liable for 70% of all fatal infections in febrile 
neutropenic patients is complex.83-85 The classic clinical complaints of cough, pain and dyspnoea 
should not be neglected but bronchoscopy and radiological examination of the chest by a CT-scan 
represent the cornerstones of all diagnostic procedures. Typically, chest radiographs performed 
early in the evolution of infection in patients with profound granulocytopenia fail to show 
infiltrates. It may take more than 3 days for the infection to generate enough necrosis with 
haemorrhage and oedema to produce a visible infiltrate. The critical decision faced by the 
clinician at the bedside of patients with pulmonary infiltrates is whether to undertake invasive 
procedures such as bronchoscopy with or without bronchoalveolar lavage, transbronchial biopsy, 
transthoracic aspiration, thoracoscopy-guided biopsy, or open lung biopsy. The exact role of 
these diagnostic procedures in the optimal management of patients is still controversial because 
the yield depends on the collaboration and skills of various specialists. Moreover, concurrent 
thrombocytopenia precludes simple invasive diagnostic procedures in many patients. The 
radiologic pattern of a possible infiltrate is often suggestive of its cause. A diffuse opacity, 
usually of both lungs, is seldom of bacterial or fungal origin. Although viruses and Pneumocystis	
jeroveci typically cause diffuse, bilateral pulmonary infiltrations, it should be kept in mind that a 
similar picture of pneumonitis can be seen secondary to radiation, fluid overload, cytotoxic drugs 
such as methotrexate, cytarabine and bleomycin, and in pulmonary haemorrhage. Pneumocystis	
jeroveci pneumonia is manifested in patients with deficient cellular immunity as fever, pro-
gressive hypoxemia with dry cough, and dyspnoea, typically beginning after discontinuation 
of corticosteroid therapy given for other reasons.85 High-dose trimethoprim-sulfamethoxazole 
with adjuvant corticosteroids for hypoxemic patients (PO2 < 70 mmHg) has become the preferred 
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therapy for these infections.86 Alternatives include intravenous pentamidine, oral dapsone in 
combination with trimethoprim, or oral atovaquone suspension alone. Antiviral drugs are 
indicated only if there is clinical or laboratory evidence of viral disease. With the exception of 
a cytomegalovirus related pneumonitis in allogeneic bone marrow transplant recipients with 
graft-versus-host disease, there appears to be no need for empiric cover of respiratory viruses, 
such as respiratory syncytial virus, influenza and adenoviruses.87,88 Ganciclovir, valganciclovir 
and foscarnet have established activity in the treatment of cytomegalovirus infection and 
their timely use might be life-saving. Mycoplasma	pneumoniae with or without cold agglutinins 
is remarkably infrequent in patients treated for leukaemia. In more acutely ill patients, the 
possibility of acute lung injury following transfusion of a cellular blood product or a respiratory 
distress syndrome related to streptococcal sepsis should be considered. Particularly patients 
with an infection by Streptococcus	mitis, which has been linked with severe MBI and high-dose 
cytarabine are at risk.53,54 The incidence of an acute respiratory distress syndrome in such cases 
is more than 20 percent and the mortality is substantial. The pathophysiology of an adult 
respiratory distress syndrome following streptococcal bacteraemia in a neutropenic patient is 
poorly understood. Probably several factors are involved, such as a deleterious effect of micro-
organisms superimposed on preexisting tissue damage. Even patients who had received the 
appropriate antimicrobials from the onset of fever were reported to experience shock and 
death.54-56 Therefore, next to supplementary antibiotics, corticosteroids should be considered 
in the management of patients affected by this complication. Bacterial infections of the lung, 
accompanied by a bacteraemia in about 50 percent of cases, usually create shadows on a CT-
scan that are confined to one or more lobes. Pneumonias caused by Pseudomonas	aeruginosa 
and Staphylococcus	aureus	do have a bad reputation but enterobacteriaceae, Haemophilus 
influenzae and Streptococcus species are hardly less dangerous.89,90 Given the uniformly poor 
outcome of pulmonary infections in clinical trials, the empiric use of a combination of antibiotics 
is recommended with the addition of vancomycin in centers that face resistance of Streptococcus 
pneumoniae to penicillin and macrolides. Outbreaks of Legionella pneumophila, an infection 
characterized by patchy interstitial or nodular pulmonary infiltrates and sometimes accompanied 
by headache or gastrointestinal symptoms, have been observed among compromised patients 
in units with contaminated water systems.91 Therefore, if a case of legionellosis is encountered 
other patients with similar symptoms on the same ward should be protected with a macrolide 
or a fluoroquinolone from the start of antimicrobial therapy. Conversely, a nodular pattern of 
pulmonary infiltrates should urge the physician to consider the possibility of atypical pneumonia 
or, more commonly, a pulmonary fungal infection but for such cases diagnostic procedures 
rather than immediate institution of antifungal drugs should be given priority.69 Especially in 
patients with a concomitant impairment of the cell-mediated immunity, pulmonary aspergillosis 
has to be distinguished from tuberculosis. Infections with Mycobacterium	tuberculosis in patients 
with impaired cell-mediated immunity are manifested as either localized pulmonary disease 
or devastating miliary tuberculosis. Nontuberculous mycobacteria are still rather rare in patients 
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with acute leukaemia, but the introduction of purine analogues such as cladribine and fluda-
rabine, which cause severe and prolonged depression of cellular immunity, may change this 
picture in the near future.92
OTHER FOCI OF INFECTION
Urinary tract infections are astonishingly uncommon in patients who are treated for a leukaemia 
or lymphoma and since gram-negative bacteria are the predominant pathogens the choice for 
a single broad-spectrum β-lactam is fully justified.12 Malignant otitis externa is very serious 
infectious complication that can emergence after the administration of aggressive chemo-
therapy for a hematological malignancy.93 At the outset the patient will complain of a painful, 
discharging ear, whereas physical examination will reveal a vulnerable oedematous ear canal. 
Local maceration and humid conditions favour the growth of Pseudomonas	aeruginosa which, 
indeed, can be isolated frequently from swabs taken from the superficial lesions. Subsequently, 
the infection will penetrate into underlying soft tissues, filling the retromandibular and parotid 
area. Likewise, spreading to the middle ear, the mastoid air cells and adjacent temporal bone 
is possible. Once osteomyelitis has been established extension to the basic of the skull with 
invasion of the cranial nerves and local thrombosis poses a direct danger to the patient’s life. 
A CT-scan may be helpful to discover tissue damage in an early phase. Prolonged antibiotic 
therapy with ceftazidime or ciprofloxacin in combination with surgical debridement constitutes 
the treatment of choice.93 Occasionally, a similar clinical picture can be the result of an infection 
by Staphylococcus	aureus or Aspergillus	fumigatus. In such cases surgery should be combined 
with flucloxacillin or vancomycin and voriconazole, respectively. 
An insidious onset of fever accompanied by headache and confusion might be indicative of 
meningitis when localization of the leukaemia or lymphoma has been excluded by cytologic 
examination of the cerebrospinal fluid. In case of infection, the cerebrospinal fluid is usually 
clear with a moderate protein elevation. The prevalent pathogens are Listeria	monocytogenes, 
Cryptococcus	neoformans and Toxoplasma	gondii.65 Recovery of one of Listeria	monocytogenes94 
and Cryptococcus	neoformans from blood cultures should, provided that no intracranial hyper-
tension is detected, always prompt a lumbar puncture even in the absence of neurological 
symptoms. Considering their low incidence and the relatively reliable diagnostic possibilities, 
there is no need to provide cover for these infections with a specifically adapted empiric regimen.
MANAGEMENT ON AN OUT-PATIENT BASIS
When potent oral broad-spectrum antibiotics became available in the late eighties many a 
clinician felt tempted to use these drugs in the treatment of febrile neutropenic patients. Several 
groups around the world took the responsibility to assess the options and limitations of this 
seemingly revolutionary approach systematically.95-97 These analyses showed that it is possible 
44
Chapter 2
to define risk factors that can be used to classify patients into low or high-risk categories. In fact, 
these studies offered nothing more than identification of objective parameters that corroborate 
the gut’s feeling of the experienced clinician in an era of litigation. Since the time of Bodey, it 
was already obvious that patients with absolute neutrophil count between 0,1 and 0.5 x 109/l 
(100-500/ml) carry a minor risk when compared to those with a count of less than 0.1 x 109/l 
(100/ml) but now other factors have been added.1 Patients with concurrent mucosal damage 
or impaired cellular immunity, as well as those with clinically documented infections or dubious 
vital signs are at high risk deserve optimal vigilance and cannot be considered candidates for 
antibiotic treatment on an out-patient basis. The vast majority of patients under treatment for 
an acute leukemia are considered high-risk patients and should continue to receive intravenous 
broad-spectrum antibiotics. The remaining low-risk patients, namely those with unexplained 
fever who are clinically stable, may be safely treated with oral antibiotics provided that they have 
been seen at a qualified medical center promptly after the onset of fever.95,96 The possible use 
of antibiotic prophylaxis does not pre-empt the need for a thorough check-up but limits the 
choice of drugs that can be used for treatment. Patients with increasing granulocyte counts 
are considered to be better candidates for outpatient therapy than are patients without an 
indication of bone marrow recovery. Among the oral regimens that have been evaluated are 
ofloxacin, ciprofloxacin, and ciprofloxacin plus amoxicillin-clavulanate. It is crucial to make 
sure that the patient is informed about the risk of unremitting fever during a neutropenic 
episode and that he or she fully understands the importance of seeking immediate medical 
advice in case any unexpected incident occurs. Vigilant observation at home by a relative or 
professional health care worker and prompt access to appropriate medical care must be 
assured 24 h per day, seven days a week.98-101 As an alternative to initial outpatient therapy, 
early discharge with continued outpatient therapy for selected patients may be considered 
after a brief admission during which intravenous therapy is initiated, fulminant infection is 
excluded, and appropriate culture specimens are taken.102,103
Two studies have demonstrated that children who lack signs of sepsis and severe MBI, who 
are afebrile for >48 h, who have neutrophil counts of >100 cells/mm3 (>0.5 x 109/l ), and who 
are at low risk for complications may have their intravenous antibiotic treatment safely 
stopped to be substituted by oral cefixime.104,105
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MANAGEMENT OF FEVER AFTER THE EMPIRIC 
EPISODE
PRINCIPLES 
After starting empiric treatment, fever will persist or return in about one third of patients. The 
average duration of fever in serious infections, in eventually successfully treated neutropenic 
patients is 4-5 days (Table 2, Figure 1).4,9,13,14,34-44 
Figure 1. Typical course of fever after institution of empiric antimicrobial therapy in 
neutropenic patients4
 
Although fever can be inconvenient for the patient, it is important to realize that it is part of 
the body’s defence system.106 Indeed, some retrospective studies have suggested that fever 
is associated with improved survival and shortened disease. Uncontrolled studies have reported 
an association of increased mortality with the absence of fever in polymicrobial or gram-negative 
sepsis and in elderly patients with community acquired pneumonia.107,108 So, when the body 
temperature remains above normal during three or four days on apparently effective broad-
spectrum antibiotics, this should not be considered a complete waste of time, particularly not 
if the time is used for an appropriate diagnostic work-up. It should be kept in mind that empiric 
administration of antibiotics is only meant as an immediate cover for rapidly fatal bacteria 
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such as gram-negative rods and Staphylococcus	aureus, thereby, so to say, buying time for 
consideration of the next therapeutic interventions and for waiting for the results of the diag-
nostic procedures. When the results of the cultures have become available and the infection 
has had the time to blossom clinically, there is a more solid basis for decisions on necessary 
adjustments of an antibiotic regimen.
Unfortunately, all large, randomized clinical trials on empiric antibiotic therapy in the febrile 
neutropenic patients during the past 30 years have been pharmaceutical company-driven for 
purposes of attaining governmental agency approval.23,24 By consequence, the design of these 
studies focused primarily on the efficacy of a particular drug in comparison with another drug or 
a combination of drugs. According to the protocols for these trials, only patients who survived 
the episode without a change in the allocated regimen could be labeled as successes, where-
as any change in therapy, independent of the trigger, had to be denoted a failure. Therefore, 
modification of the test regimens was discouraged, which constitutes a rather artificial situation, 
as clinicians are inclined to adjust an antibiotic regimen for no other reason than a subjective 
feeling of dissatisfaction with the current antibiotics. Changes often reflect the lack of confi-
dence on the part of the clinician rather than any deficiency in the regimen used. When 
restrictions surrounding a clinical trial do not apply, juggling antibiotics against an undulating 
line on a temperature chart is a well-known happening on a ward with patients suffering from 
a hematological malignancy care. Indeed, in daily practice many modifications are not based 
on objective criteria and are made outside office hours, i.e. by often less experienced physicians 
on call.103,109 However, it is generally recognized that exposure to many different antibiotics as 
a result of haphazard changes of regimens enhances the risk of drug-related adverse and seldom 
improves the outlook for the patient under treatment. Moreover, such a policy of unmotivated 
changes of antibiotics might wrongly decrease the perceived need for further diagnostic 
procedures in poorly responding patients. Since there is evidence from clinical trials on what 
to do after the empiric phase, some experts have been propagating so-called algorithms of 
planned progressive antibiotic therapy to treat neutropenic patients with fever. A planned 
progressive strategy involves adjustment of therapy every two to three days, until the patient 
becomes febrile or until all the potential causes of infection are covered by the best available 
microbial agents, irrespective of the development of additional symptoms. It is clear that algo-
rithms featuring planned progressive therapy are destined to lead to over-treatment with 
unnecessary expenses and drug exposure.108 It appears more intellectually attractive not to 
rely on fixed algorithms but to weigh several different, patient-specific parameters, including 
fever and the clinical response, as a guidance for modification of an empiric regimen. It goes 
without saying that spending time at the bedside is crucial for those who feel attracted by the 
role of attending physician because careful observation often provides early clinical clues for 
a rational adaptation of the actual regimen. The need for individuality is not only dictated by 
variations in the signs and symptoms of the patient that accompany persisting fever but also 
by the differences in skills and expertise amongst the attending specialists in the various centers. 
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For example, centers with excellent and interested departments of medical microbiology will 
rely more heavily on their findings than do centers with a poorly functioning facility, whereas 
units with an active radiology may benefit from the locally available know-how in this particular 
field. 
MODIFICATIONS IN POORLY RESPONDING 
PATIENTS
CASE-BY-CASE MODIFICATION OF AN INITIAL EMPIRIC REGIMEN
Once an empiric antibiotic therapy has started the patient must be monitored continuously 
for non-response, emergence of secondary infections, adverse effects, and the development 
of drug-resistant organisms. This implies that the start of antibacterial agents cannot be seen 
as an impetus to stop diagnostic procedures. Daily blood cultures are certainly justified as long 
as patients remain febrile and when a new temperature peak occurs because breakthrough 
bacteraemia or fungaemia may develop. Close monitoring of sites that are prone to infection 
should start before the onset of fever and has to be continued after empirical antibacterial 
therapy has commenced. Subtle changes must bring diagnostic tools into play to confirm 
or exclude the presence of an infectious focus. Regular CT-scans of the chest, preferably in 
combination with serological monitoring for Aspergillosis	antigen, have an established value 
in patients who are at increased risk of fungal infections.92
As a rule, approximately 65 percent of patients without a focus of infection, of which 30 percent 
with positive blood cultures, will have shown some clinical improvement after three days of 
broad-spectrum empiric cover in spite of persisting fever in a substantial number. In most cases 
defervescence will follow rapidly. Elements that should be incorporated in clinical decision 
making include the course of fever and clinical condition with special attention for the vital 
signs, evolving symptoms of infection in relation to the granulocyte count, CRP levels, presence 
of antigens, and antiviral titers. The results of all cultures taken at the onset of fever have to 
be assessed and it is recommended to analyse surveillance cultures, if any, to identify possibly 
colonizing resistant organisms. Without clinical deterioration or proof of an infection caused 
by a micro-organism resistant to the allocated antibiotic regimen, persisting fever after 72 to 
96 hours of empiric therapy is an unsatisfactory basis for changing the actual antibacterial 
regimen. It is better to alter the regimen only when there are objective reasons to do so: 
deterioration of vital signs, isolation of a resistant pathogen without clinical improvement, 
persistence of a pathogen, antibiotic-related adverse events, occurrence of a new focus of 
infection or progression of an existing focus in the absence of granulocyte recovery, unex-
plained fever persisting for more than 5 days, new fever, a new pathogen or recognition of 
a local epidemic with a resistant organism. In most patients antimicrobial therapy can be 
adjusted objectively on the basis of clinical or microbiologic findings but such an individually 
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tailored approach requires careful daily assessment of all possible parameters involving all 
consulting specialists, including microbiologists, pulmonologists and radiologists. In contrast to 
the moment of the onset of fever there is ample time for deliberation and contemplation in a 
situation where the patient’s fever persists for three or more days while on antibiotics because 
the origin of fever is obviously not a rapidly fatal micro-organism that needs immediate cover. 
Fever that persists for more than three days suggests that the patient has a nonbacterial 
infection, a resistant bacterial infection, a second infection, or a non-infectious cause of fever 
like drug fever (Table 5).22,110
Table 5. Possible causes for lack of response to antibiotics
•  a bacterial infection resistant to the antibiotics 
•  cell wall-deficient bacteraemia
•  infections at a avascular site (e.g., abscesses or catheters) 
•  inadequate serum and tissue levels of the antibiotics
•  slow response to the drugs in use
•  the emergence of a second infection
•  a nonbacterial infection
   o   fungal
   o   viral
   o   post-transplant lymphoproliferative disease
   o   parasitic 
•  pyrogenic substances
   o   cytokines
   o   (auto)immune reactions
   o   blood product antigens
   o   toxins
   o   drugs (antibiotics!)
   o   tissue (tumor) products
 
Despite extensive cultures, only around 30 percent of all febrile patients will be shown to have 
microbiologically defined infections. In 30 percent of patients organ involvement is already 
obvious when fever arises and an additional 10 percent will show a clinically defined infection 
within next 72 hours (Figure 2).  
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Figure 2. Identified causes of infection at onset of fever and at the end of the 
empiric episode
URTI = upper respiratory tract infection, including oral mucositis. 
Others have neither a focus of infection, nor a positive culture and are defined as unexplained 
fevers. Using clinical well-being as a leading parameter, there are roughly three possible situa-
tions after three days of treatment: the patient’s condition is a) improving (approximately 55 
percent of cases); b) stable (approximately 35 percent); or c) has deteriorated (10 percent) 
(Table 6). Patients belonging to each of these three categories can suffer from either a micro-
biologically documented infection, a clinically documented infection or unexplained fever. 
All these factors that are partly subjective and partly objective can be exploited to steer the 
modification of an empiric regimen whenever there is a perceived need to do so. Ultimately, 
only 15 to 20 percent of patients with a persisting unexplained fever would require a continued 
empiric approach after 72 hours of broad-spectrum antibacterial therapy. Whichever modification 
is planned, it cannot be overemphasized that maintenance of appropriate anti-gram-negative 
cover is mandatory as long as a patient is febrile and neutropenic.22
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Table 6. Considerations for modification of antibiotic regimens in febrile neutropenic
patients
Improving clinical condition
• microbiologically documented infection
  o maintain gram-negative cover
  o consider adjustment on the basis of susceptibility pattern
  o consider switch to an oral regimen 
• clinically documented infection
  o continue running regimen
• unexplained fever 
  o maintain gram-negative cover
  o consider switch to an oral regimen
Stable clinical condition
• microbiologically documented infection
  o maintain gram-negative cover
  o consider adjustment on the basis of susceptibility pattern
  o consider switch to an oral regimen 
• clinically documented infection
  o continue running regimen
  o consider adaptation on the basis of focus-specific pathogens
• unexplained fever 
  o maintain gram-negative cover
  o consider further diagnostic procedures
Deteriorating clinical condition
• microbiologically documented infection
  o maintain gram-negative cover at maximally tolerated doses 
  o consider adjustment on the basis of susceptibility pattern
• clinically documented infection
  o maintain gram-negative cover at maximally tolerated doses 
  o maximal cover of focus-prevalent pathogens
• unexplained fever 
  o cover relevant potential gaps in the spectrum of the actual regimen
  o consider further diagnostic procedures
  o consider institution of intravenous antifungals
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MICROBIOLOGICALLY DOCUMENTED INFECTIONS 
When the patients is improving or stable there appears to be no imminent need to adjust a 
running regimen. Depending on the micro-organism isolated, a change to an oral regimen 
could be considered with caution. In case a gram-negative isolate is identified, broad-spectrum 
antibiotic coverage should be maintained in full dose. If, besides a gram-negative isolate, 
another pathogen is found a specific agent should be added. Whereas the clinical relevance 
of a blood culture positive for gram-negative bacilli is never a matter of controversy, the 
implication of recovery of particular gram-positive cocci is questionable. Single blood cultures 
positive for Staphylococcus	 aureus, Streptococcus	 pneumoniae, or Enterococcus	 faecalis in 
neutropenic patients should be regarded as significant and indicative for the choice of further 
treatment. Viridans group streptococci, with an average mortality of 15 to 20 percent are perhaps 
the most feared among the bacteraemias today.54-56 Although viridans streptococci are common 
blood contaminants in the general population, positive blood cultures in patients with MBI 
should not be disregarded, certainly not when it concerns Streptococcus	mitis.53,54 Isolation 
of rare micro-organisms should prompt to evaluation of the appropriateness of the starting 
antibiotic regimen, when the patient is not responding optimally. On the other hand, isolation 
of in vitro resistant organisms such as CoNS and, more rarely, Stenotrophomonas	maltophilia, 
from the blood of a clinically evidently improving patient poses an interesting challenge. 
Many would be inclined to modify the actual regimen but there is no evidence that this tactic 
is beneficial as other bacteria that were not grown on the culture plate could have been the 
culprits in the current febrile episode. A blood culture that yields Candida species or another 
fungus should be taken very seriously and dictates immediate institution of antifungal thera-
py.111-113 The availability of the candins has extended the therapeutic options.114-116
Adaptations of an antibiotic regimen in a patient who is clearly not responding is straightforward 
when a micro-organism has been isolated; the results of the cultures, supplemented by suscep-
tibility testing, will assist in selecting the proper antibiotics.
CLINICALLY DOCUMENTED INFECTIONS 
All clinical trials so far have demonstrated consistently that patients diagnosed with a clinically 
documented infection respond much slower and remain febrile for a longer time than those 
without a focus of infection.19,27,51 Moreover, due to problematic penetration into avascular sites 
infections associated with abscesses or prosthetic devices usually respond poorly to antimicro-
bial therapy. Attending physicians should, therefore, be more hesitant to change antibiotics in 
patients who are not deteriorating. On the other hand, there are indications that early addition 
of specific agents might be useful for a more rapid control of the infection. For instance, 
considering the probable involvement of anaerobes, switching to a carbapenem, if not given 
initially, or addition of metronidazole to a standard anti-gram-negative regimen appears a 
logical choice when fever is accompanied by abdominal symptoms. In cases with a clinically 
documented site, who do not improve or stabilize, coverage of micro-organisms known to 
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prevail at the involved site of infection (Table 4) appears appropriate. Clinically documented 
infections that emerge later during the course of febrile neutropenia carry a dismal prognosis 
and is presumed to be related to the occurrence of resistant micro-organisms, including invasive 
fungi, in combination with a persisting immunodeficiency as a result of a refractory underlying 
disease.20,69
PERSISTENT UNEXPLAINED FEVER OR FEVER OF UNKNOWN ORIGIN
If the patient with an unexplained fever clinically improves or remains stable after 72 hour of 
empirical treatment and re-evaluation by physical examination and diagnostic tests yields no 
new information, and no isolate was found, the initial antibiotic regimen can be continued or can 
be switched to an oral compound. The latter decision will be strengthened if the neutropenia 
can be expected to resolve within the ensuing days. If vancomycin is a component of the initial 
antimicrobial regimen, withdrawal of the drug should be considered if the results of the cultures 
do not support its use.22
Deteriorating cases without any microbiological or clinical sign of infection pose a dilemma. 
Unexplained fever accompanied by deterioration can imply that the patient has a non-bacterial 
infection or a non-infectious cause of fever, but foremost a resistant bacterial infection or the 
emergence of a second infection should be taken into account.19,110 An initial response rate 
of about 35 percent may be expected in patients with shock, as compared with 70 percent 
in patients without shock, which suggests the presence of an undetected toxin-producing 
pathogen. A fortification of the actual antibacterial regimen is mandatory in critically ill 
patients, independent of the level of fever.106 Escalation might include filling theoretical gaps 
in antibiotic cover and enhanced monitoring for any change in the patient’s condition. Under 
these circumstances, the selection of agents should be guided by knowledge of locally prevalent 
virulent pathogens and the actual susceptibility pattern, which implies the necessity of a close 
cooperation with local microbiologists. Addition of vancomycin appears logical in view of the 
relatively low yield of blood cultures and the fact that the spectrum of antibacterial drugs in 
traditional empiric regimens usually does not cover for coagulase-negative staphylococci, 
methicillin-resistant Staphylococcus	aureus, enterococci, and some strains of penicillin-resistant 
Streptococcus	 pneumoniae and viridans streptococci.11 On the other hand, liberal use of 
vancomycin has confronted the medical community with vancomycin-resistant enterococci 
and staphylococci, which led to the introduction of new agents like quinupristin-dalfopristin 
and linezolid in the treatment of febrile neutropenic patients.22 When the starting regimen 
has consisted of a single, broad-spectrum β-lactam, the addition of an aminoglycoside seems 
to be an attractive option to provide a better protection against infections by resistant gram-
negative rods.46,47 However, it has to be emphasized that development of resistance during 
therapy is extremely rare and that aggressive gram-negative organisms typically push the 
infection in a stage beyond cure within a few days in most cases. Hence, if the local resistance 
pattern or a particular concern in an individual patient prompts the use of an aminoglycoside 
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it should be prescribed from the start in optimal doses with monitoring of the peak and serum 
levels.46,47 Besides, clinical deterioration in a persistently neutropenic patient with unexplained 
fever is an important but rather rare event in daily practice and applies to only a quarter of the 
10 percent of cases that show deterioration while on broad-spectrum antibacterial treatment. 
Moreover, it is noteworthy that the success rate of empiric modifications is less than 20 percent, 
whereas more than 50 percent of cases will respond to specifically customized modifications.41
SPECIFIC CONSIDERATIONS
INVASIVE FUNGAL DISEASE
Invasive fungal infections are encountered in up to 40 percent of autopsies in patients with 
hematological malignancies.20 Fungi have been found to be responsible for two thirds of all 
super-infections, which surface during broad-spectrum antibiotic treatment of neutropenic 
patients. More than 20 years ago, when diagnostic facilities were virtually non-existent and the 
choice of effective antifungal agents limited, two prospective, randomized trials laid the scien-
tific foundation for the addition of systemically active antifungals to a purportedly insufficient 
antibacterial regimen.111,112 This strategy appeared to reduce the incidence of invasive fungal 
infections in patients without any further sign of a clinically documented infection. Solid statis-
tical evidence to support the validity of this empiric approach was never obtained in further 
statistically valid, placebo-controlled trials. This so-called empiric antifungal therapy has 
remained popular as it seemed to make life easy for clinicians. The lack of reliable diagnostic 
tools in combination with a very poor outcome of invasive fungal infections that were not 
timely treated contributed greatly to this popularity.117,118 However, in most cases empirically 
given antifungals are redundant because there is simply no invasive fungal infection at all. A 
better understanding of the pathophysiology of invasive fungal disease in combination with 
better diagnostics allows for a more differentiated approach.117-120 An optimal diagnostic work-up 
in conjunction with careful clinical observation will likely render routine empiric antifungal 
therapy superfluous in most cases because appropriate application of presently available 
diagnostic tools enables timely pre-emptive institution of appropriate antifungal therapy by 
experienced clinicians.121-123 The most common initial presentation of invasive aspergillosis is 
unremitting fever despite broad-spectrum antibacterial treatment, eventually accompanied in 
most patients by pulmonary infiltrates or sinusitis. Clinicians should suspect the diagnosis in a 
patient with pleuritic pain, hemoptysis, and a localized rub. The halo sign ( a dense central nodule 
with surrounding less dense infiltrate) on a CT-scan of the chest, though not pathognomonic, 
is highly suggestive of an early phase of pulmonary aspergillosis or other mould pneumonia in 
immunosuppressed patients.124-126 Even when gram-negative pathogens, including Pseudomonas	
aeruginosa and Enterobacter	cloacae, are concomitantly isolated from the sputum or blood of 
such patients, aspergillosis should be the leading consideration. If no infiltrate is found in a 
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high-risk patient with persisting fever, the investigation has to be repeated within a few days, 
preferably supported by a bronchoalveolar lavage and additional assays such as screening for 
the presence of galactomannan in the blood.121 Even in adequately responding patients the 
CT-scan will usually show some enhancement of the lesion when the neutrophils return with, 
eventually, development of a cavitation within the infiltrate, the so-called air-crescent sign.124-126 
This finding is suggestive of aspergillosis, although mucormycosis and other agents may cause 
an identical picture. Whether the increased incidence of non Aspergillus	mould is due to more 
extensive use of new azoles like voriconazole or to the use of more immunosuppressive treatment 
schemes remains to be seen.127,128 Isolation of an Aspergillus species from sputum or bron-
choalveolar lavage specimens connotes either invasive infection or bronchial colonization, the 
latter conferring high risk for invasive aspergillosis. When voriconazole or posaconazole have 
been used as prophylaxis, it is sensible to select an antifungal compound with a different mode 
of action when therapy becomes mandatory.129,130 Surgery is indicated for patients in whom 
lesions near the pulmonary hilus pose a threat of invasion of a major vessel with the risk of 
fatal haemorrhage or for debridement of dead tissue after a period of antifungal therapy.126 
Low risk patients who test negative for Aspergillus in all diagnostic procedures do not need to 
be started on intravenous antifungals. Treatment should be stopped for those patients started 
on antifungals pending diagnostic test results. A more conservative wait-and-see approach can 
be implemented successfully once clinicians learn to accept that negative diagnostic results 
constitute sufficient evidence that there is no fungal infection in many persistently febrile 
neutropenic patients.121,123 
Fluconazole given as prophylaxis has virtually eliminated infections with Candida	 albicans. 
However, Candida species or other fungi are still occasionally identified as causes of disseminated 
infections in humans, albeit that there has been a shift from Candida	albicans	to non-albicans 
species.131,132 A candidemic patient typically presents with an irregular fever sometimes 
accompanied by polymyalgia and polyarthralgia. In about 10 percent of cases characteristic 
pinkish-purple, nontender subcutaneous nodules may arise anywhere on the body. Biopsy 
specimens should be cultured and histologically screened at multiple levels in an attempt to 
establish a final diagnosis. Candida ophthalmitis is seldom seen in leukemic patients since the 
distinctive retinal exudates are the result of an inflammatory response that involves granulocytes. 
Upon return of the neutrophils or tapering of corticosteroids, complaints of abdominal discomfort 
and elevation of alkaline phosphatase levels with or without hepatosplenomegaly may emerge. 
At this stage an abdominal ultrasound or CT-scan will display rather distinctive multiple 
abscesses in the liver and/or spleen, known as “bull’s eyes”.133,134 The mortality of an invasive 
yeast infection may be as high as 40 percent, particularly when the start of antifungal therapy 
has been postponed. Trichosporonosis and fusariosis can produce a clinical syndrome identical 
to candidemia.135-137   
55
2
Managing fever during neutropenia
BIOLOGICAL RESPONSE MODIFIERS
Up to now empirical antimicrobial therapy has been the backbone of improving survival of 
febrile neutropenia in leukemic patients. Hematopoietic growth factors have been studied as 
adjunctive therapy for febrile neutropenic patients in several randomized, controlled trials. 
Granulocyte colony stimulating factor (G-CSF; filgrastim) and granulocyte-macrophage colony-
stimulating factor (sargramostim) when used as part of the treatment of febrile neutropenic 
patients were shown to consistently shorten the duration of neutropenia defined as a neutrophil 
count below 0.5 x 109/l (500/ml). However, the duration of absolute neutropenia, i.e. count of 
less than 0.1 x 109/l (100/ml), was not influenced, which might help to explain why neither a 
decrease in infection-related mortality rates nor a significant effect on morbidity, including 
duration of fever and use of anti-infectives, were observed.138,139 Therefore, the use of growth 
factors should be restricted to complicated cases for which there appears to be no rational 
alternative therapeutic option.140-142 This concept also applies to the use of granulocyte trans-
fusions. Transfusion of high numbers of granulocytes harvested after administration of G-CSF, 
with or without dexamethasone, to a donor is done by some clinicians without there being 
unequivocal evidence of its efficacy. Patients with a profound neutropenia, not expected to 
recover before long, and an uncontrolled clinically documented infection, such as severe 
cellulitis or sinusitis, appear to be the primary candidates for treatment with granulocyte 
transfusions, whereas administration of G-CSF should be favored when a return of the neutrophils 
is imminent.22 Significant toxicities in granulocyte-transfusion recipients include transmission 
of cytomegalovirus, alloimmunisation associated with fever, graft-versus-host reactions if 
granulocytes are not irradiated, progressive platelet refractoriness, and, possibly, respiratory 
insufficiency associated with concomitant administration of amphotericin B. While granulocyte 
transfusion therapy remains an experimental therapeutic intervention, it is clear that appropriate 
transfusion of thrombocyte- and erythrocyte-suspensions to prevent overt hemorrhage and 
hypoxemia or heart failure, respectively, offer an important contribution in the battle against 
infectious complications that occur during the treatment of patients suffering from acute 
leukaemia.22 New approaches with agents designed to protect the mucosa, like recombinant 
human Interleukin 11 and keratinocyte growth factor palifermin, show promising results in 
terms of reduction of severity of MBI and occurrence of fever and bacteraemia in neutropenic 
patients.143-145  
CESSATION OF ANTIMICROBIAL THERAPY
ANTIBACTERIAL THERAPY
It is widely believed that antibiotic treatment should be continued for a minimum of 7 days or 
until culture results indicate that the causative organism has been eradicated, infection at all 
sites has resolved, and the patient is free of major signs and symptoms. Ideally, the neutrophil 
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count should be >500 mm3 (0.5 x 109/l) before treatment is stopped.111,146 When no infection 
has been identified after three days of treatment and the patient has become afebrile for 48 
hours in association with a neutrophil count that has exceeded 500 cells/mm3 (0.5 x 109/l), 
antibiotic therapy may be stopped.22 In addition, if a persistently neutropenic patient has no 
complaints and displays no clinical, radiological, or laboratory evidence of infection, cessation 
of antibiotic therapy or a change to oral antimicrobials should be considered after 4 days 
without symptoms. If antibiotics are discontinued while the patient is still neutropenic, the 
patients must be monitored closely and intravenous antibiotics restarted immediately on the 
recurrence of fever or any other evidence of bacterial infection, since infection may have only 
been suppressed, not eradicated. One should consider continuous administration of antibiotics 
throughout the neutropenic period in patients who have a profound neutropenia, MBI, or any 
other identified risk factor. Some experts suggest, in patients in whom hematological recovery 
cannot be anticipated, a change from the therapeutic regimen to one of the prophylactic 
schemes after 2 weeks of therapy with intravenous antimicrobials.22 When the suspicion of 
a non-infectious cause of the fever is high, interruption of the antibiotic therapy after ~4 days 
seems warranted in clinically well patients without any evidence of infection apart from per-
sisting fever. Under these conditions, meticulous monitoring has to be maintained to guarantee 
the patients timely protection against subsequent infections that are likely to occur.
ANTIFUNGAL THERAPY
The decision to start antifungals may appear complex but is not as difficult as the decision to 
discontinue. If a systemic fungal infection has been identified, the course of antifungal therapy 
will be determined by the causative agent and the extent of the disease. In patients with 
pulmonary infiltrates or other suspicious lesions it is essential to see a clinical and, preferably, 
a radiological response before one may start to ponder cessation of antifungal therapy. However, 
if no fungal infection is found it is not clear how long antifungal drugs should be administered.147 
For clinically well patients with prolonged neutropenia, it is suggested that antifungal agents 
can be stopped after two weeks of treatment, provided that no conspicuous lesions can be 
found by clinical evaluation or by CT-scanning of the chest and the abdominal organs. In the 
patient who appears ill or is at high risk, continuation of antifungal therapy throughout the 
neutropenic episode is recommended.22 Conversely, when neutropenic fever subsides, the 
patient is clinically well, and CT-scan of the abdomen and chest reveals no suspicious lesions, 
antifungals may be discontinued, particularly when the criterion for commencing antifungal 
therapy had been simply fever unresponsive to antibiotics. This approach also applies when 
the presumptive diagnosis becomes questionable during the course of granulocytopenia. 
When a patient diagnosed with and treated for a proven or probable invasive fungal disease 
requires further chemotherapy or a bone marrow transplantation, protection against the 
offending pathogen has to be provided, irrespective of the previous response to antifungal 
therapy. The risk of relapse of invasive fungal disease is so high that secondary prophylaxis is 
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warranted, thereby ensuring that a full dose of the most effective antifungal is administered.148,149 
After introduction of routine CT scanning it became apparent that solitary lesions caused by 
invasive fungal disease are utterly rare and this observation reduced the enthusiasm for surgical 
interventions. However, if the number of lesions is limited or a difficult-to-treat pathogen, 
such as a zygomycosis, has been found, extirpation has to be considered, especially when the 
lesions are located close to a large vessel.150   
CONCLUSION
Modern chemotherapy offers hope of a cure to many cancer patients, but it confronts the 
medical community with continuous new challenges. Infection remains an inevitable side-effect 
of the myeloablative therapy for acute leukemia and is the principal cause of morbidity and 
mortality amongst these patients. Optimal care can be delivered only by those who pay scru-
pulous attention to the patient’s clinical condition and are aware of the evolving therapeutic 
and diagnostic modalities. It cannot be denied that time remains an important factor in the 
management of infectious complications but we must try to distinguish more accurately between 
patients truly in need of immediate therapy and those who are not. Fixed treatment algorithms 
are only acceptable if they allow individual interpretation and reasoned deviations. Maintaining 
guidelines that dictate second line treatment of a population of which more than half of patients 
do not have serious disease is not justifiable in view of the potential adverse events and the 
economical burden. The demand for an alternative strategy, build on clinical skills, modern and 
more accurate laboratory tests and imaging techniques, has become apparent and a broad 
application of this principle may change the scene of antimicrobial treatment in neutropenic 
patients completely. Overuse of antimicrobial agents, both antibacterial and antifungal, has 
become all too common in the belief that a broader cover will benefit the patient. Unfortu-
nately, prescription of antimicrobials according to a preset scheme may give a false feeling of 
confidence with a reduced ambition to make a diagnosis, whereas diagnostic considerations 
should prevail whenever patients do not respond satisfactorily to an antibacterial regimen. In 
addition, neutropenia cannot longer be seen as the major compass to steer antimicrobial 
therapy in a febrile patient because neutropenia is not the one and only factor predisposing 
for infection. A damaged mucosa and impairment of the T cell-mediated immunity have 
altered the pattern of causative micro-organisms. This change has not only consequences for 
the selection of the antimicrobial agents but may also foster development of totally different 
treatment modalities such as biological response modifiers that might reduce the need for 
antimicrobial agents. Undoubtedly, unwarranted widespread use of antibiotics has contributed 
to the development of resistance amongst the micro-organisms. Resistance of previously suscep-
tible pathogens to drugs like penicillins, cephalosporins, glycopeptides, fluoroquinolones and 
azoles has become all too familiar, but the threat of diminished susceptibility casts an even 
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longer shadow in the direction of macrolides, carbapenems and quinolones with an extended 
spectrum of activity. Prophylactic or empiric use of antimicrobial agents is not recommended 
to make the physician’s life easy but to help the patients most at risk to survive a difficult episode. 
In this context it is crucial for doctors always to be sceptical about what they are doing whereas 
they should be very sure about what they are going to do next.
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ABSTRACT
 
Hematopoietic stem cell transplantation (HSCT) is highly effective for treating hematological 
malignancies, and other disorders. However, preparation for HSCT is often complicated by 
mucosal barrier injury (MBI). MBI involves the entire digestive tract and plays an important 
role in post-transplant complications, including inflammatory and infectious complications, 
malnutrition and the occurrence of graft-versus-host disease. 
This review shows that the amino acid citrulline is a reliable biomarker of MBI and can be 
measured by a simple and relatively inexpensive blood test. Its use enables standardized 
assessment of MBI which improves the management of MBI- related complications. Classifying 
the gastrointestinal MBI induced by conditioning regimens by measuring citrulline can help 
to determine the need for antimicrobial therapy, total parental nutrition, hospital admission 
and the use of preventive and therapeutic anti-inflammatory therapies for a certain regimen. 
Furthermore citrulline can be used for exploring ways to ameliorate MBI. 
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INTRODUCTION
In recent years it has become increasingly clear that mucosal barrier injury (MBI) following 
reduced-intensity (RIC) and myeloablative (MA) conditioning to prepare for a hematopoietic 
stem cell transplant (HSCT) plays an important role in the occurrence of transplant-related 
complications.1-3 Virtually every patient who receives MA therapy for a HSCT develops MBI 
and the incidence for RIC regimens is approximately 40-50%.4,5 Oral mucositis (OM) is the 
clinical manifestation of MBI affecting the oral cavity and has been singled out as the worst 
complication of this type of conditioning.6 OM is characterized by pain, oedema, erythema, 
the formation of painful oral lesions as well as dryness and the production of viscous mucus. 
However, MBI is not restricted to the mouth but affects the entire alimentary tract and is 
characterised by nausea, vomiting, reduced appetite and watery diarrhoea, any of which can 
have an important impact on the short-term quality of life. Moreover, in extreme cases, abdomi-
nal pain can herald neutropenic enterocolitis. However these signs and symptoms can also be 
associated with other complications including infection. MBI can only be considered the true 
aetiology once other causes have been excluded. 
MBI may reduce the chance of survival of patients with cancer as a consequence of postponing 
or reducing the dose of chemotherapy. It can result in transplant-related complications including 
malabsorption, fever and bacteraemia making necessary the use of antimicrobial agents, 
nutritional support and analgesics.3  MBI also has negative consequences for health economics 
being associated with longer hospital stay, higher hospital charges, and an increase in the 
100- day mortality.2
Nevertheless, MBI has been largely ignored and is regarded as an inevitable complication that 
patients just have to “grin and bear” as there were no reliable remedies. Besides, MBI eventually 
resolves spontaneously. Yet, early identification and monitoring of MBI can have important 
implications. This article sets out to explore how monitoring of the amino acid citrulline can 
help determine the presence and the course of MBI so as to improve the management of 
HSCT recipients. 
 
MUCOSAL BARRIER INJURY
1. PATHOGENESIS 
MBI of the gastrointestinal (GI) tract induced by RIC and MA regimens to prepare for a HSCT 
is a complex pathobiological process. The current hypothesis for the development of MBI 
involves five overlapping phases7: initiation phase in which nuclear factor-kappa B (NF-kB) is 
activated directly by the given conditioning regimen and indirectly from formation of reactive 
oxygen species, DNA, and non-DNA damage8; the up-regulation and message generation 
phase in which NF-kB leads to the release of cytokines and chemokines (IL-1β, IL-6, IL-8, 
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TNFα, IL-23, interferon-gamma (IFNγ)) by tissue macrophages, dendritic cells, and release of 
danger-associated molecular patterns (DAMPS) and the secretion of matrix metalloproteinases 
is stimulated9,10; an amplification and signalling phase of these cytokines leading to epithelial 
cell apoptosis and increased mucosal permeability11; an ulcerative phase with translocation 
of microbes or pathogen-associated molecular pattern (PAMPS)12-14 and finally a healing phase 
in which the damage is restored. Although this model was developed for oral MBI it is most 
likely also applicable for intestinal MBI.15-16 Furthermore it is suggested that the deregulation 
of the microbial homeostasis upon conditioning treatment could influence all the phases of 
this mucositis model.17
The induction of MBI of the GI tract appears central to the pathogenesis that leads to un-
restrained inflammation resulting from excessive release of pro-inflammatory cytokines in HSCT 
recipients. MBI is associated with fever and other inflammatory and infectious complications 
such as non-cardiogenic pulmonary oedema, idiopathic pneumonia syndrome, engraftment 
syndrome, graft-versus-host disease (GvHD), sepsis and acute lung injury (Figure 1).18
Figure 1. Mucosal barrier injury and inflammatory and infectious complications
post-HSCT
Chemotherapy and radiotherapy damage the oral and GI mucosa initiating an  
inflammatory cascade that culminates in mucosal barrier injury (MBI). Activation of 
NF-kB, release of DAMPS and increased mucosal permeability resulting in the trans-
location of PAMPS which activate PRR-pathways ultimately result in uncontrolled 
mucosal inflammation and de-regulated host-microbial interactions. This becomes 
manifest as SIRS (fever) and contributes to the occurrence of inflammatory and  
infectious complications including non-cardiogenic pulmonary oedema, idiopathic 
pneumonia syndrome, engraftment syndrome, acute GI-GvHD, septic shock and 
acute lung injury. 
Abbreviations: NF-kB = Nuclear factor kappa beta, ROS = reactive oxygen species, MMP = matrix 
metalloproteinases, DAMP = danger-associated molecular pattern, PAMP = pathogen-associated 
molecular pattern, PRR = pathogen recognition receptor, SIRS = systemic inflammatory response 
 syndrome, GvHD = graft-versus-host disease.
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The pathology of MBI involves increased apoptosis located in crypts, followed by hypoplastic 
villous atrophy and loss of enterocyte height (Figure 2).10,18,19  However endoscopic examination 
with biopsy is seldom undertaken on a routine basis. Scoring the severity of MBI is therefore 
based on signs and symptoms, permeability tests or markers.  
Figure 2. Histological findings of mucosal barrier injury  
         Normal mucosa                MBI
 
This figure shows the jejunum of Winstor rats that were injected with methotrexate (MTX, 60 mg/kg  
intravenously) (right panels) and NaCl 0.9 % intravenously (controls, left panels). Upper pictures show 
morphology by hematoxylin and eosin (H&E) staining, bottom pictures show goblet cell distribution by 
alcian blue staining. 
MTX-treated rats demonstrate histological signs of mucositis, with profound villous atrophy and blunting 
with irregular sometimes even vacuolized enterocytes. Furthermore an influx of inflammatory cells 
into the stroma of villi is seen (see arrows, right upper picture). In the controls (bottom picture on the 
left) goblet cells (for the production of mucus) were evenly distributed along the crypt-villous axis. 
Whereas, on the contrary, in MTX-treated rats goblet cells were restricted along the villi or solely present 
on villous loops (bottom picture on the right) (photograph courtesy of M. Fijlstra).19
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2. METHODS FOR MEASURING MBI
2.1	 Signs	and	symptoms	
Most assessment scales for MBI are focused on OM, since it is relatively easy to recognise. The 
World Health Organization and the National Cancer Institute- Common Terminology Criteria for 
Adverse Event (NCI-CTCAE) scales are commonly used.20-21 These scoring systems combine 
objective signs of OM (erythema and ulcer formation) with subjective and functional outcomes 
(pain and ability to eat). Their reliability is dependent on inter- and intra- observer variation 
which can be improved by training.22  
Intestinal MBI presents a quite different challenge as it cannot be seen. The signs and symptoms 
such as nausea, vomiting, diarrhoea and abdominal cramps affect almost every HSCT recipient 
at some time during the immediate post-transplant period. Furthermore these symptoms are 
non-specific and can be caused or influenced by the given conditioning, infections as well as 
other medications like opioids.
2.2	 Permeability	tests
Since the principal features of intestinal MBI are loss of epithelial surface and change in 
permeability, functional tests have been used to gain an impression of the severity and course 
of the mucosal damage.23 The permeability of 51Cr-labeled ethylenediaminetetracetic acid (51Cr-
EDTA) can be tested and will increase shortly after the start of conditioning. Unfortunately, 
51Cr-EDTA is radioactive and therefore not suitable for routine use.24 Sugar permeability  tests 
show an increase of absorption two days after starting intensive chemotherapy probably as 
a result of local inflammation.25 The peak of gut permeability has been shown to occur 
10-14 days after starting intensive chemotherapy.25,26  No real difference could be found in 
the overall pattern of perturbed gut integrity and the absorptive capacity of patients given 
various myeloablative regimens.
Nevertheless, sugar permeability tests can determine the onset of disruption and dysfunction of 
the mucosal barrier of the small intestine.25  Although sugar permeability tests are non-invasive, 
they are cumbersome and wholly dependent on patient compliance. Furthermore both 51Cr-
EDTA and sugar permeability tests are influenced by extraneous factors such as bowel transit 
time, gastric emptying and renal function.
2.3	 Biomarkers
The most common markers that have been investigated to study MBI are: albumin, intestinal 
fatty acid binding protein and citrulline.
2.3.1	 Albumin
Albumin will decrease over time after starting conditioning and is often used by clinicians as 
an indicator of MBI.27  A recent study of Van der Velden et	al. showed that albumin levels are 
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greatly influenced by inflammation confirming it to be a “negative acute phase protein”. After 
MA treatment, albumin levels followed the course of inflammation induced by GI damage. 
A decrease in albumin levels was seen also on day 6 after starting conditioning that included 
anti-thymocyte globulin (ATG) reflecting the cytokine release induced by ATG. These dynamic 
changes in albumin levels are mostly a result of decreased albumin synthesis in the liver and 
an extra-vascular shift (capillary leakage) and not caused by malnutrition as albumin has an 
estimated half-life of 20 days. Consequently albumin is not a suitable marker of intestinal 
MBI.28  
2.3.2	 Intestinal	fatty	acid	binding	protein
The plasma concentration of intestinal fatty acid binding protein (I-FABP) has been shown 
to be a highly specific and sensitive method for assessing the extent of mucosal injury.29,30 
I-FABP is a low molecular weight (12-15 kDa) intracellular protein that is only found in the 
epithelial cells of the intestinal mucosal layer.30,31  It is released as soon as the cell membrane 
integrity is compromised so is not normally found in plasma. FABPs bind and transport fatty 
acids and protect the cell against their undesirable effects.32  An increase in plasma I-FABP is 
seen after chemotherapy and precedes intestinal complaints. This rise is followed by a rapid 
decline. Tissue expression of I-FABP is relatively low and more sensitive immunoassays need to 
be developed to fully exploit the potential of this marker and also to establish proper reference 
values for healthy subjects. Furthermore, a study that looked for the best longitudinal functional 
markers of the small intestine of piglets after weaning showed marked variability in I-FAPB 
values.33   
2.3.3	 Citrulline
Citrulline is an amino acid that can be measured in the blood. The amino acid is produced 
predominately by the gut enterocytes and is not a substrate for metabolism but rather functions 
as a transporter of nitrogen for the kidney where it is converted to arginine (Figure 3).34 This 
gives citrulline the very useful property of indicating the loss of functional small bowel epithelial 
cells i.e. the enterocytes. Hence, citrulline has the potential of being a dependable instrument 
to measure intestinal MBI.35 
3. CITRULLINE
3.1	 Historical	perspective	
A century ago, Koga and Odake isolated an amino acid from the juice of watermelon (Citrullus	
vulgaris)36 and in 1930, Wada defined the chemical formula and structure and named the 
amino acid citrulline.37  Two years later, Krebs and Heinseleit reported citrullines’ importance 
as intermediate in the formation of urea in the liver.38  However it was almost 70 years before 
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citrulline found a role in the clinic when Crenn et	al. identified it as a marker for enterocyte 
mass and intestinal failure in humans.39
In 2004, Blijlevens et	al. showed citrulline to be a potential  marker for intestinal epithelial 
damage following myeloablative conditioning therapy.35  Lutgens et	al. showed that citrulline 
is more sensitive and more specific for measuring small bowel enterocyte loss than sugar 
permeability tests.40
Figure 3. The interorgan exchanges of citrulline (ARG/GLN-CIT-ARG cycle).
Citrulline is produced in the intestine mainly from glutamine. It is then released in the systemic circula-
tion, i.e. the caval vein. No other site, but the intestine has been identified so far that releases significant 
amounts of citrulline under physiological conditions. Citrulline is extracted by the kidneys from the blood 
and used to synthesize arginine. 
Abbreviations: ARG= arginine, ORN= ornithine, CIT= citrulline, GLU= glutamate, GLN=glutamine, 
ARGase= arginase, GLNase= glutaminase, OCT=ornithine carbamoyl transferase, OAT=ornithine 
aminotransferase, P5Cs= pyrroline-5-carboxylate synthase, ASS= argininosuccinate synthetase, 
ASL= argininosuccinate lyase.
3.2	 Biology
An important distinguishing characteristic of citrulline is the fact that it is not incorporated into 
proteins. Hence circulating citrulline in the blood depends almost entirely on de	novo	synthesis.41 
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Daily ingestion of 6 cups of watermelon juice, a rich source of citrulline, for three weeks 
showed no significant changes in fasting citrulline levels. In normal subjects there is no signif-
icant effect of protein intake on plasma citrulline 3 hours after a protein meal.42   
Moreover citrulline is almost exclusively synthesized and released in the circulation by the 
proximal small bowel (duodenum and jejunum) most likely from the middle and upper parts of 
the villi.43 Glutamine is the main precursor of citrulline and accounts for 80% of the production.44 
Arginine and certain other amino acids such as proline also contribute to the intestinal 
production of citrulline.45 After it is released into the bloodstream, citrulline passes through 
the liver virtually unchanged since hepatic metabolism is neglible except under certain patho-
logical conditions such as liver metastasis. Furthermore there is no significant influence on 
circulating citrulline by systemic or intestinal inflammation.43,46 Being a small molecule, citrulline 
is easily filtered by the renal glomerulus and subsequently reabsorbed and metabolized in the 
proximal tubule. Approximately 83% of the citrulline released by the gut is metabolized by cells 
of the proximal tubules of the nephron and converted into arginine, which is then converted 
to nitrogen (Figure 3).47
Consequently, the concentration of circulating citrulline depends only on the production and 
release of citrulline by the enterocytes mass and on renal excretion. Individuals with normal 
intestinal mucosal function and normal renal function given a Western diet have citrulline 
levels between 30 and 50 μmol/L with a median of 40 μmol/L, as determined by ion-exchange 
chromatography.43 An increase in citrulline levels is seen in kidney failure and severe renal failure 
is characterized by hypercitrullinaemia.48   
 
3.3	 Function	
Citrulline measured in serum or plasma can therefore act as a potential marker for the mass of 
viable or metabolically active enterocytes, with lower values reflecting an impaired enterocyte 
function. Theoretically, increased utilization could lead to lower values though this has never 
been described. Importantly, the concentration of circulating citrulline does not indicate an 
specific aetiology but is solely a marker of intestinal damage.34,39,46,49-53  Crenn et	al. showed that 
citrulline levels correlate with the severity and extent of villous atrophy disease by comparing 
plasma citrulline concentrations with the anatomical enterocyte mass estimated from small 
bowel length and villous height of patients with coeliac disease and other causes of small 
bowel villous atrophy. A citrulline level < 10 μmol/L is associated with total villous atrophy and 
defines hypocitrullinaemia. Citrulline levels of 10-20 μmol/L are predictive only of proximal 
villous atrophy with a citrulline level > 20 μmol/L indicating partial villous atrophy.34 In patients 
with small bowel syndrome, plasma citrulline is correlated with the length of the residual 
small bowel. Citrulline concentrations are consistent with small bowel absorption capacity.51  
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Table 1. Function of citrulline as marker of enterocyte mass in several patient populations
CITRULLINE 
THRESHOLD 
(ΜICROMOL/L)
PATIENT POPULATION SIGNIFICATION OF 
< 10
Pts with villous atrophy disease Total villous atrophy32
HSCT recipients, first 30 days Increased risk of bacteraemia61
HSCT recipients, > 30+ days 
post- allogeneic transplantation
Increased risk of GI aGVHD75,76
Pts with HIV disease Indication for parenteral nutrition47
< 11 Pts with short bowel syndrome Indication for parenteral nutrition67
> 11
Pts with HIV disease Weaning off parenteral support / Indication for 
enteral support47, 67
Pts with short bowel syndrome
< 13
Recipients of intestinal transplant, 
three months ago
Graft rejection or severe infection50
≥ 13
Recipients of intestinal transplant, 
three months ago
No moderate or severe rejection50
10-20 Pts with villous atrophy disease Proximal only total or subtotal villous atrophy32
< 20
Pts with short bowel syndrome, 
past the 2-year adaptive period
Permanent chronic  intestinal failure39
> 20
Pts with villous atrophy disease Partial villous atrophy32
Pts with short bowel syndrome, 
past the 2-year adaptive period
Transient  chronic  intestinal failure39
Abbreviations: Pts= patients, HSCT= hematopoietic stem cell transplantation, GI GvHD= gastro-intestinal 
graft versus host disease, HIV= human immunodeficiency virus.
Furthermore during follow-up after small bowel transplantation, citrulline levels were shown 
to be a potent indicator of acute cellular rejection.52,53  Regular monitoring of serum samples 
during the pre-and postoperative period after intestinal allograft has now become common 
practice (Table 1). 
3.4	 Measurement
Citrulline can be determined in the blood by methods based on high pressure liquid chroma-
tography either using an ion exchange column or a reversed phase column.54,55 These methods 
have been compared in the past and the results of these studies have been established the 
equivalence of these methods.56 Furthermore, there is no significant difference in results 
or interpretation between analytical methods using serum or plasma for determination of 
citrulline.43 A fast and rapid method for measuring plasma citrulline was recently reported 
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using ultra-performance liquid chromatography tandem mass- spectrometry.57  Citrulline con-
centrations can be determined in as little as 10 microL of plasma or serum within 30 minutes 
of receipt of the sample and at least 12 assays per hour can be determined. Postal transport 
to the laboratory is also feasible as citrulline is stable in plasma and serum for at least 2 days at 
room temperature. A single measurement of citrulline is sufficient and timing is not important 
as levels do not change much during the course of the day for HSCT recipients as they tend 
not to eat and are sustained by parenteral nutrition.  Each assay costs as little as 20 euro per 
sample. 
There are two citrulline-based assessment scores. One is based on the level of citrulline using 
severity thresholds, and the second on the area under the reciprocal (10/citrulline (μmol/l)) 
curve. Both scores are able to discriminate between damage induced by different conditioning 
regimens. The score based on the area under the reciprocal curve of citrulline requires only 
a few measurements to estimate the score, but is probably only appropriate for research 
purposes. For clinical purposes, a scoring system based on absolute citrulline concentrations 
is more practical for determining intestinal MBI.58
4. CITRULLINE AS BIOMARKER FOR MBI FOLLOWING CONDITIONING FOR  
  HSCT 
Citrulline levels decrease in proportion with the damage to the mucosa following conditioning 
treatment. Monitoring citrulline helps to understand the process of MBI in relation to post-
transplant complications so that certain complications can be anticipated and, if necessary, 
appropriate changes in management can be arranged.
4.1	 Defining	the	course	of	MBI	following	conditioning	
A rapid decline in circulating citrulline is seen soon after the start of conditioning therapy, 
which first reaches a nadir, after which there is a gradual increase back to normal levels.33 
Citrulline does not appear to be influenced by inflammation in adults or children.28,59,60 By 
using citrulline, it is possible to discriminate between the severity and duration of intestinal 
MBI induced by different conditioning regimens.3 MA regimens are associated with severe and 
prolonged intestinal damage shown by a rapid decline in citrulline to < 10 μmol/L a mean of 
10 days after starting chemotherapy with hypocitrullinaemia usually lasting for a week or so. 
By contrast, there is an early but short decline in citrulline levels following non- myeloablative 
(NMA) conditioning though few patients develop hypocitrullinaemia.3,61
5.  ROLE OF MONITORING CITRULLINE TO GUIDE THE APPROACH REGARDING  
  MBI-RELATED POST-TRANSPLANT COMPLICATIONS 
5.1	 Risk	prediction	for	fever	and	infections	
MBI has been shown to be the main determinant of fever and inflammation in HSCT recipients.3 
This means that some HSCT recipients develop fever simply as manifestation of MBI-related 
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inflammation and not infection. The term “febrile mucositis” has been proposed to distinguish 
this from “febrile neutropenia”.62 Indeed, bacteraemia appears to develop as a result of severe 
damage to the intestine, i.e. during hypocitrullinaemia.61,63 MBI probably allows bacteria to 
easily translocate from the gut lumen into the blood due to the villous atrophy that occurs. The 
bacteraemia that occurs can, in some cases, result in fulminant sepsis. Indeed, studies of Costa 
et	al. and Ruescher et	al. confirmed that bacteraemia in HSCT recipients typically originates 
from the gut.64,65 MBI therefore represents a breach in the first line of defence but, since it 
occurs simultaneous with neutropenia, the second line of defence consisting of phagocytic 
cells is no longer able to prevent translocation or dissemination.66,67
Citrulline levels are able to distinguish between the MBI induced by different conditioning 
regimens.3 This allows the period of increased risk for inflammatory and infectious problems 
to be predicted as it coincides with the occurrence of severe intestinal damage.3,61 For MA 
conditioning, the period of high risk for infections can be expected to begin around 10 days 
after the start of the conditioning regimen which would be a signal to start taking extra measures 
such as more intensive monitoring of vital signs including body temperature to help recognise 
complications early (Figure 4, Table 2). Currently, such intensive controls are usually started as 
soon as neutropenia starts or even earlier. With a relative short period of hypocitrullinaemia 
the burden on nursing personnel would be less releasing them for other tasks. Furthermore, 
better planning of the HSCT could ensure that the period of greatest risk does not occur during 
the weekend. Hence, simply knowing that infectious problems are most likely to occur during 
the week makes managing HSCT recipient outside the hospital feasible and safe provided it is 
accompanied by regular outpatient visits. HSCT recipients will also be less exposed to other 
risk associated with weekends such as limited access to supportive facilities. 
The expected risk of developing inflammatory and infectious problems for patients receiving 
a NMA regimen is much lower than in those treated with MA treatment and few patients do 
develop bacteraemia.61 Hence there is even less reason to keep them in hospital during the 
immediate post-transplant phase.
Since fever could be the result either of bacteraemia or local infection or MBI inflammation 
empirical treatment with parenteral antimicrobial therapy should still be instituted though it 
cannot be predicted who will benefit and who will not. However, if fever can be shown to be 
related solely to MBI inflammation rather than infection, currently considered fever of uncertain 
origin, simply switching or adding antimicrobial agents would be futile and should be discour-
aged. Instead, every attempt should be made to diagnose or exclude microbiologically and 
clinically defined infections. Further therapy could then be directed by the findings whether 
they confirm or exclude an infectious aetiology.62
Incorporating citrulline into the standard of care for managing fever and infections could reduce 
the work-load for nursing personnel, hospital admissions, the length of stay, and overuse of 
antimicrobial treatment thereby lowering the risk of emerging antimicrobial resistance.58,61,63 
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Figure 4. Course of citrulline reflecting intestinal MBI & its relationship with neutro-
penia, inflammation, bacteraemia and nutritional support in a myeloablative regimen
Citrulline concentrations rapidly decline after the given MA regimen, reflecting intestinal MBI. A nadir is 
reached, which is followed by a gradually increase back to normal levels. There is a striking pattern of 
inflammation (shown by the course of CRP) that in time correlates with the occurrence of intestinal 
MBI. Fever (>80%) and bacteraemia (30-50%) coincide with the presence of severe intestinal MBI,  
designated by hypocitrullinaemia (citrulline values below 10 μmol/L).3 Neutropenia (ANC ≤ 0.5 x 109/L) 
is reached prior to hypocitrullinaemia, and the period of neutropenia is also longer than the period of 
hypocitrullinaemia. However no major impact of neutropenia has been seen on occurrence of fever 
and  bacteraemia in former studies.3,61 In patients who are not eating, the choice of nutritional support 
can be determined by the course of citrulline. Parenteral nutrition should especially be given to  
patients that receive a myeloablative regimen that induce a long duration of hypocitrullinaemia.68  
Citrulline above a certain level will allow weaning off parenteral nutrition.69  
Abbreviations: EN= enteral nutrition, PN= parenteral nutrition.
Table 2. Clinical advice based on citrulline thresholds in HSCT recipients during the first 30 
days after transplant 
CITRULLINE 
THRESHOLD 
(ΜICROMOL/L)
CLINICAL RECOMMENDATIONS
< 10
Indication for:
• (Prophylactic) antimicrobials 
• Switch from oral to i.v. administration of several drugs, including quinolones 
• Parenteral nutritional support
• Increased monitoring of vital controls
• Administration of drugs that ameliorate MBI, if available
>10
Possible indication for: 
• Weaning off parenteral nutrition 
• Starting enteral support 
• Outpatient treatment
0 5 10 15 20
Days after start of chemotherapy 
Neutrophils Citrulline CRP
Fever & Bacteraemia 
Citrulline 
decreases due to 
intestinal 
damage 
          EN                  TPN   EN choice of nutritional support 
Citrulline < 10 μmol/L   Neutropenia 
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5.2	 Guidance	of	nutritional	intervention	
Patients that receive a HSCT often need nutritional support. Whereas low dose enteral nutrition 
is better for the trophic effects, more calories can be given by total parenteral nutrition (TPN). 
MBI is likely to be the main determinant for choosing not only nutritional support (because 
the complaints that are caused induce anorexia) but also how it is given. TPN is still the only 
option when there is severe malfunction of the gut, GI-fistulae or prolonged ileus14 but patients 
will benefit more from enteral support once intestinal reconstitution occurs.68 Measuring 
citrulline could be valuable to determine the best approach regarding nutritional support as 
it has shown to be consistent with small bowel absorption capacity.39 It is also conceivable 
that patients receiving MA regimens might benefit most from TPN as the chemotherapy they 
are given induces a protracted period of hypocitrullinaemia. Patients can be weaned off 
parenteral nutrition once citrulline attains a certain level. For instance, for patients with HIV none 
with a plasma citrulline concentration < 10 μmol/L could be weaned of parenteral nutrition.49 
By contrast, a study among children with short bowel syndrome weaning off parenteral nutrition 
was possible above a level of 11 μmol/L (Table 1).69 
Moreover, TPN is probably only necessary for a limited time after MA conditioning (Figure 4, 
Table 2). Patients given NMA regimens probably benefit more from enteral nutrition. Studies are 
eagerly awaited in HSCT recipients to investigate this more thoroughly.  If citrulline levels are 
able to guide the best approach for nutritional support this will most likely lead to a reduction 
of TPN use as well as thrombosis and catheter related infections. 
 
5.3	 Guidance	on	the	route	of	administration	of	drugs,	including	antimicrobials
Intestinal damage due to MBI can affect the absorption, resorption or excretion of medication 
although this is generally overlooked. Intestinal metabolic enzymes, such as cytochrome P 450 
(Cyp3A), are abundant in the intestinal epithelium present. Damage to the GI mucosa could 
therefore influence the bioavailability of certain medications positive or negatively depending 
on the uptake mechanisms and intracellular distribution. Citrulline levels could be useful in 
determining the best route for administering medication during the different stages of MBI in 
order to obtain the optimal effect. For example, the small intestine is the site of absorption of 
the quinolones which are given orally as antimicrobial prophylaxis in HSCT recipients. In 
healthy subjects the oral bioavailability of ciprofloxacin and ofloxacin is, respectively, 55-85% 
and almost 100%.70 However malabsorption will occur when there is mucosal damage leading 
to a significant lower exposure (Table 2).71,72
Hence, administration of quinolones should change from the oral to the intravenous route 
once a certain threshold of citrulline levels is attained in order to maintain therapeutic drug 
levels, which deserves further investigation.
5.4	 Role	of	citrulline	in	graft-versus-host	disease	of	the	gastrointestinal	tract		
GvHD is frequently seen after allogeneic HSCT suggesting another role for biomarkers of gut 
damage. Acute GvHD is a leading cause of non-relapse mortality and morbidity following 
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allogeneic HSCT and primarily affects the skin, liver and GI tract. Acute GvHD results from 
an allo-immune response directed at host antigens and is accompanied by the activation of 
alloreactive T-lymphocytes that attack the host tissues. MBI following conditioning plays an 
important role in the initiation phase of acute GvHD.73-75 The incidence of acute GvHD ranges 
from 35-80%, and is highly dependent on the intensity of conditioning, the donor type, HLA 
match, and graft characteristics.73 GI GvHD affects approximately 30-50% of cases with GvHD 
but is often clinically indistinguishable from other causes of GI dysfunction such as conditioning 
regimen-related toxicity, infection and drug side effects, as they all can present with diarrhoea. 
The diagnosis of GvHD relies on the production of profuse diarrhoea together with specific 
histology of gut tissue obtained by biopsy in the absence of infections such as Clostridium	 
difficile and cytomegalovirus. The severity of acute GvHD is graded clinically from I-IV using a 
standardized system that evaluates three principal target organs, with increased mortality 
rates in severe acute GvHD (grade III-IV).76 GI-GvHD is graded on the volume of diarrhoea, 
but scoring diarrhoea is difficult, cumbersome and unpleasant. Moreover, stool volume can 
be affected by many factors including oral intake, the use of opioids and concomitant infection. 
Consequently, several studies have focused on the use of biomarkers to detect, grade and 
predict the outcome of acute GvHD. 
Measuring citrulline before engraftment might predict those who are at risk for GI-GvHD 
since MBI following conditioning is a predisposing factor. Indeed, Van der Velden et	al. showed 
that profound hypocitrullinaemia following allogeneic HSCT is correlated with the occurrence 
of acute GI GvHD.3 In this study none of the patients treated with a NMA conditioning regi-
men developed severe acute GvHD unlike 6-10% following MA therapy who developed the 
complication early suggesting citrulline could be used to predict it. Low citrulline levels have 
also been observed in paediatric patients suffering from GI-GvHD. Vokurka et	 al. reported 
significantly low citrulline levels among a group of patients considered as suffering from 
GI-GvHD 43-142 days post-transplant.77 Merlin et	al. evaluated citrulline as a marker for acute 
GI-GvHD in 31 children undergoing an allogeneic HSCT of whom 19 had been diagnosed with 
GvHD, seven with GI symptoms. Hypocitrullinaemia one month or longer after the start of 
conditioning therapy correlated strongly with the occurrence of acute GI-GvHD (Table 1). 
Furthermore, citrulline levels increased in 3 of the 7 cases with acute GI-GvHD after initiating 
GvHD therapy but before the clinical symptoms improved.78 A study of Gosselin et	al. showed 
significantly lower citrulline levels in subjects with acute GI-GvHD. It is also possible that 
citrulline may be a preclinical marker of GvHD since the nadir in citrulline concentration 
(median day 10) preceded the diagnosis of acute GvHD (median day 19).79 This suggests that 
citrulline can be used as an early marker for the response of GvHD. Furthermore, no increase 
in citrulline levels after the start of GvHD treatment could be a sign of refractory GvHD. 
However, further studies are needed to explore this and assess the value of citrulline monitoring 
compared to other markers including albumin and Regenerating Islet-derived Protein 3-alpha 
(REG-3α). 
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6. ROLE OF CITRULLINE IN GASTROINTESTINAL INFECTIONS
HSCT recipients can develop GI infections caused by bacteria (e.g. Clostridium	difficile), viruses 
and less frequently, protozoa and parasites.  Citrulline levels may also prove a general indicator 
of intestinal mucosal dysfunction when these GI infections induce severe damage to the mucosa. 
Intestinal transplant rejection was established by measuring citrulline and viral enteritis has 
been shown to affect citrulline levels too.52 This should provide an impetus for study among 
HSCT recipients with mucosal damage due to other transplant-related complications. 
7. ROLE OF CITRULLINE IN THE INVESTIGATION OF STRATEGIES TO 
  AMELIORATE MUCOSAL BARRIER INJURY 
Unfortunately there are few remedies available to ameliorate MBI. Palifermin was shown to 
have some effect on OM in patients treated with a TBI containing regimen, but the effect on 
intestinal MBI was not clear.80,81 The use of growth factors to stimulate intestinal stem cells, 
e.g. R-spondin-1, IL-22 and glucagon-like peptide that are now being considered as potential 
tests for acute GI-GvHD could be of interest for managing MBI, as could modulations in the gut 
microbiota.82-84,85 Guidelines for managing intestinal MBI already suggest that treatment with 
probiotics containing Lactobacillus species may have a protective effect against chemotherapy-
and radiotherapy induced diarrhoea in patients with pelvic malignancies.86 Another approach 
might be to exploit pathways that enable tissue repair and resolution of the inflammatory 
process, by using anti-inflammatory cytokines (such as interleukin 10), or cytokines inhibitors 
(such as IL-1Ra), or scavengers that neutralize the effects of PAMPs and DAMPs (like anti-HMGB-1), 
or by correcting deficiencies in antimicrobial peptides (e.g. lactoferrin and defensins).87-90 A 
citrulline-based score could be used as an objective biomarker to evaluate the effect of these 
potentially useful strategies to prevent or treat MBI.58  
FUTURE DIRECTIONS
Citrulline is a valuable biomarker of intestinal MBI in HSCT recipients and allows for a stan-
dardized assessment of MBI. This can support the management of MBI-related complications. 
Citrulline levels can also be used to guide clinical decisions since the severity and duration of 
MBI plays an important role in the need for antimicrobial therapy and nutritional support in 
HSCT recipients as well as determining the optimal route for administering medication. 
Citrulline may also have a role in measuring the intestinal damage associated with GI-GvHD 
and in monitoring the response to treatment thereby allowing timely adjustments in the case 
of failure. Furthermore, citrulline can be used to explore remedies to ameliorate MBI. 
Future studies are needed to determine the specific thresholds of citrulline levels at which 
certain actions should be taken or the course of actions changed. GI infections should be 
investigated in relations to citrulline levels. Clearly, formal studies are necessary to evaluate 
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whether actions based on the severity of MBI really do lead to the expected improvements in 
the management of HSCT recipients in terms of reduced morbidity and mortality, better quality 
of life and lower health care costs.  
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 ABSTRACT
INTRODUCTION
Currently, objective tests are lacking that enable the extent and duration of intestinal 
mucosal injury (MBI) induced by myeloablative (MA) chemotherapy to be determined. To 
address this problem we explored a citrulline-based assessment score as this amino acid is a 
simple quantitative marker of intestinal failure.
PATIENTS AND METHODS
From March 2004 to June 2007 citrulline concentrations were determined at baseline and at 
least once weekly after start of MA chemotherapy until 30 days thereafter among 94 allogeneic 
or autologous hematopoietic stem cell transplant recipients. The patients were divided into 
three groups according to the regimen they received: (1) BEAM/HDM, (2) Cyclo-TBI+-ATG and 
(3) idarubicin-containing regimens. Intestinal MBI was described either by level of citrulline 
on each day, based on different thresholds of citrulline indicating the severity of villous atrophy, 
and by AUC using reciprocal value of 10/citrulline.
RESULTS
Regimens that incorporated idarubicin induced the most severe intestinal toxicity. Scores based 
on level of citrulline, using severity thresholds and on the area under the reciprocal curve are able 
to discriminate between the damage induced by different high-dose chemotherapy regimens. 
CONCLUSION
A citrulline-based assessment score appears objective, validated, reproducible, reliable, specific 
and sensitive making it a suitable first choice for measuring and monitoring intestinal MBI.
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INTRODUCTION
Mucositis, also called mucosal barrier injury (MBI) is a common adverse effect of myeloablative 
chemotherapy or radiotherapy used to prepare patients for a hematopoietic stem-cell transplant 
(HSCT).1 Patients describe oral MBI as the most debilitating complaint though the entire 
alimentary tract is affected. Clinical consequences of MBI include dehydration, malnutrition, 
potentially life threatening infections and possibly even increased mortality.2 MBI can have a 
direct impact on morbidity-prolonged hospital stay, increased antibiotic usage and the need 
for parental nutrition, and is a serious economic burden.3
Consequently, early detection, assessment and monitoring of mucosal damage is necessary 
for effective management. Therefore ideally we should have a scoring system that is objective, 
validated, reproducible, reliable (without inter- and intra-observer variation), sensitive and 
precise, and requires minimal training as set out by the Multinational Association of Supportive 
Care in Cancer and the International Society for Oral Oncology (MASCC/ISOO).4
Most assessment scales for mucosal damage are focused on oral MBI, since it is easy to recog-
nize. Both the WHO scale and the NCI/CTCAE (National cancer institute/ common terminology 
criteria for adverse event) version 3.0 scale are commonly used.5,6 These combine objective 
signs of mucositis (erythaema and ulcer formation) with subjective and functional outcomes 
(pain and the ability to eat).  Their reliability is dependent on inter- and intra-observer variation, 
which can be improved by training.7 
Intestinal MBI presents a different challenge as it cannot be seen or readily detected. Endoscopy 
with or without biopsy is often precluded because of the high likelihood for bleeding complications 
as MBI develops contemporaneously with bone marrow aplasia, so patients are also profoundly 
thrombocytopenic.8 Certain non-invasive tests such as the sugar permeability tests can detect 
alterations in permeability due to loss of the epithelial surface, but are cumbersome, wholly 
dependent on patient compliance and cannot distinguish between mucosal damage induced 
by different myeloablative regimens.9 The CNI/CTCAE version 3.0 scale is considered the best 
scale for intestinal MBI10 and is based on signs and symptoms related to gastrointestinal (GI) 
changes, including nausea, vomiting and diarrhea.5 However this scale suffers from several 
drawbacks that include a lack of reliability and validation, as the signs and symptoms are 
influenced by the use of antiemetics and opioids for analgesia, which induce constipation. 
Furthermore, the score is neither specific nor objective. 
Consequently, the lack of a diagnostic tool to measure intestinal MBI impedes good clinical 
management and hampers the development of clinical studies. We and others have explored 
using the amino acid citrulline as it can be determined in blood and has been shown to be a 
reliable and objective biochemical marker of small bowel enterocyte mass.11-16  Injury to the 
small intestine after high-dose chemotherapy is characterised by crypt apoptosis, hypoplastic 
villous atrophy and loss of enterocytes, and can be measured by the decline in circulating 
citrulline with low concentrations corresponding with severe intestinal damage.12,17  In patients 
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with small bowel disease and recipients of an intestinal transplant citrulline provides an in-
dication of global function and a useful nutritional prognosis.18  We therefore undertook an 
observational audit to explore an assessment scale for intestinal mucosal barrier damage based 
on the levels of circulating citrulline that had been measured in patients who had received a 
T-cell depleted allogeneic HSCT or an autologous HSCT to treat a hematological malignancy.
PATIENTS AND METHODS
PATIENTS
Between March 2004 and June 2007 a cohort of 94 patients participated. 51 patients had received 
a T-cell depleted allogeneic HSCT (including 20 recipients of a matched unrelated donor (MUD) 
transplant) and 43 patients who had received an autologous HSCT.
The myeloablative (MA) regimens consisted of high dose melphalan (HDM), carmustine, etopo-
side, cytarabine and melphalan (BEAM), cyclophosphamide, antithymocyte globulin and total 
body irradiation (Cyclo-ATG-TBI), cyclophosphamide and total body irradiation (Cyclo-TBI), 
idarubicin, cyclophosphamide and total body irradiation (Ida-Cyclo-TBI) and idarubicin, busulfan 
and cyclophosphamide (Ida-Bu-Cyclo).  On admission all transplant recipients had a central 
venous catheter inserted. Parenteral nutrition was started during conditioning. Cyclosporine 
was given to allogeneic HSCT recipients for prophylaxis against graft-versus-host disease 
(GvHD). Patients were given ondansetrone for antiemesis. Hematopoietic growth factors were 
not used. Anti-microbial prophylaxis and therapy were given according to a standard protocol 
and consisted of valaciclovir and ciprofloxacin. Agents that might ameliorate MBI were not 
given. Renal function was determined to allow for dosage adjustment of melphalan when the 
creatinine clearance was lower than 30 mL/min and to identify high concentrations of citrulline 
which increase when creatinine clearance falls below 50 mL/min.19 The glomerular filtration 
rate (GFR) was estimated thereafter from the serum creatinine using the formula of Cockcroft 
and Gault.20
CITRULLINE MEASUREMENTS 
Since the MA therapy determines the severity of MBI21, plasma was obtained at baseline i.e. 
before the start of the conditioning regimen and at least once per week after the start of the 
regimen till 30 days. Plasma was stored at –80 °C until required. Citrulline concentrations (μmol/L) 
were measured by a standard procedure for determining amino acids using high-performance 
liquid chromatography (Shimadzu©).22
DATA-ANALYSIS
The patients were divided into three groups, according to the MA regimen: (group 1) BEAM or 
HDM, (group 2) Cyclo-TBI +- ATG and (group 3) all regimens containing idarubicin. 
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Citrulline was described in two ways: 
a. by the level of citrulline on each day (mean ± SD), based on different thresholds of citrulline. 
We applied thresholds that indicate severity of villous atrophy documented in patients with 
coeliac disease, i.e. citrulline level <10 μmol/L is considered predictive of total villous atrophy, 
citrulline level 10-20 μmol/L is predictive of proximal only total or subtotal villous atrophy and 
>20 μmol/L indicating only partial villous atrophy.11 The nadir of each regimen was determined 
and the duration and frequency of a citrulline below 10 μmol/L was calculated.  
b. by the AUC using rescaled reciprocal of the citrulline value (10/citrulline) analogous to 
the analysis reported by Wardley et	al, who showed that for oral MBI MA regimens could be 
distinguished according to the area under the oral MBI curve.21
We modelled the 10/citrulline profile over the first 30 days (or until discharge if this occurred 
earlier) after the start of conditioning for each patient using linear mixed models treating the 
‘patient’ as a random factor, ‘conditioning regimen’ as a fixed factor in combination with a six 
degrees polynomial function of time. Using this modelling approach we could adequately deal 
with missing values resulting from only 3 or 4 citrulline measurements per week per patient.
One-way Analysis of Variance or the Kruskall-Wallis test was used to compare the three groups 
with respect to continuous variables. The severity of intestinal MBI was measured in each 
regimen by depth of citrulline curve (nadir), the duration of citrulline below 10 μmol/L, and 
the area under the 10/citrulline curve. In order to develop an assessment scale we sought to 
discriminate between the different regimens by using the two different approaches. A P-value 
of <0.05 was considered to indicate significance. SAS version 8.2 software (SAS, Inc. Cary, NC, 
USA) was used for statistical analysis.
RESULTS
The mean age of the 94 patients was 49 (range 17-65) years. Group 1 consisted of 40 patients 
who received an autologous HSCT. 29 patients were treated for multiple myeloma with HDM. 
11 patients were treated for non- Hodgkin’s lymphoma with BEAM. Group 2 consisted of 29 
patients who were treated with Cyclo-TBI +-ATG. 8 received a sibling donor allogeneic HSCT and 
were treated with Cyclo-TBI. 21 patients received a MUD transplant, and were treated with 
Cyclo-ATG-TBI. Group 3 contained 25 patients treated for several hematological diseases with 
Ida-Bu-Cyclo or Ida-Cyclo-TBI preceding a HSCT. Three patients in group 3 received an autologous 
HSCT and 22 patients an allogeneic HSCT. The demographic data of the HSCT recipients divided 
into the three groups, according to the MA regimen are summarized in Table 1.
There were no treatment-related deaths and every patient had a GFR above 50 ml/min, hence 
there was no need to adjust the dose of melphalan or to correct citrulline concentrations for 
renal dysfunction.
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Table 1. Demographic data of HSCT recipients treated with myeloablative regimens
Group Regimen Doses Freq. Days Type of HSCT
(Day)
M/F Disease
1
(N =40)
HDM
Melphalan
100 mg/m2 od 1, 2 Autologous,
Day 4
17/12 MM
BEAM
Carmustine
Etoposide
Cytarabine
Melphalan
300 mg/m2
100 mg/m2
100 mg/m2
140 mg/m2
od
bd
bd
od
1
2-5
2-5
6
Autologous,
Day 7
7/4 NHL
2
(N =29)
Cyclo-TBI
Cyclophosphamide
TBI
60 mg/kg
4.5 Gy
od
od
1, 2
5, 6
Allogeneic,
Day 7 
6/2 NHL/CLL (7)
MDS/AML (1)
Cyclo-ATG-TBI
Cyclophosphamide
ATG
TBI
60 mg/kg
2 mg/kg
4.5 Gy
od
od
od
1, 2
3-6
7, 8
MUD,
Day 9
16/5 NHL/CLL (6)
CML (3)
MDS/AML (9)
ALL (2)
Myelofibrosis (1)
3
(N =25)
Ida-Bu-Cyclo
Idarubicin
Busulfan
Cyclophosphamide
42 mg/m2
60 mg/kg
4.5 Gy
In 48h
od
od
1
7, 8
11, 12
Allogeneic (12) 
Autologous (2)
Day 13
12/2 CML (1)
MDS /AML (10) 
ALL (3)
Ida-Cyclo-TBI
Idarubicin
Cyclophosphamide
TBI
42 mg/m2
60 mg/kg
4.5 Gy
In 48h
od
od
1
7, 8
11,12
Allogeneic (10)
Autologous (1)
Day 13
10/1 NHL/CLL (4) 
MDS /AML (5) 
ALL (1)
M.Waldenstrom (1)
Abbreviations: ATG: anti-thymocyte globulin, Gy  = gray, TBI = total body irradiation, od = once daily; bd = two 
times daily; MM = multiple myeloma, NHL = Non-Hodgkin’s lymphoma, CLL = Chronic lymphocytic leukemia, 
MDS = myelodysplastic syndrome, AML = acute myeloid leukaemia, ALL = acute lymphocytic leukaemia.
The course of observed citrulline means in the three groups is shown in Figure 1.  Mean citrulline 
at start of the conditioning regimen for all patients was: 22.1 μmol/L ± 8.1 (mean ± SD). No 
significant differences were found at baseline between the three groups (P= 0.276). A significant 
decrease was seen in all groups immediately after the start of MA therapy, with citrulline 
reaching 10 μmol/L around day 9 (Group 1: 9.6 ± 3.2, Group 2: 8.4 ± 3.3, group 3: 9.4 ± 4.3). 
A nadir was reached respectively on day 14.4 ± 2.6 for group 1, day 15.3 ± 4.7 for group 2 (dis-
regarding the outlying mean value at day 10, based on a single observation) and day 16.5 ± 2.9 
for group 3 (with a significant difference between groups 1 and 3;  P=0.008 Mann-Whitney-U). 
All patients in group 3 had citrulline values below 10 μmol/L (reflecting total villous atrophy) 
for at least one day, compared to 88% (35 out of 40 patients) in group 1 and 84% (21 out of 
25 patients) in group 2. During the first 30 days after the start of the conditioning, patients in 
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group 3 experienced 21 ± 5 days of citrulline below 10 μmol/L in comparison to 16 ± 7 days 
for group 1 and 17 ± 7 days for group 2 (Kruskal-Wallis; P=0.005). 
Figure 1. Course of citrulline (in μmol/L) after the start of the conditioning regimen
by the level of citrulline on each day
 
Horizontal axis: day after start conditioning.
Vertical axis: observed mean citrulline values in μmol/L. Numbers refer to the groups, 1: BEAM and 
HDM,   2: Cyclo-TBI ±ATG, 3: Ida-Bu-Cyclo and Ida-Cyclo-TBI. Horizontal reference lines correspond to 
citrulline = 10 μmol/L (solid), citrulline = 20 μmol/L (dotted).
The conditioning regimens incurring the most severe intestinal MBI were those that incorporated 
idarubicin based on the course of citrulline. Group 3 had on average lower citrulline levels 
starting from day 13 compared to groups 1 and 2, and based on the AUC. The mean area under 
the modelled 10/citrulline-curve of group 3 was 44.7 (day/ μmol/L) compared to 32.8 (day/ 
μmol/L) for group 1 and 32.6 (day/ μmol/L) for group 2 (P<0.0001, one-way ANOVA; Figure 2). 
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Figure 2. Course of citrulline over 30 days from start of the conditioning regimen
depicted by average predicted values of 10/citrulline
Horizontal axis: day after start conditioning.
Vertical axis: predicted  values of 10/citrulline in 10/μmol/L. Numbers refer to groups,
1: BEAM and HDM, 2: Cyclo-TBI ± ATG,  3: Ida-Bu-Cyclo and Ida-Cyclo-TBI. Horizontal reference lines 
correspond to citrulline = 10 μmol/L (solid), citrulline=20 μmol/L (dotted). 
DISCUSSION
This observational audit shows that the course of citrulline is able to discriminate between 
different regimens. This makes a score based on citrulline more specific and sensitive than either 
the NCI-CTCAE assessment score or sugar permeability tests.5,9 Citrulline as a marker for regi-
men-induced intestinal damage is highly reproducible, showing the same course of citrulline 
for each single patient treated in a certain regimen. Furthermore citrulline is a quantitative 
and objective value, lacking inter- and intra-observer variation.12,23
Low citrulline concentrations represent intestinal failure independent of the underlying cause 
and also correlate with the clinical condition of different diseases including small bowel disease, 
villous atrophy diseases, immunodeficiency virus enteropathy or severe intestinal infectious 
disease.18 
In adult patients with short bowel syndrome a citrulline threshold of 20 μmol/L permits the 
classification into either transient (N=20) or permanent (N=37) chronic intestinal failure, with 
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92% sensitivity, 90% specificity, 95% positive and 86% negative predictive value respectively.15 
Almost the same is true for children (citrulline cut-off: 19 μmol/L).24 Circulating citrulline 
concentrations can also help evaluate the graft rejection three months after intestinal transplant, 
the sensitivity for the detection moderate or severe acute rejection was high (sensitivity of 96%; 
specificity 68,6%, negative predictive value > 99%) when a < 13 μmol/L was adopted as a cut-off.16
Thus an assessment score based on citrulline is objective, validated at least by analogy, repro-
ducible, reliable, specific and sensitive and meets the criteria proposed by MASCC and ISOO4 
better than any other scoring systems to measure intestinal MBI.  
Moreover, an assessment score can be based either on the level of citrulline or on the area 
under the curve. Both are able to discriminate between different regimens which is important 
for research and practical purposes. 
The area under the 10/citrulline is probably only appropriate for research purposes since the MA 
regimen is the main determinant of the course of intestinal MBI21, and only a few measurements 
will be necessary to estimate the AUC. This version resembles the oral mucositis assessment 
scale (OMAS) designed as a research tool for determining and following the progress of oral 
MBI.25 The OMAS measures a consensus of indicators of oral MBI severity and both the mean 
mucositis score and the extent of severe mucositis score, calculated over time either as the 
AUC or as the average of the three highest values, produce scores that are reproducible and 
responsive to change. 
For clinical purposes, a scoring system based on absolute citrulline values seems practical for 
determining intestinal MBI. The level of citrulline following MA chemotherapy may help select 
those patients who will benefit from parenteral nutrition as is the case for those with villous 
atrophy, where a citrulline level below 10 μmol/L (hypocitrullinaemia) is highly predictive for 
the need of parental nutrition whereas a level above 10 μmol/L will allow weaning off of 
parenteral nutrition.11,18 Furthermore, we have shown low citrulline concentrations to be 
associated with bacteraemia,26 which could indicate that extra measures should be taken, for 
example more intensive monitoring of vital signs and temperature registration. The duration 
of citrullinaemia below a certain threshold might also prove useful for grading the severity of 
intestinal MBI as is now the cases with grade 4 neutropenia of less than 7–10 days for which 
the course of antibiotic therapy is shorter than for those with a more protracted duration.27 
For intestinal MBI it is conceivable that parenteral nutrition should only be given to patients 
receiving regimens that induce a long duration of hypocitrullinaemia since parenteral nutrition can 
promote villous atrophy, increase intestinal permeability and enhance bacterial translocation. 
Furthermore knowledge of the expected duration of hypocitrullinaemia may help clarify when 
cytoprotective drugs are necessary and also when antimicrobial therapy should be initiated. 
An assessment-score based on circulating citrulline concentrations offers a promising approach 
to study the relationship between intestinal MBI and post-transplant complications in general 
including GvHD. Further studies are necessary to explore the predictive value of citrulline for 
individual patients and to define suitable cut-off values. It is likely, that a citrulline-based as-
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sessment-score could also be of help in the development of successful preventive interventions 
of agents such as interleukin11 and keratinocyte growth factor that ameliorate GI MBI.28,29 
Patients treated with reduced intensity regimens, those being treated for solid tumours or with 
radiotherapy may also benefit from the availability of a better tool for measuring intestinal MBI. 
CONCLUSION
Circulating citrulline concentrations are able to discriminate between the extent and duration 
of intestinal mucosal damage induced by different high dose chemotherapy regimens in the 
clinical setting. A citrulline-based assessment score should be considered the first choice for 
measuring and monitoring intestinal damage following myeloablative chemotherapy. 
 
REFERENCES 
1. Rapaport AP, Miller Watelet LF, Linder T et al. Analysis of factors that correlate with mucositis in recipients of  
autologous and allogeneic stemcell transplants. J Clin Oncol 1999; 17: 2446-2453. 
2. Sonis ST, Oster G, Fuchs H et al. Oral mucositis and the clinical and economic outcomes of haematopoetic stem 
cell transplantation. J Clin Oncol 2001; 19: 2201-2205.
3. Elting LS, Cooksley C, Chambers M et al. The burdens of cancer therapy: clinical and economic outcomes of  
chemotherapy-induced mucositis. Cancer 2003; 98: 1531-1539.
4. Sonis ST, Elting LS, Keefe D et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis,  
measurement epidemiology, and consequences for patients. Cancer 2004; 100: 1995-2025.
5. National Cancer Institute, August 2006. Common Terminology Criteria for Adverse Events Version 3.0 (v3.0).  
Cancer Therapy Evaluation Program. 
6. World Health Organization. Handbook for reporting results of cancer treatment. Vol 48. Geneva, Switzerland . 
WHO Offset Publications, 1997. 
7. Quinn B, Potting CM, Stone R et al. Guidelines for the assessment of oral mucositis in adult chemotherapy,  
radiotherapy and haematopoietic stem cell transplant patients. Eur J Cancer 2008; 44(1): 61-72.
8. Fallows G, Rubinger M, Bernstein CN. Does gastroenterology consultation change management of patients  
receiving hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 28: 289-294.  
9. Blijlevens NMA, Donnelly JP, Pauw BE. Prospective evaluation of gut mucosal barrier injury following various  
myeloablative regimens for haematopoietic stem cell transplant. Bone Marrow Transplant 2005; 35: 707-711.
10. Keefe DM. Intestinal mucositis: mechanisms and management. Curr Opin Oncol 2007; 19(4): 323-327. 
11. Crenn P, Vahedi K, Lavergne-Slove A et al. Plasma citrulline: a marker of enterocyte mass in villous atrophy- 
associated small bowel disease. Gastroenterology 2003; 124: 1210-1219.
12. Blijlevens NMA, Lutgens LCHW, Schattenberg AVMB, Donnelly JP. Citrulline: a potentially simple quantitative marker 
of intestinal epithelial damage following myeloablative therapy. Bone Marrow Transplant 2004; 34(3): 193-196.
103
4
Citrulline based assessment score
13. Lutgens LC, Deutz NE, Geuelette J et al. Citrulline: a physiologic marker enabling quantification and monitoring  
of epithelial radiation-induced small bowel damage. Int J Radiat Oncol Biol Phys 2003; 57(4): 1067-1074.
14. Crenn P, De Truchis P, Neveux N et al. Plama citrulline is a biomarker of enterocyte mass and an indicator of parental 
nutrition in HIV-infected patients. Am J Clin Nutr 2009; 90: 587-594.
15. Crenn P, Coudray-Lucas C, Thuillier F et al. Postabsorptive plasma citrulline concentration is a marker of absorptive 
enterocyte mass and intestinal failure in humans. Gastroenterology 2000; 119(6): 1496-1505.
16. David AI, Selvaggi G, Ruiz P et al. Blood citrulline level is an exclusionary marker for significant acute rejection after 
intestinal transplantation. Transplantation 2007; 84(9): 1077-1081.
17. Keefe D, Brealey J, Goland G, Cummins A. Chemotherapy for cancer causes apoptosis that precedes hypoplasia 
in crypts of the small intestine in humans. Gut 2000; 47(5): 632-637.
18. Crenn P, Messing B, Cynober L. Citrulline as a biomarker of intestinal failure due to enterocyte mass reduction. 
Clin Nutr 2008; 27(3): 328-339.
19. Ceballos I, Chauveau P, Guerin V et al. Early alterations of plasma free amino acids in chronic renal failure. Clin 
Chim Acta 1990; 188: 101-108. 
20. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
21. Wardley AM, Jayson GC, Swindell R et al. Prospective evaluation of oral mucositis in patients receiving  
myeloablative conditioning regimens and haematopoietic progenitor rescue. Br J Haematol 2000; 110: 292-299.
22. Van Eijk HM, Rooyakkers DR, Deutz NE. Rapid routine determination of amino acids in plasma by high-performance 
liquid chromatography with a 2-3 microns Spherisorb ODS II column. J Chromatograph 1993; 620: 143-148.
23. Lutgens LC, Blijlevens NM, Deutz NE et al. Monitoring myeloablative therapy-induced small bowel toxicity by serum 
citrulline concentration: a comparison with sugar permeability tests. Cancer 2005; 103: 191-199.
24. Rhoads JM, Plunkett E, Galanko J et al. Serum citrulline levels correlate with enteral tolerance and bowel length 
in infants with short bowel syndrome. J Pediatr 2005; 146(4): 542-547. 
25. Sonis ST, Eilers JP, Epstein JB et al. Validation of a new scoring system for the assessment of clinical trial research 
of oral mucositis induced by radiotherapy or chemotherapy. Cancer 1999; 85(10): 2103-2113.
26. Herbers AH, Blijlevens NM, Donnelly JP, de Witte TJ. Bacteraemia coincides with low citrulline concentrations  
after high-dose melphalan in autologous HSCT recipients. Bone Marrow Transplant 2008; 42(5): 345-349.
27. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia. Risks, consequences and new directions 
for its management. Cancer 2004; 100: 228-237.
28. Ellis M, Zwaan F, Hedstrom U et al. Recombinant human interleukin 11 and bacterial infection in patients with 
haematological malignant disease undergoing chemotherapy: a double-blind placebo-controlled randomised  
trial. Lancet 2003; 25: 275-280.
29. Spielberger R, Stiff P, Bensinger W et al. Palifermin for oral mucositis after intensive therapy for hematologic cancer. 
N Engl J Med 2004; 351: 2590-2598.
  
 
 
105
5
Citrulline versus Albumin
CHAPTER 5 
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ABSTRACT
INTRODUCTION
Intestinal mucosal barrier injury (MBI) is a common side effect of intense chemotherapy to 
prepare patients for hematopoietic stem cell transplantation (HSCT). Measuring intestinal 
damage objectively remains difficult and clinicians often rely on albumin levels as an indicator 
of intestinal MBI, but citrulline might be a more specific marker, which has in the past been 
shown to correlate with clinical signs of intestinal MBI. 
PATIENTS AND METHODS
We evaluated the course of albumin and citrulline following different conditioning regimens for 
HSCT and studied their relatedness to the subsequent inflammatory response using C-reactive 
protein. 
RESULTS 
Patterns of albumin and citrulline differed significantly between myeloablative and non-myeloab-
lative conditioning regimens. After myeloablative regimens, decreasing citrulline levels preceded 
the occurrence of inflammation unlike albumin levels, which decreased thereafter. Albumin 
levels were greatly influenced by inflammation, confirming it to be a “negative acute-phase 
protein”, whereas citrulline levels were not. 
CONCLUSION
Citrulline appeared a better biomarker of intestinal MBI than did albumin. Measuring citrulline 
might prove useful in clinical decision making, in identifying intestinal MBI, and it would also 
be of interest to see how it compares with other biomarkers in the setting of acute intestinal 
graft-versus-host disease.
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INTRODUCTION
Oral and gastrointestinal mucosal barrier injury (MBI) are common side effects of conditioning 
therapy for hematopoietic stem cell transplantation (HSCT).1,2 The degree of MBI is determined 
by the nature and intensity of the chemotherapy and is associated with adverse clinical and 
economic outcomes.3 For example, intestinal MBI results in abdominal pain and diarrhea, 
increases the risk of infection, and plays a role in graft-versus-host disease (GvHD).4
Intestinal MBI is a manifestation of tissue damage to the intestinal mucosal barrier, and several 
tools have been employed to assess and grade the extent of damage induced by cytotoxic 
therapy. These include scoring the frequency and volume of diarrhea, measuring oral caloric 
intake, determining sugar permeability and 51Cr-EDTA absorption. More recently, it has been 
shown that the concentration of citrulline in serum and plasma determines the degree of 
intestinal damage in conditions that are accompanied by intestinal failure.5-7 Citrulline concen-
trations reflect the enterocyte mass and are not influenced by the presence of inflammation.5,8 
Citrulline levels have also been shown to be an objective, reproducible, and reliable means of 
determining intestinal MBI in the setting of HSCT,9 with low citrulline levels correlated with 
the clinical scores of intestinal toxicity including diarrhea, and even seemed more reliable as stool 
volumes and frequency were influenced by oral intake and the use of drugs like opioid analge-
sics.10,11 In addition citrulline levels were related to the occurrence of bacteraemia, the post-
conditioning inflammatory response, as well as acute GvHD.11,12 Citrulline might be also useful as 
a predictor of inflammation as its decline usually precedes elevations in C-reactive protein (CRP).
However in practice, physicians tend to rely on noting the presence of diarrhea. This is not 
specific and can have several causes besides intestinal mucositis. Moreover we showed that 
citrulline and a daily gut score, that included diarrhea, corresponded well, but measuring the 
amino acid allowed better monitoring of the progress of gut dysfunction as well as its extent.10
None the less we wished to see whether serum albumin could also be used to monitor the 
toxicity resulting from chemotherapy, as this is determined routinely and is more familiar 
to clinicians. Despite its widespread use there are few reports on the clinical usefulness of 
monitoring albumin.13,14 Moreover, several factors can contribute to hypoalbuminemia of 
the HSCT recipient, including the underlying disease, nutritional status, occurrence of acute 
and chronic inflammation, as well as protein-losing enteropathy resulting from MBI. There is 
also evidence that albumin is, in fact, a “negative acute-phase protein” as low concentrations 
correlate strongly with body temperature, elevated inflammatory markers including (CRP), 
interleukin-6 and tumor necrosis factor-α and infection.15,16 Indeed serum albumin concen-
trations inform us about the general state of health and inflammatory status of HSCT recipients, 
but we wished to explore its value for assessing intestinal mucositis per	se. Consequently we 
evaluated the course of albumin and citrulline following conditioning treatment to prepare 
for a HSCT, studied their relatedness to the inflammatory response and post-conditioning 
intestinal damage, and investigated which marker is more valuable for assessing intestinal MBI.
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PATIENTS AND METHODS
STUDY POPULATION AND CONDITIONING
Forty-eight (48) patients who had received an autologous and 58 receiving an allogeneic HSCT 
were included in this analysis. Data had been collected prospectively in all these patients, 
as they had participated in supportive care trials performed at our hematology department. 
Patients had given their informed consent to the prospective collection of data and plasma 
samples for investigational use. The local ethics committee (CMO Regio Arnhem-Nijmegen) 
approved these studies. 
Demographic data and the conditioning regimens are depicted in Table 1 and 2 respectively. 
All patients had been treated according to the same protocol.12,17 All patients receiving mye-
loablative conditioning were managed with a central venous catheter. In those patients total 
parental nutrition commenced when patients had insufficient oral intake for 48 hours or 
more. Gut infections had been excluded in patients included in this analysis.
The sampling had been performed from the start of conditioning (day 1, Figure 1) until discharge. 
Due to differences in length of stay the period of sampling was different amongst conditioning 
regimen, being 18, 22, 30, 25 and 22 days for HDM, BEAM, Ida-Cyclo-TBI, Cyclo-ATG-TBI, and 
Cyclo-Flu, respectively. Because the conditioning started 12 days before HSCT in Ida-Cyclo-TBI 
conditioned patients the follow-up was considerably longer. The period of sampling ended in 
most patients at full engraftment, that is on average 14 days post-HSCT. The period did not 
include episodes with acute GvHD, which occurred later. CRP had been measured daily and 
albumin twice weekly and samples of plasma had been collected thrice weekly and stored at 
-80°C for later determination of citrulline. Planned data collections were achieved most of the 
time, with no more than 5% missing samples (CRP 93/2328 (4%), albumin 36/699 (5%), and 
citrulline 48/1054 (4.5%)).
Unfortunately, clinical data on intestinal mucositis, in this case diarrhea, were not available for 
all patients. However as mentioned earlier studies have shown citrulline levels to correlate with 
clinical gut toxicity and an even more objective and reliable marker than measuring diarrhea.10
109
5
Citrulline versus Albumin
 
 
 
Table 1. Demographics characteristics of patients, stem cell transplantation and GvHD 
for each conditioning regimen
Conditioning 
regimen
HDM 
(N=30)
BEAM 
(N=18)
Ida-Cyclo-TBI 
(N=21)
Cyclo-ATG-
TBI (N=26)
Cyclo-Flu 
Age, mean (range), years 53 (35-64) 49 (21-65) 46 (18-64) 44 (22-58) 54 (39-65)
Gender: M/F 35/21 16/2 12/9 18/8 9/2
Diagnoses
- MM
- NHL/CLL
- AML
- ALL
- MDS
- CML/MPD
30 (100%)
-
-
-
-
-
-
18 (100%)
-
-
-
-
-
4 (19%)
11 (52%)  
2 (10%) 
4 (19%)
-
11 (42%)
7 (27%)
2 (8%)
3 (11.5%)
3 (11.5%)
11 (100%)
-
-
-
-
-
Type of conditioning MA MA MA MA NMA
Type of HSCT Autologous Autologous Matched sibling 
allogeneic
Matched 
unrelated 
allogeneic
Matched sibling 
allogeneic
aGvHD, N (%)1 
- Grade 1-4
- Grade 2-4
NA NA 10 (48%)
7 (33%)
9 (35%)
7 (27%)
5 (45%)
3 (27%)
Onset GvHD from day of 
HSCT, mean (95%CI)
NA NA 28 (19-36) 46 (29-63) 40 (21-61)
Abbreviations: AML/ALL = acute myeloid and lymphatic leukemia, CLL = chronic lymphatic leukemia, 
CML/MPD = chronic myeloid leukemia/myeloproliferative disease, aGvHD = acute graft-versus-host disease, 
MA = myeloablative, MDS = myelodysplastic syndrome, MM = multiple myeloma, NMA = non-myeloablative, 
NHL = non-Hodgkin lymphoma, NA= not applicable.
Table 2. Conditioning regimen used for the preparation of autologous and allogeneic HSCT 
Regimen Doses Freq. Days Type of 
conditioning
Type of HSCT, day
HDM (N=30)
Melphalan 100 mg/m2 od 1, 2
MA Autologous, day 4
BEAM (N=18)
Carmustine 
Etoposide
Cytarabine
Melphalan
300 mg/m2
100 mg/m2
100 mg/m2
140 mg/m2
od
bd
bd
od
1
2-5
2-5
6
MA Autologous, day 7
Ida-Cyclo-TBI (N=21)
Idarubicine
Cyclophosphamide
TBI
42 mg/m2
60 mg/kg
4.5 Gy
In 48h
od
od
1
7, 8
11, 12
MA Allogeneic 
Matched related donor, day 13
Cyclo-ATG-TBI (N=26)
Cyclophosphamide
Thymoglobuline
TBI
60 mg/kg
2 mg/kg
4.5 Gy
od
od
od
1, 2
3-6
7, 8
MA Allogeneic 
Matched unrelated donor, day 9
Cyclo-Flu (N=11)
Cyclophosphamide
Fludarabine
1200 mg/m2
30 mg/m2
od
od
1-4
1-4
NMA Allogeneic 
Matched related donor, day 7
Abbreviations: ATG = anti-thymocyte globulin, Gy = gray, od = once daily, bd = two times daily, MA = myeloablative, 
NMA = non-myeloablative, TBI = total body irradiation
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CRP, ALBUMIN AND CITRULLINE 
Hypoalbuminemia was defined according the CTC version 3.0 criteria by any concentration 
below 30 g/L. CRP concentrations ≥ 50 mg/L were considered a significant rise from baseline 
(normal value < 5 mg/L).18 CRP was chosen over cytokines as measurements are rapid, cheap, 
and easy, and CRP levels are correlates with pro-inflammatory cytokines such as IL-6 and IL-8. 
The time course of events was related to the start of conditioning therapy, designated day 1.
Citrulline concentrations were determined by a standard procedure for determining amino-acids 
using HPLC with mass-spectometry detection.12 Citrulline levels below 10 μmol/L were deemed 
to indicate hypocitrullinemia, and regarded as reflecting severe intestinal MBI.5 
STATISTICAL ANALYSIS
We graphically described the development over time of three outcome measures (citrulline, 
CRP, and albumin) in four conditioning regimen groups (HDM and BEAM were analyzed together). 
We calculated for each day the mean of the observed values and showed the course over time 
of these means by connecting the values with straight line segments. 
Missing values were dealt with by using all data points and applying the Loess smoother with 
smoothing parameter of 30%.19 At each point in the dataset a straight line was fitted to a subset 
of the data consisting of the 30% nearest neighbors with respect to the time axis. This regression 
line was fitted using weighted least squares giving more weight to points near the point being 
estimated and less weight to points further away. The value of the regression function for the 
point was then obtained by evaluating the local regression line using the value of time after 
transplant for that data point. The fit was complete after regression function values had been 
computed for all data-points. 
We defined three types of events; citrulline < 10 µmol/L, CRP ≥ 50 mg/L, and albumin ≤ 30 g/L, and 
distinguished between six possible patterns of first occurrences of these events. We evaluated 
the differences in distribution of patterns between four conditioning regimen groups using 
Fisher’s exact test or, if needed, a Monte-Carlo approximation using 10,000 samples.
RESULTS AND DISCUSSION
TIME COURSE OF ALBUMIN AND CITRULLINE AFTER MYELOABLATIVE  
CONDITIONING
Sixty-nine patients received a myeloablative (MA) conditioning regimen to prepare for an 
autologous HSCT (HDM/BEAM) and matched related donor allogeneic HSCT (Ida-Cyclo-TBI). 
The pattern of citrulline, CRP and albumin is shown in Figure 1A and B. Early after the start of 
conditioning there was a rapid decline in citrulline concentrations which reached a level below 
10 μmol/L on day 10. This converged with the start of a systemic inflammatory response 
shown by a rise in CRP concentrations starting around day 10-11 reaching 50 mg/L by day 12. 
Consequently, the decline in citrulline preceded the inflammatory response, indicating that GI 
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damage induces the inflammatory response seen after conditioning.12 The course of albumin 
levels was different with the gradual descent lagging behind that of citrulline (Figure 1A and B) 
reaching levels of ≤ 30 g/L on day 13, hence 3 days after the nadir of citrulline had been reached 
and after the inflammatory response had commenced. This suggests that hypoalbuminemia 
did not precede but rather followed the occurrence of inflammation induced by GI damage. 
 
Figure 1. Citrulline, CRP and albumin values of the different conditioning regimen
A = HDM and BEAM, B = Ida-Cyclo-TBI, C = Cyclo-ATG-TBI, D = Cyclo-Flu. Days from the start of condi-
tioning. Black lines = observed mean values, Red lines = loess smoothed means. Thresholds depicted in 
the figure are 10 μmol/L, 50 gr/L, and 30 gr/L for citrulline, CRP, and albumin, respectively.
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TIME COURSE OF ALBUMIN AND CITRULLINE AFTER MYELOABLATIVE  
CONDITIONING CONTAINING ANTI-THYMOCYTE GLOBULIN 
The course of events was different for the group of 21 patients who had received ATG in their 
MA-regimen for a matched unrelated donor (MUD) HSCT. The course of citrulline was similar, 
but now albumin levels declined with levels approaching 30 gr/L already on day 6 (Figure 1C). 
This coincided with an inflammatory response (day 3) resulting from cytokine-release induced 
by ATG which resulted in the development of fever in most patients.20 Hereafter the decline 
in albumin halted and levels remained rather constant until day 12, following which, there 
was a progressive decline as seen in the other MA regimens coinciding with the inflammation 
resulting from intestinal damage producing a second peak of CRP  from day 11-12 (Figure 1C).
TIME COURSE OF ALBUMIN AND CITRULLINE AFTER NON-MYELOABLATIVE 
CONDITIONING 
Only 11 patients had received a non-myeloablative (NMA) regimen. Nevertheless less damage 
was expected as the chemotherapy was less mucotoxic and was reflected in a limited and 
short-lived decline in citrulline levels with only a few patients experiencing hypocitrullinaemia. 
There was no inflammation attributed to intestinal damage. An early modest rise in CRP in 
some cases coincided with the administration of chemotherapy and the second rise in CRP 
was mostly late occurring during engraftment reaching modest levels below 50 mg/L.12 Four 
patients had a significant rise above 50 mg/L; two during engraftment, one due to a thrombo-
phlebitis and another due to pneumonia. The decline in albumin levels was less pronounced 
although most patients reached levels below 30 g/L, but in contrast with what was seen for 
MA regimens, this did not occur simultaneously with a rise in CRP (Figure 1D).
ALBUMIN AND CITRULLINE LEVELS ARE NOT EQUAL AS BIOMARKERS OF  
INTESTINAL MBI
Additional statistical analysis confirmed the observed differences in the pattern of post- 
conditioning events amongst the groups (Figure 1, Monte Carlo approximation of Fisher exact 
test, P <0.0001). There was no difference in patterns of events between groups A and B (P = 
0.42), but there were differences in pattern between C and A/B , D and A/B, and C and D  (with P 
values based on Fisher exacts tests: <0.0001, 0.006, and 0.003, respectively). These differences 
are further illustrated graphically in Figure 2. Following HDM/BEAM and Ida-Cyclo-TBI, citrulline 
levels declined before or at the time CRP levels became elevated and albumin levels declined 
thereafter. Following ATG-Cyclo-TBI, a regimen considered equally mucotoxic, the course of 
albumin but not citrulline was very different. The first peak in CRP levels preceded a decline 
in albumin levels, which was then followed by a second peak in CRP levels that coincided with 
the development of hypocitrullinaemia and a further decline in albumin levels. Following Cyclo-
Flu the attenuated GI damage precluded the marked hypocitrullinaemia and the corresponding 
inflammation in most cases. Albumin levels did not correspond to citrulline levels as these 
were already rising whilst albumin levels were decreasing. Also the relationship between the 
occurrence of hypoalbuminemia and inflammation was less clear.
5Citrulline versus Albumin
Figure 2. Comparison of regression lines of citrulline, CRP and albumin amongst the 
conditioning regimen groups
A = HDM and BEAM, B = Ida-Cyclo-TBI, C = Cyclo-ATG-TBI, D = Cyclo-Flu. The course of citrulline, C-re-
active protein and albumin differed statistically amongst the different conditioning regimens (P < 0.01)
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Hence it seems fair to conclude that albumin and citrulline levels are not equal with regard to 
measuring intestinal MBI. Citrulline follows a distinctive course that is clearly different for MA 
and NMA regimens which is almost certainly due to the mucotoxicity induced. The variation 
in citrulline concentrations was also less and the course of levels more consistent than was 
found for albumin. Moreover citrulline can be considered a more reliable marker of intestinal 
damage because it is a very specific biomarker of enterocyte mass.5,9  By contrast, albumin levels 
appear mainly influenced by the occurrence of inflammation that resulted either from the 
host response to intestinal damage, the occurrence of infection, or to the cytokines released 
by the conditioning therapy particularly that containing ATG. The decline in albumin levels seen 
was not likely the result of malnutrition as hypoalbuminemia occurred early after the start of 
conditioning therapy when the food intake is still adequate for most patients.21 Dynamic 
changes in albumin levels are mostly due to changes in catabolic rate and extra-vascular shift 
(capillary leakage) and not to malnutrition as albumin has an estimated half-life of 20 days.21-23 
Albumin decline after day 12 might be the result of the loss of proteins from the damaged 
intestinal tract as has been suggested for GvHD, and not solely from extra-vascular shift (capillary 
leakage) seen with inflammation. Nevertheless, the decline occurred late, sometime after 
intestinal damage and the related inflammatory response had already occurred. Hence hypo-
albuminaemia following HSCT might be better regarded as a “negative acute-phase response” 
or a late sequel of intestinal MBI that comes with protein loss. Whichever is the case, citrulline 
levels appear a better biomarker of intestinal damage resulting from chemo- and radiotherapy 
than albumin. 
Since citrulline is a better biomarker of intestinal MBI, and may even be a suitable surrogate 
marker, it would be of particular interest to see how useful a biomarker it is to score and measure 
GvHD that involves the intestinal tract. Albumin has been shown to be a biomarker of  gastro-
intestinal GvHD, as it correlates with its severity24,25, but this might be confounded by the 
inflammatory response that occurs with GvHD. 
CONCLUSION
Citrulline provides a better biomarker of chemotherapy and radiotherapy-induced intestinal 
MBI, than does albumin. Determining citrulline levels might prove useful in helping decide 
whether and when therapeutic and nutritional interventions are necessary for patients treated 
with intensive chemotherapy and radiotherapy. 
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PART III
FEBRILE NEUTROPENIA 
OR 
FEBRILE MUCOSITIS?
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CHAPTER 6 
BACTERAEMIA 
COINCIDES WITH LOW 
CITRULLINE 
CONCENTRATIONS AFTER 
HIGH-DOSE MELPHALAN 
IN AUTOLOGOUS HSCT 
RECIPIENTS
AHE Herbers, NMA Blijlevens, JP Donnelly and TJM de Witte.
Bone Marrow Transplant 2008; 42(5): 345-349.
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 ABSTRACT
INTRODUCTION
Mucosal damage to the intestines induced by myeloablative (MA) conditioning for allogeneic 
hematopoietic stem cell transplantation (HSCT) can be determined by the concentration of 
citrulline, which is a functional marker of small intestinal enterocytes. Low citrulline concen-
trations in blood coincide with and are a response to severe mucosal barrier injury.  
The aim of this study was to explore the kinetics of plasma citrulline concentrations in patients 
receiving high-dose melphalan 200 mg/m2 (HDM), given in two days to prepare for an autologous 
HSCT and to determine the relationship between these levels and bacteraemia.
PATIENTS AND METHODS
Plasma samples from 29 patients were collected, starting before the MA regimen and 3 times 
per week thereafter until discharge. 
RESULTS
The average citrulline concentration at baseline was 27.6 μmol/L ± 4.0 (mean ± 95% confidence 
interval (CI) and concentrations declined rapidly thereafter reaching a nadir averaging 6.7 
μmol/L ± 2.7, 12 days after starting HDM. Citrulline concentrations, only increased gradually 
and were still low (12 μmol/L ± 4) at discharge. A total of 20 patients developed fever, which 
was associated with bacteraemia in 10 cases. Their mean citrulline concentrations were lower 
(5.5 μmol/L ± 1.5) than were those of patients without bacteraemia (10.2 μmol/L ± 3.9). 
Importantly, neither the number of preceding neutropenic days nor the mean C-reactive protein 
(CRP) concentration at the onset of fever was different between these two groups. 
CONCLUSION
Citrulline concentrations rapidly decline after HDM reflecting intestinal mucosal barrier injury. 
Low citrulline, rather than the duration of neutropenia, is associated with bacteraemia indicating 
the importance of an intact mucosal barrier in neutropenic patients.
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INTRODUCTION
Mucositis is the clinical manifestation of mucosal barrier injury (MBI) and is the most frequent 
cause of morbidity associated with  myeloablative (MA) treatment to prepare for  hematopoietic 
stem cell transplant (HSCT).1 Impaired integrity of the mucosal barrier induced by anticancer 
therapy is thought to promote translocation of micro-organisms from the lumen of the digestive 
tract to the blood stream resulting in bacteraemia.2  Whereas oral MBI is relatively easy to 
recognise, detection of intestinal mucosal injury is more demanding. Recently, it was shown that 
citrulline appeared to be particularly useful to detect intestinal damage, as blood concentrations 
of this amino acid directly reflect functioning small intestinal cell mass.3 Furthermore, low 
plasma concentrations of citrulline coincided with the MBI of the small intestine induced by 
the intensive MA therapy used to prepare for a T-cell depleted allogeneic hematopoietic stem 
cell transplant (HSCT). These levels also corresponded to the severity and extent of gut injury.4 
We explored the kinetics of citrulline concentrations in a cohort of patients treated with 200 
mg/m2 melphalan, given in two days (HDM), to prepare for an autologous HSCT. Furthermore, 
we determined the relationship of citrulline concentrations to bacteraemia, as the risk is 
known to be increased by MBI.5
PATIENTS AND METHODS
PATIENT MANAGEMENT
From May 2004 to May 2005, 29 consecutive patients (12 female; 17 male) with a mean age 
of 55 years (range 30 - 65) were admitted to undergo an autologous HSCT to treat multiple 
myeloma (MM). Each patient was managed with a triple-lumen central venous catheter (CVC) 
and received melphalan at a dose of 100 mg/m2 on days –3 and –2 before transplant. Each 
patient received parenteral nutrition from the day of transplant onwards and ondansetrone 
as an antiemetic. Anti-infective prophylaxis consisted of ciprofloxacin and valaciclovir. Flucon-
azole was given only to patients who were colonised by Candida	albicans. No hematopoietic 
growth factors or keratinocyte growth factors were used. 
DEFINING BACTERAEMIA
At the onset of fever (single axillary temperature of ≥ 38.5 °C) during neutropenia (neutrophil 
count of ≤ 0.5 x 109/l ), a single 10 ml sample of blood was obtained from each lumen of the 
central venous catheter (CVC) and inoculated into an aerobic BACTEC plus (BD Diagnostic System, 
Sparks, USA) blood culture bottle. A further two 20 ml samples of blood were drawn from 
separate peripheral veins and were each inoculated equally into a blood culture set comprising 
an aerobic and anaerobic BACTEC plus culture bottle. Ceftazidime was administered immediately 
afterwards. Bacteraemia was defined by any single blood culture yielding bacteria except for 
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coagulase-negative staphylococci (CoNS), which required the same strain to be recovered 
from two separate cultures. C-reactive protein (CRP) was measured daily until discharge using 
turbidimetric immunoassay (Aeroset©, Abbott). 
CITRULLINE ANALYSIS
Blood was collected in heparin from each patient through the CVC before starting therapy and 
on each Monday, Wednesday, and Friday thereafter until discharge. Plasma was prepared and 
stored at –80°C for later analysis. Citrulline concentrations (μmol/L) were measured by a stan-
dard procedure for determining amino acids using high-performance liquid chromatography 
(Shumadzu©).6
ORAL MBI ASSESSMENT
Oral MBI was scored daily by trained nurses who recorded the presence of pain, lesions, erythema, 
oedema, bleeding, dryness and of viscous mucus allocating a score of 0 for normal to 3 for severe.7 
The separate values were summed up to yield a daily oral mucositis score (DMS).
GASTROINTESTINAL (GI) MBI ASSESSMENT
GI MBI was determined from the frequency of vomiting and diarrhoea, the occurrence of nausea, 
abdominal complaints, faecal incontinency and the volume of diarrhoea. Each item was scored 
from 0 (normal) to 3 (severe) and the values were summed to yield the daily gut score (DGS).1 
All gut toxicities developed following chemotherapy were attributed to MBI unless there was 
a more plausible alternative cause such as an adverse drug reaction or a proven infection.
DATA ANALYSIS
SPSS for windows software (release 12.1) was used for statistical analysis. All results are 
expressed as the mean and 95% confidence interval (CI). The time course of citrulline was 
estimated from the day cytotoxic therapy was given (day 1).8 The number of days with neutro-
penia before the onset of fever was counted and the DMS, DGS, the concentrations of citrulline 
and CRP, and the absolute leukocyte and neutrophil count on that day were noted. Missing 
data were replaced with the values for the day before or after the onset of fever. A two-sided 
unpaired Student’s t-test was used to calculate significant differences with respect to baseline. 
Analysis of variance was used to test differences between and within groups. A P-value of < 0.05 
was considered statistically significant. 
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RESULTS
All patients had an estimated renal creatinine clearance above 50 ml/L at admission using the 
Cockcroft & Gault formula,9 and no adjustments were made to the dose of melphalan. None 
of the patients developed an invasive fungal disease and all survived the first 6 weeks after 
transplant. 
The average citrulline concentration (mean ± 95% CI) at baseline for all patients was 27.6 
μmol/L  ± 4.0 and concentrations declined rapidly thereafter reaching a nadir averaging 6.7 
μmol/L ± 2.7 12 days after starting HDM (on day +8 of HSCT) (Figure 1). Citrulline concentrations 
then increased gradually but were still markedly low with a mean of 12 μmol/L  ± 4 at discharge.
Figure 1. Time course of serum citrulline concentration (μmol/L)
Box-plot display of the time course of citrulline concentrations in all 29 HSCT recipients.
 
All patients became profoundly neutropenic (mean onset 8.5 ± 0.3 days after starting HDM) 
with a mean duration of neutropenia of 10.2 days ± 2.7. 20 patients (69%) developed fever 
which was accompanied by bacteraemia in 10 cases, five of which were due to a single species 
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(two Streptococcus	mitis, two Staphylococcus	epidermidis and one Staphylococcus	haemolyticus) 
and five due to two species (one case each of Streptococcus	mitis & Staphylococcus	epidermidis, 
Streptococcus	mitis & Staphylococcus	hominis, Streptococcus	mitis & Staphylococcus	capitis, 
Staphylococcus	 epidermidis & Staphylococcus	 hominis and Staphylococcus	 epidermidis & 
Staphylococcus	saprophyticus). Cultures drawn from peripheral and from central lines yielded 
the same bacteria. The mean citrulline level at onset of fever among patients with bacteraemia 
was 5.5 μmol/L ± 1.5 and was significantly lower than that of patients without bacteraemia (10.2 
μmol/L  ± 3.9) (P < 0.05). However, there was no difference in the time to onset of fever from 
neutropenia, in CRP concentrations, leukocyte counts, DGS or DMS on the day of fever between 
the groups (Table 1). Neither was a difference found between the mean baseline citrulline 
concentrations, which were, respectively, 23.0 μmol/L ± 3.5 for patients with bacteraemia 
compared with 31.3 μmol/L ± 3.4 for those without bacteraemia. 
Table 1. Mean ± 95% CI of citrulline concentrations, oral mucositis (DMS), gut toxicity 
(DGS), CRP and leukocytes on first day of fever and total neutropenic days before onset 
of fever in patients with neutropenic fever with or without bacteraemia 
On first day of fever (N=20)
(mean ± 95%CI)
Bacteraemia
present 
(N=10)
absent
(N=10)
P-value
Citrulline (μmol/L) 5.5 ± 1.5 10.2 ± 3.9 0.02
DMS 5.3 ± 1.6 6.0 ± 2.3 ns
DGS 4.3 ± 1.2 3.8 ± 1.1 ns
CRP (mg/l) 63 ± 33 56 ± 31 ns
Leucocytes  (x109/l) 0.1 ± 0.03 0.1 ± 0.03 ns
Neutropenic days before the onset of  fever 4.0 ± 1.1 3.6 ± 1.2 ns
Abbreviations: CI = confidence interval; CRP = C-reactive protein; DGS = daily gut score; DMS = daily oral 
mucositis score; ns = not significant.
 
DISCUSSION
The plasma concentrations of citrulline for all patients reached a nadir within 12 days after 
starting myeloablative therapy indicating intestinal mucosal damage, with the lowest citrulline 
concentrations coinciding with the onset of bacteraemia. Patients with bacteraemia had 
significantly lower citrulline concentrations on the first day of fever than did those without 
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bacteraemia. But there was no difference in the total days before the onset of fever after 
patients became neutropenic. This suggests that the severity of gut MBI determines whether 
bacteraemia occurs or not rather than neutropenia per	se. 
Neutropenia (granulocytes ≤ 0.5 x 109/l) has been used for 40 years to recognise those 
patients who are at imminent risk of developing infectious complications following intensive 
chemotherapy.10 This formed the foundation for developing a successful strategy for managing 
these patients, namely administering broad-spectrum antimicrobial therapy promptly as soon as 
fever occurs during neutropenia. Indeed, empirical antibacterial therapy is still the backbone 
of the supportive care given to these patients.11 However, it has become clear that MBI plays 
a distinct role in determining the outcome of HSCT.12 With mucosal damage being indicated 
by declining citrulline levels, we may be able to identify more effectively the risk period for 
developing bacteraemia in neutropenic patients. Of the 29 patients we investigated, 20 became 
febrile but only half of them developed bacteraemia and their citrulline concentrations were 
lower than those found in the other patients. Moreover, these concentrations correspond to 
diffuse total villous atrophy.3 
Interestingly, the maximum World Health Organization scale grade of oral MBI was also shown 
to occur on day 12 after starting cytostatic chemotherapy.13 In our study, neither DMS nor DGS 
were significantly different between those with and without bacteraemia, confirming that 
these instruments measure different features of digestive tract injury compared to citrulline 
concentrations.14
We also found that CRP was not useful for detecting or predicting bacteraemia as has been 
noted by others.15,16  Most likely, this is because CRP marks a response to a variety of stimuli 
other than infection and its elaboration is relatively slow. However, the time course of CRP is 
relevant. A study with rats treated with 5-fluorouracil (5-FU) showed that the release of pro-
inflammatory cytokines was associated with evolving gastrointestinal (GI) MBI and preceded 
bacterial translocation.17 Consequently, an increase in CRP levels may reflect the severity of 
GI MBI.4 
All the episodes of bacteraemia that we observed were due either to coagulase-negative 
staphylococci (CoNS) or oral viridans streptococci (OVS). This is most likely a direct consequence 
of giving ciprofloxacin as prophylaxis, which effectively prevents bacteraemia due to Gram-
negative bacilli, while giving selective advantage to the less susceptible Gram-positive bacteria.18 
The blood cultures of 5 of the 10 patients with bacteraemia yielded two bacterial species 
which might simply reflect greater sampling efficiency, as we obtained a total of 70 ml of 
blood for blood cultures, which is more than others report.19
OVS are primarily oral commensal flora; however, molecular analysis of the microbiota in the 
stomach shows these bacteria can be found in large numbers along with Helicobacter	pylori.20 
In children treated for acute myeloid leukaemia (AML), there was an association between 
the presence of GI toxicity and the development of OVS bacteraemia.21 Similarly, CoNS have 
been assumed to originate from central venous catheters. However, there is a growing body 
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of evidence that these bacteria may, in fact, also originate from the GI tract.22 Indeed, molecular 
analysis of CoNS isolated from blood cultures indicated that the mucosa was the origin in most 
of the cases.23 Moreover, bacteraemia due to these staphylococci has been shown to occur 
mostly within the first 2 weeks after transplant when gut integrity is markedly disturbed.1 
A recent study reported a threefold increase in documented infections in patients with GI MBI, 
though there was no relationship between MBI and the depth or duration of neutropenia.24 
Our results concur suggesting that MBI is an independent risk factor for the bacterial trans-
location that precedes bacteraemia. A small study of Ellis et	 al.25 showed treatment with 
recombinant human Interleukin-11 resulted in less bacteraemia and, although a protective 
effect on the mucosa was not observed, gut permeability improved. Hence, agents such as 
recombinant human Interleukin-11 and the keratinocyte growth factor palifermin,26 which 
are designed to protect the mucosa, may prove helpful in reducing bacterial infection in 
neutropenic patients. Indeed, in the recent study of palifermin, there were fewer episodes of 
bacteraemia among those given the drug than was found among those given placebo (15 
versus 25%). However the difference was not statistically significant and no details were 
provided on the aetiology of bacteraemia.
Severe disruption of the mucosal barrier is clearly not the only risk factor for developing 
bacteraemia, which affected only a third of our patients with low citrulline concentrations. To 
identify those patients at risk for bacteraemia, citrulline measurements need to be combined 
with other tests. For instance, the Multinational Association of Supportive Care of Cancer 
(MASCC) developed a risk-score to predict at the onset of fever during neutropenia which 
patients are at high risk for development of serious medical complications.27 Endothelial cells, 
like the epithelial cells of the gut, play an important part in the innate immune system in 
neutropenic patients and produce interleukin-8 when exposed to bacteria.28  Hence, perhaps 
monitoring interleukin-8 levels29,30 combined with the MASCC risk score, when patients have 
low citrulline concentrations, might help distinguish those at risk of developing bacteraemia 
from those who are not.
CONCLUSION
This study provides more evidence that the damage induced by cytostatic chemotherapy to the 
mucosa plays an important role in the morbidity and mortality after intensive chemotherapy. 
Preventing or restoring damage to the mucosa may offer a more effective means of preventing 
bacteraemia after transplant than giving antimicrobial agents. Citrulline may provide added 
utility in the diagnostic work-up of neutropenic patients to help recognise those who are at 
increased risk for developing bacteraemia.
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 ABSTRACT
INTRODUCTION 
Hematopoietic stem cell transplantation (HSCT) is still complicated by the occurrence of fever 
and inflammatory complications attributed to neutropenia and subsequent infectious complica-
tions. The role of mucosal barrier injury (MBI) of the intestinal tract therein has received little 
attention. 
PATIENTS AND METHODS
We performed a retrospective analysis in 163 HSCT recipients of which data had been collected 
prospectively on intestinal damage (citrulline), inflammation (C-reactive protein), and neutro-
phil count. Six different conditioning regimens were studied: 5 myeloablative (MA) and 1 
non-myeloablative (NMA). Linear mixed model multivariate and AUC analyses were used to 
define the role of intestinal damage in post-HSCT inflammation. We also studied the relationship 
between the degree of intestinal damage and the occurrence of early post-HSCT complications. 
RESULTS
In the 5 MA regimens there was a striking pattern of inflammatory response that coincided 
with the occurrence of severe intestinal damage. This contrasted with a modest inflammatory 
response seen in the NMA regimen in which intestinal damage was limited. With linear mixed 
model analysis the degree of intestinal damage was shown the most important determinant 
of the inflammatory response, and both neutropenia and bacteraemia had only a minor impact. 
AUC analysis revealed a strong correlation between citrulline and CRP (Pearson correlation r = 
0.96). Intestinal damage was associated with the occurrence of bacteraemia and acute lung 
injury, and influenced the kinetics of acute graft-versus-host disease. 
CONCLUSION
The degree of intestinal damage after myeloablative conditioning appeared to be the most 
important determinant of the inflammatory response following HSCT, and was associated 
with inflammatory complications. Studies should explore ways to ameliorate cytotoxic therapy-
induced intestinal damage in order to reduce complications associated with myeloablative 
conditioning therapy. 
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INTRODUCTION
Treating patients with hematological malignancies by use of hematopoietic stem cell transplan-
tation (HSCT) is still complicated by the occurrence of infectious and inflammatory complications 
including sepsis, acute lung injury, and graft-versus-host disease (GvHD). Historically the focus 
was on neutropenia and fever (“febrile neutropenia”) and its relation to infections.1 However, 
a substantial number of HSCT recipients develop fever unrelated to infection (“unexplained 
fever”),2 resulting from other causes including cytotoxic therapy-induced mucosal barrier injury 
(MBI).3,4
Many studies have shown associations between the magnitude of the C-reactive protein (CRP) 
response and cytokine release and post-HSCT complications,5-9 and these complications might 
therefore best be regarded as manifestations of a systemic inflammatory response syndrome 
(SIRS).8 Other studies have shown that infections may contribute to non-infectious complications 
including acute GvHD.10,11  However, few if any of these studies addressed the role of MBI per	
se as an isolated cause of inflammation and risk factor for infections, nor its role in the patho-
genesis of inflammatory complications. Animal models have enhanced our understanding of 
the inflammatory processes that take place in the intestine following chemotherapy,12-14 and 
in the clinical setting of HSCT the relationship between intestinal damage and the inflammatory 
response has become better appreciated.4,15 Mucosal damage and deregulated host-microbial 
interactions have also been shown to contribute to SIRS and post-HSCT complications such as 
acute GvHD.16,17 Therefore, we hypothesized that intestinal damage could be the most important 
determinant of early SIRS following conditioning with chemotherapy and radiotherapy and 
that the degree of damage correlates with the occurrence of post-HSCT complications. 
Studying damage to the gastro-intestinal (GI) tract during HSCT remains difficult, since it remains 
hidden and hitherto only indirect and non-specific tests were available.18,19  Measuring serum 
or plasma citrulline levels provides a more direct and specific way of determining intestinal 
damage of certain conditions that are accompanied by gut failure.20  Recently, citrulline-based 
assessment of intestinal damage has also shown to be objective, reproducible, specific and 
reliable in the setting of HSCT.21,22 To test our hypothesis we studied the relationship between the 
magnitude of the inflammatory response and the degree of intestinal damage as measured by 
citrulline, the duration of neutropenia, and the occurrence of bacteraemia. To achieve this we 
selected recipients of a HSCT for which 5 cohorts of patients had been given different myeloab-
lative (MA) conditioning regimens and a single cohort had received a non-myeloablative 
(NMA) conditioning regimen. We also investigated whether we could determine a relationship 
between the degree of intestinal damage and the occurrence of early post-HSCT complications.
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PATIENTS AND METHODS
STUDY POPULATION
This was a retrospective analysis of 163 patients who had received an autologous or allogeneic 
HSCT in our hospital from May 2004 to December 2007. Plasma had been collected prospec-
tively and stored for later analysis of citrulline, but other data including CRP, temperature, and 
clinical and microbiological infections had been prospectively gathered from the day of starting 
chemotherapy. Patients had given their informed consent to the prospective collection of data 
and plasma samples for investigational use. The local ethics committee (CMO Regio Arnhem-
Nijmegen) judged that no formal approval for this study was necessary regarding the fact that 
data were used anonymously and the analysis would not reveal results harming contributing 
patients.
CONDITIONING REGIMENS AND STEM CELL TRANSPLANTATION
The MA and NMA regimens are depicted in Table 1. All patients received a stem cell graft on 
the day scheduled. Autologous HSCT grafts contained at least 2.0 x 106 CD34+ cells per kg, 
and allogeneic HSCT partially T cell-depleted grafts contained on average 3.0 x 106 CD34+ cells 
per kg and 0.5 x 106 CD3+ cells per kg. 
Table 1. Conditioning regimens 
Regimen Doses Freq. Days Type of 
conditioning
Type of HSCT, day
HDM
Melphalan 100 mg/m2 od 1, 2
MA Autologous, day 4
BEAM
Carmustine (BCNU)
Etoposide
Cytarabine
Melphalan
300 mg/m2
100 mg/m2
100 mg/m2
140 mg/m2
od
bd
bd
od
1
2-5
2-5
6
MA Autologous, day 7
Ida-Cyclo-TBI
Idarubicine
Cyclophosphamide
TBI
42 mg/m2
60 mg/kg
4.5 Gy
In 48h
od
od
1
7, 8
11, 12
MA Allogeneic 
Matched related donor, day 13
Cyclo-ATG-TBI
Cyclophosphamide
Thymoglobuline
TBI
60 mg/kg
2 mg/kg
4.5 Gy
od
od
od
1, 2
3-6
7, 8
MA Allogeneic 
Matched unrelated donor, day 9
Cyclo-TBI
Cyclophosphamide
TBI
60 mg/kg
4.5 Gy
od
od
1, 2
5, 6
MA Allogeneic 
Matched related donor,
day 7
Cyclo-Flu
Cyclophosphamide
Fludarabine
1200 mg/m2
30 mg/m2
od
od
1-4
1-4
NMA Allogeneic 
Matched related donor, day 7
Abbreviations: Freq. = frequency, MA = myeloablative, NMA = non-myeloablative, od = once daily, bd = two 
times daily, TBI = total body irradiation.
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TREATMENT PROTOCOL
All patients were treated according to the same protocol, which has been described earlier.23 
GvHD prophylaxis consisted of cyclosporine only. Anti-microbial prophylaxis consisted of cipro-
floxacin and valaciclovir. Fever was defined by a single axillary temperature ≥ 38.5 °C. At the 
onset of fever 40 mL of peripheral blood was obtained for culture together with 10 mL from 
each lumen of the catheter, patients were examined for any sign of local infection, and empirical 
therapy with ceftazidime was started.24 
Neutropenia was defined as granulocytes ≤ 0.5 x 109/L, and the duration and depth was record-
ed. CRP levels (mg/L) were determined every day and the maximum CRP (CRPmax) recorded. 
Plasma citrulline was determined to estimate intestinal damage before the start of conditioning 
and 3 times weekly thereafter until discharge. Citrulline concentrations (μmol/L) were measured 
by a standard procedure for determining amino acids using high-performance liquid chromato-
graphy.21 Citrulline levels below 10 μmol/L were deemed to indicate hypocitrullinemia, and 
were regarded as reflecting severe intestinal damage.20 
DEFINITION OF STEM CELL TRANSPLANTATION COMPLICATIONS
Clinical and microbiologically defined infections were defined according to the Consensus 
definitions of Immunocompromised Host Society.2 A blood culture was considered to represent 
bacteraemia if one or more bottles yielded a microorganism, except in the case of  coagulase-
negative staphylococci (CoNS), which required recovery of the same strain from two separate 
positive blood cultures.24 The incidence of bacteraemia that occurred on the day of fever was 
documented and compared among the regimens. Invasive fungal diseases were scored according 
to the EORTC/MSG consensus guidelines.25 Acute lung injury (ALI) was defined according to 
current guidelines.26 Acute GvHD, GvHD occurring the first 100 days after HSCT, was graded 
according to the criteria of Przepiorka	et	al.27 Early mortality related to HSCT complications 
was defined as any death occurring within 30 days following HSCT (day +30), but unrelated to 
the underlying disease.
DATA ANALYSIS
We employed descriptive statistics for fever, neutrophil count, CRP levels, and citrulline levels 
which were expressed as mean values together with the 95% confidence interval (Table 2). As 
citrulline was measured three times weekly, the real nadir might have been attained between 
two measurements and hence was likely missed. 
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Table 2. General characteristics
Conditioning HDM 
(N=56)
BEAM 
(N=21)
Ida-
Cyclo-TBI 
(N=28)
Cyclo-ATG-
TBI 
(N=34)
Cyclo-TBI 
(N=10)
Cyclo-Flu 
(N=14)
Age, mean (range), 
years
56 (33-65) 47 (18-65) 46 (18-64) 43 (20-58) 50 (38-59) 54 (39-65)
Gender: M/F 35/21 17/4 13/15 21/13 8/2 10/4
Diagnoses:
MM
NHL/CLL
AML
ALL
MDS
CML/MPD
56 (100%)
-
-
-
-
-
-
21 (100%)
-
-
-
-
-
7 (25%)
12 (42.5%)
3 (10.5%)
6 (22%)
-
-
13 (38%)
8 (23.5%)
4 (11.75%)
4 (11.75%)
5 (15%)
-
8 (80%)
2 (20%)
-
-
-
14 (100%)
-
-
-
-
-
Type of conditioning MA MA MA MA MA NMA
Type of HSCT Autologous Autologous Matched 
sibling 
allogeneic
Matched 
unrelated 
allogeneic
Matched 
sibling 
allogeneic
Matched 
sibling 
allogeneic
Fever (axillary 
temperature ≥ 38.5 °C)
88.0% 90.5% 100% Early: 
73.5%
Late: 100%
100% Early: 
28.6%
Late: 78.6%
Fever, day from start 
conditioning, mean 
(95%CI)
11.8 
(11.4-12.2)
13.0 
(12.2-13.9)
12.9 
(12.2-13.6)
4.1 
(3.7-4.5)
14.1 
(13.0-15.1)
13.4
 (12.0-14.8)
3.0 
(1.7-4.3)
16.0 
(14.4-17.5)
Neutrophils ≤ 0.5 
x109/L, days (95%CI)
8.4 
(8.0-8.7)
9.5 
(8.5-10.5)
15.8 
(14.6-17.0)
15.5 
(14.6-16.4)
11.1 
(9.8-12.4)
12.4 
(10.8-14.1)
Citrulline < 10 μmol/L, 
number of patients, (%)
51 
(91%)
21 
(100%)
26 
(93%)
30 
(88%)
10 
(100%)
4 
(29%)
Measurements with 
citrulline < 10 μmol/L, 
mean (95%CI)*#
3.5 
(3.2-3.9)
4.7 
(4.0-5.3)
6.2 
(4.6-7.8)
4.8 
(4.0-5.7)
3.5 
(2.4-4.6)
3.0 
(1.1-4.9)
Observed citrulline 
nadir μmol/L, mean 
(95%CI)*
6.0 
(5.4-6.6)
4.3
(3.5-5.1)
4.6 
(3.9-5.3)
5.6 
(4.9-6.3)
5.6 
(4.2-7.0)
10.8 
(8.9-12.6)
Citrulline <10 μmol/L, 
days, mean (95%CI)&#
7.9 
(7.1-8.7)
11.2 
(9.6-12.9)
17.7 
(15.6-19.8)
14.6 
(13.3-15.9)
11.0
 (7.9-14.1)
7.5 
(5.4-9.6)
Citrulline nadir μmol/L, 
mean (95%CI)&
6.5 
(5.7-7.2)
4.9 
(3.7-6.0)
4.5 
(3.5-5.7)
7.0 
(6.1-7.9)
6.6 
(5.1-8.1)
12.4
(10.2-14.6)
CRPmax (mg/L), 
mean (95%CI)
163
(136-189)
202
(160-246)
257
(222-291)
188
(162-213)
211
(154-269)
66
(38-95)
#Only those patients included with citrulline levels below 10 μmol/L. & Based on estimated values. 
MA = myeloablative, NMA = non-myeloablative, CRP = C-reactive protein, MM = multiple myeloma, 
NHL = non-Hodgkin lymphoma, CLL = chronic lymphatic leukemia, AML/ALL = acute myeloid and lymphatic 
leukemia, MDS = myelodysplastic syndrome, CML/MPD = chronic myeloid leukemia/myeloproliferative disease.
137
7
Intestinal MBI & Inflammation
To compensate for this and study the true length of time in which citrulline levels were below 
10 μmol/L we modeled the course of citrulline as a function of time during the first 30 days by 
developing a linear mixed model using first, second, third and fourth power of time as fixed 
factors to predict the citrulline levels after taking into account the within-person correlations by 
incorporating a random patient intercept. To describe the relationship of CRP to the neutrophil 
count, intestinal damage (citrulline concentration) and bacteraemia we used several linear mixed 
models for the first 30 days with random patient effect and the logarithmic transformed CRP 
(log CRP) as the outcome variable.
To assess the impact of conditioning on intestinal damage and CRP we performed an area under 
the curve (AUC) analyses. Per patient, the CRPAUC was defined as the sum of the 30 estimated 
CRP values, resulting from a piecewise linear mixed model which uses a linear time component 
for day 1-10 and a cubic time component for day 11-30. The conditioning regimen and the 
interactions between the particular regimen and time were also part of this model that also 
accounted for within person correlations by virtue of a random intercept. Likewise, the citrul-
lineAUC per patient was defined as the sum of the 30 estimated 10/citrulline values. We used 
the citrulline levels estimated by the linear mixed model described above and transformed 
these values into 10 times the inverse of the estimated value. 
Comparisons between the impact of the different conditioning regimens on neutropenia, 
CRPAUC and citrullineAUC were studied using the Kruskal-Wallis test. The correlation between 
the degree of neutropenia and CRPAUC versus citrullineAUC and CRPAUC was studied by Pearson 
correlation over the different regimens. 
Comparison of the mean onset of acute GvHD between the different regimens was done using 
one-way ANOVA. Comparison of the incidence of ALI in relation to oral viridans streptococci 
(OVS) between the different regimens was done using the χ2-test.
Analyses were performed using SAS 8.2 and a P-value of <0.05 was considered to indicate 
statistical significance.
RESULTS 
STUDY POPULATION AND PATIENT CHARACTERISTICS
Seventy-seven (77) patients received an autologous and 86 an allogeneic HSCT (Table 2). All 
but 14 patients received MA conditioning. Autologous HSCT was performed for patients with 
multiple myeloma (MM) and non-Hodgkin lymphoma, but allogeneic HSCT was employed for 
a greater variety of diagnoses including acute and chronic lymphatic and myeloid leukemia 
and myelodysplastic syndrome. NMA conditioning was employed to prepare patients who had 
received an autologous HSCT 4-6 months earlier for MM.
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Figure 1. Course of citrulline and CRP in time after start of conditioning
Five MA and one NMA conditioning regimens are shown; A = HDM,  B = BEAM, C = Ida-Cyclo-TBI, 
D = Cyclo-ATG-TBI, E = Cyclo-TBI, F = Cyclo-Flu. Observed values (•), mean values (○).
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INTESTINAL DAMAGE
MA conditioning was associated with severe and prolonged intestinal damage shown by a rapid 
decline in citrulline to < 10 µmol/L, a mean of 10 days after starting chemotherapy. The mean 
nadir of citrulline was 4.5-7.0 µmol/L, and hypocitrullinemia lasted for more than one week in 
most patients (Figure 1A-E, 2A, Table 2). Hypocitrullinemia was most pronounced in patients 
receiving idarubicin in their conditioning, lasting approximately 18 days. In contrast, an early 
and short drop of citrulline level was noticed for NMA conditioning, but hypocitrullinemia was 
not evident for most patients (Figure 1F, 2A, Table 2).
Figure 2.  Summary of the time course of citrulline (A) and CRP (B) for all 6 regimens  
Day 1 is the day of start of conditioning. To correct for unobserved citrulline and CRP values we modeled 
the course of citrulline and CRP as described in methods.
1 = HDM, 2 = BEAM, 3 = Ida-Cyclo-TBI, 4 = Cyclo-ATG-TBI, 5 = Cyclo-TBI, 6 = Cyclo-Flu. Mean CRP in 
mg/L, mean citrullline in μmol/L.
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INFLAMMATORY RESPONSE MEASURED BY C-REACTIVE PROTEIN AND FEVER
The course of CRP during HSCT of the different conditioning regimens is illustrated in Figure 1 
and 2B. Within each type of MA conditioning, patients showed similar patterns of inflammatory 
response, although there was some variation in the precise onset, peak and resolution of CRP 
levels. Those without bacteraemia did not have a different course when compared to those 
with; although in general CRP levels were lower (data not shown). As for intestinal damage, the 
CRP response was highest in patients receiving idarubicin. Resolution of inflammation occurred 
with engraftment and restoration of the intestinal damage defined by rising citrulline levels. 
In Cyclo-ATG-TBI conditioning the first peak of CRP was related to ATG induced lymphocyte 
depletion and cytokine release, but the second peak resembled that seen for the other MA 
regimens. Also some patients treated with Cyclo-TBI and BEAM had an early peak in CRP during 
conditioning, which was probably related to chemotherapy induced cytokine release.
Only a moderate inflammatory response occurred after NMA regimen (Figure 1F and 2B). 
Also, the timing was different when compared to MA regimens with a peak occurring early 
during conditioning and a second peak much later. The latter occurred during engraftment and 
thereby resembled to some extent the inflammatory complication designated engraftment 
syndrome.28 
Virtually every patient who had received MA treatment developed fever as did 80% of those 
given NMA conditioning. Some patients receiving Cyclo-ATG-TBI and Cyclo-Flu also experienced 
an early episode with fever during conditioning (25 and 4 patients, respectively). In MA regimens 
fever occurred on days 12-14, 2-3 days after CRP had become elevated (Figure 1, Table 2). 
By contrast, fever occurred late during engraftment at a mean of day 16 after starting NMA 
conditioning.
RELATION INTESTINAL DAMAGE TO INFLAMMATION
In MA conditioning CRP levels started to increase from 10-11 days following the start of 
conditioning which coincided with the development of hypocitrullinemia (Figure 1A-E and 2). 
The peak of the inflammatory response coincided with the nadir of citrulline levels. Although 
interindividual differences existed the occurrence of inflammation was related to the devel-
opment of intestinal damage in almost every patient.
Additional AUC analysis was used to grade the impact of conditioning on intestinal damage 
and CRP. There were significant differences in both CRPAUC and citrullineAUC between the various 
conditioning regimens (Kruskal-Wallis P <0.001), except between BEAM, Cyclo-TBI, and Cyclo-
ATG-TBI. Interestingly, a very strong correlation between the degree of intestinal damage and 
the inflammatory response was seen for the different regimens (Pearson correlation 0.96, Figure 
3). By contrast, there was only a weak correlation between the duration of neutropenia and 
inflammation (Pearson correlation 0.48, Figure 3). 
 
141
7
Intestinal MBI & Inflammation
Figure 3.  Pearson correlation between mean degrees of neutropenia (NP in days) 
and inflammation (CRPAUC) vs intestinal MBI (CitrullineAUC) and inflammation over
different regimens  
1 = HDM, 2 = BEAM, 3 = Ida-Cyclo-TBI, 4 = Cyclo-ATG-TBI, 5 = Cyclo-TBI, 6 = Cyclo-Flu.
In univariate linear mixed model analysis, 10/citrulline, the type of conditioning regimen, 
neutropenia and bacteraemia were significantly associated with log CRP. In multivariable 
analyses only citrulline and type of conditioning regimen remained important. 
STEM CELL TRANSPLANTATION COMPLICATIONS
BACTERAEMIA
There was a significant difference between MA and NMA regimens regarding bacteraemia on 
the day of fever (Table 3) with up to 85% of patients experiencing bacteraemia predominantly 
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due to oral viridans streptococci (OVS) and CoNS after MA conditioning, compared with none 
of those  receiving NMA (P <0.001). OVS was recovered with CoNS in 20/55 (36%) of cases. A 
minority of patients experiencing a bacteraemia with CoNS on the day of fever had any clinical 
or radiological signs of a CVC related tunnel infection or thrombophlebitis at the same time 
(5/55 (9%)).
ACUTE LUNG INJURY (ALI)
The overall incidence of ALI was 18/163 (11%), with 14/18 (78%), being associated with OVS 
bacteraemia. Conversely, ALI affected 14/53 (26.4%) patients with OVS bacteraemia. However, 
this incidence varied significantly between conditioning regimens and was related to the 
severity of intestinal damage as ALI occurred in 3/22 (13.6%), 4/13 (30.8%) and 4/7 (57.1%) in 
patients receiving HDM, Cyclo-ATG-TBI, and Ida-Cyclo-TBI conditioning, respectively (P =0.03) 
(Table 3).
ACUTE GRAFT-VERSUS-HOST DISEASE
No differences were seen in the total incidence of acute GvHD, although there were no cases 
of acute GvHD III-IV in the group with NMA; with only skin acute GvHD being encountered. 
However, there was a significant difference in the onset of acute GvHD. In Ida-Cyclo-TBI and 
Cyclo-TBI, despite receiving a partially T-cell-depleted graft, acute GvHD occurred early with 
a mean onset on day +25 post-HSCT. In both Cyclo-ATG-TBI and Cyclo-Flu the onset was 
delayed, with a mean onset on day +46 and +40 post-HSCT, respectively (P =0.02). 
EARLY MORTALITY
Overall, early mortality was low 6/163 (3.7%), and related to ALI and acute GvHD, and all but 
one death occurred following MA conditioning for an allogeneic HSCT.
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Table 3. Hematopoietic stem cell transplantation complications
Post-HSCT complications HDM 
(N=56)
BEAM 
(N=21)
Ida-
Cyclo-TBI 
(N=28)
Cyclo-ATG-
TBI 
(N=34)
Cyclo-TBI 
(N=10)
Cyclo-Flu 
(N=14)
Bacteraemia on day of fever
OVS
CoNS
Other
29
22 (39.3%)
12 (21.4%)
2 
10
6 (28.5%)
7 (33.3%)
-
18
7 (25%)
12 (46.5%)
1 
29
13 (38%)
21 (65%)
1 
6
5 (50%)
3 (20%)
-
0
-
-
-
Concomitant OVS/CoNS 7 3 2 6 2 NA
Candidemia 1 0 3 1 0 0
Clinically defined infection
Phlebitis superficial vein
Tunnel infection/infected 
thrombosis
Pneumonia
Probable/Proven IA
5
-
1
4
-
5
-
3
2
-
9
-
5
2
1
7
-
6
-
1
3
-
1
1
1
3
1
-
2
-
ALI
ALI following OVS bact.
4/56 (7.1%)
3/22 (13.6%)
2/21 (9.5%)
1/6 (16.7%)
6/28 (21.5%)
4/7 (57.1%)
4/34 (11.8%)
4/13 (30.8%)
2/10 (20%)
2/5 (40%)
0
Early mortality (day + 30) 
ALI
Acute GvHD
0
-
-
1
1
-
2
1
1
1
-
1
2
1
1
0
-
-
aGvHD I-IV, all (N, %)
Grade II-IV
Grade III-IV
NA NA 13/28 (46%)
8 (28.5%)
2 (7%)
12/34 (28%)
7 (20.5%)
2 (6%)
6/10 (60%)
3 (30%)
1 (10%)
6/14 (43%)
4 (28.5%)
-
Onset from day HSCT, mean 
(95%CI)
NA NA 26 (16-36) 46 (29-63) 23 (19-27) 40 (19-61)
IA = invasive Aspergillosis, ALI = acute lung injury, OVS bact. = bacteraemia with oral viridans streptococci. 
Grading of acute GvHD was done according to the criteria of Przepiorka et al27 and probable/proven IA was 
defined according to EORTC/MSG consensus definitions.25
DISCUSSION
In this study we show the course and extent of intestinal damage and inflammatory responses 
following various conditioning regimens used to prepare for a HSCT. There was a striking pattern 
of inflammatory response coinciding with the occurrence of severe intestinal damage for patients 
receiving MA conditioning, defined by hypocitrullinemia.20 Moreover, the degree of intestinal 
damage seemed the most important determinant of inflammation and was highly correlated 
with the magnitude of the inflammatory response measured by CRP. Neither neutropenia nor 
bacteraemia had a major impact on this. The close relationship between intestinal damage 
and inflammation was further underscored by the fact that the NMA regimen resulted in only a 
modest inflammatory response with a completely different time course, and the virtual absence 
of severe intestinal damage. Consequently, intestinal damage appears the primary determinant 
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of inflammation following MA conditioning with chemo- and radiotherapy in the setting of 
autologous and allogeneic HSCT. 
While there are limitations associated with retrospective analysis and the potential for bias 
resulting from selection, the relationship of intestinal damage to HSCT complications was 
remarkable. As expected, there was a significant difference in occurrence of bacteraemia 
between those receiving MA and NMA conditioning.29 The similar duration of neutropenia and 
the marked difference in intestinal damage, suggest that the gut may have been the origin of 
bacteraemia.30 Moreover, most pathogens recovered from blood cultures are known residents 
of the gut.31,32  Notably, a considerable proportion of patients had bacteraemia with both 
CoNS and OVS, which was probably due to simultaneous intestinal translocation.31 
A strong relationship has been found between the occurrence of OVS bacteraemia and septic 
shock and ALI in neutropenic patients, which was explained by virulence factors and pulmonary 
cytotoxicity of chemotherapy.33-35  Interestingly, we saw that in patients with OVS bacteraemia 
the incidence of ALI was related to the degree of intestinal damage. It is known that barrier 
dysfunction facilitates bacterial translocation, but intestinal damage also seems to determine 
the resulting inflammatory response. This was confirmed in our linear mixed model, which 
showed citrulline but not bacteraemia related to the CRP response. Although ALI seems 
directly associated with OVS bacteraemia this might be only coincidental, as both complications 
are consequences of severe intestinal damage. So intestinal damage ‘primes’ the immune 
system with subsequent aggravated cytokine release following activation of pattern recognition 
receptors from translocating microbial motifs.13 
This ‘priming’ of the immune system also applies to the occurrence acute GvHD in which the role 
of intestinal damage has been acknowledged.16 Although we found no apparent differences in 
the citrulline and CRP levels between patients with and without acute GvHD within any given 
regimen, between regimens there was a clear difference in the kinetics of acute GvHD. In 
addition severe acute GvHD did not develop after NMA, as opposed to 6-10% after MA, and 
GvHD of liver or gut did not occur. The early onset of acute GvHD after Ida-Cyclo-TBI and 
Cyclo-TBI suggests that the tissue inflammation resulting from the profound intestinal damage, 
contributes to the accelerated allo-reactive T-cell response,36 even in the setting of partial T 
cell-depletion. The delay in onset of acute GvHD in patients conditioned with ATG results from 
additional in vivo T cell-depletion creating a ‘time-window’ between the intestinal damage 
induced inflammation and T cell recovery. After NMA treatment we also saw a delay in the 
onset of acute GvHD, which is in accordance with previous data from studies in mice and 
humans.37,38 This altered kinetics of acute GvHD was, at least in part, related to the absence 
of significant intestinal damage and tissue inflammation. Differences in the kinetics of acute 
GvHD in NMA regimens have been largely attributed to alterations in antigen presenting cell 
chimerism, T cell chimerism and regulatory T cell activation,37 but our data underscore the 
role conditioning-induced intestinal damage plays in the complex pathogenesis of acute GvHD.
Several studies have shown correlations between CRP and the occurrence of HSCT complications 
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but they all used different cut-off values.5,7 CRP is not a specific marker since chemotherapy 
and ATG and, the process of engraftment itself, elicit inflammatory responses. Hence it is not 
possible to identify who is at risk or when that risk might occur. Citrulline could provide an 
alternative, because it is a specific marker of enterocyte mass, which decreases only when 
there is intestinal damage. Furthermore, citrulline levels correspond with the inflammatory 
responses following MA conditioning, and more importantly with HSCT complications. Clearly 
it is necessary to confirm the predictive value of citrulline for individual patients and to define 
cut-off values more precisely. Classifying other conditioning regimens, by means of measuring 
citrulline can already help determine the need for antimicrobial prophylaxis, hospital care, 
and the use of anti-inflammatory treatment. 
Given the role of intestinal MBI in complications after HSCT studies should explore ways to 
ameliorate cytotoxic therapy-induced intestinal damage in order to reduce inflammatory 
complications associated with myeloablative conditioning therapy.
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HEMATOPOIETIC STEM 
CELL TRANSPLANT  
RECIPIENTS
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 ABSTRACT
INTRODUCTION
In the 1960s it was reported that infectious complications were the main cause of fever during 
neutropenia that followed cytotoxic treatment. More recently, mucositis, also called mucosal 
barrier injury (MBI) has become recognised as an important determinant of the inflammatory 
response and infectious complications in hematopoietic stem cell transplant (HSCT) recipients. 
PATIENTS AND METHODS
The objective of this prospective study was to determine the impact of intestinal MBI, as 
measured by plasma citrulline, and neutropenia on the systemic inflammatory response (C-
reactive protein) and the occurrence of bacteraemia among two cohorts of HSCT recipients 
one composing 18 patients who had been treated with a myeloablative (MA) regimen (High dose 
melphalan: HDM) and the other involving 19 patients who had received the non-myeloablative 
(NMA) regimen (Cyclophosphamide and Fludarabine: Cyclo-Flu). Blood cultures were obtained 
for surveillance from admission onwards as well as at the onset of fever.
RESULTS
The MA regimen induced severe intestinal MBI manifest by citrullinaemia < 10 μmol/L which was 
accompanied by an inflammatory response and bacteraemia affected 8 (44%) of 18 patients 
and coincided with the nadir of citrullinaemia.  By contrast, those who had been treated with 
the NMA regimen did not develop severe intestinal MBI, had a moderate inflammatory 
response and only 2 (11%) of the 19 patients developed bacteraemia. However, both groups 
experienced profound neutropenia and its duration was significantly longer for those receiving 
the NMA regimen.    
CONCLUSION
This study suggests that severe intestinal MBI i.e. citrullinaemia < 10 μmol/L defines the period 
of risk of bacteraemia better than does neutropenia and that measuring plasma citrulline may 
prove useful in deciding who needs empirical antimicrobial therapy and when.
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INTRODUCTION
Conditioning therapy is given to prepare for a hematopoietic stem cell transplant (HSCT) and 
can be myeloablative or not (reduced intensity).1 Myeloablation is typically achieved using 
high doses of chemotherapy with or without radiotherapy and renders the recipient vulnerable 
to infectious complications which can result in significant morbidity and mortality despite 
markedly improved supportive care.
In the 1960s it became apparent that fever was often the only sign of an infection during 
neutropenia.2 This phenomenon is now referred to as “febrile neutropenia” and has become 
recognized as one of the most important complications of chemotherapy. So much that 
prevention and treatment with antimicrobial drugs has become an established standard of 
care often augmented by the use of growth factors e.g. G-CSF.3 However, a substantial number 
of patients remain febrile without an infection ever being documented.4 This is not so surprising 
since fever is induced by cytokines, the release of which is by no means solely related to 
infections. Consequently some patients are over-treated with antibiotics increasing the risk of 
adverse effects as well as antibiotic resistance among bacteria. 
Myeloablative conditioning regimens are designed to ablate the bone marrow but they also 
cause severe damage to the mucosal barrier which manifests itself as mucositis of mouth and 
the gastrointestinal (GI) tract particularly the small intestine.5,6 The amino acid citrulline 
is produced by enterocytes and released into the bloodstream and has been shown to be a 
biomarker for intestinal mucosal barrier injury (MBI).7,8 It has also been shown that HSCT 
recipients receiving chemotherapy experienced more fever (with or without infections) in the 
presence of severe MBI9 and that intestinal MBI plays a role in the occurrence of bacteraemia.10,11
The aim of the current prospective study was to determine the impact of intestinal MBI (as 
determined by citrulline) and neutropenia on the systemic inflammatory response (as deter-
mined by C-reactive protein) and the occurrence of bacteraemia (daily blood cultures) among 
patients receiving either a myeloablative (MA) (high dose melphalan: HDM) or a non-myeloab-
lative (NMA) regimen (Cyclophosphamide and Fludarabine: Cyclo-Flu) before HSCT.1   
METHODS
PATIENT MANAGEMENT
From January 2007 to December 2008, 37 patients participated in this observational single 
centre study. A cohort of 18 patients received an autologous stem cell transplant (8 female 
and 10 male) after preparation by the MA regimen. Another cohort of 19 patients (9 female 
and 10 male) were given an allogeneic stem cell transplant following the NMA regimen. 
All patients had given their informed consent to the prospective collection of plasma samples 
for investigational use. Formal approval of this study was not required by the local ethics 
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committee (CMO regio Arnhem-Nijmegen) provided that patient data were handled anonymously 
in compliance with Dutch laws on privacy. 
Patients’ characteristics are shown in Table 1A. 
Table 1A. General characteristics
Conditioning HDM 
N=18
Cyclo-Flu 
N=19
Age in years: mean (range) 58 (43-65) 54 (38-66)
Gender: male/female 10/8 10/9
Diagnoses Multiple myeloma/plasma cell leukemia (N; %) 18 (100%) 4 (21%)
B-cell Non Hodgkin’s lymphoma (N; %) 0 (0%) 7 (37%)
MDS/AML (N; %) 0 (0%) 2 (11%)
B-cell chronic lymphocytic leukemia (N; %) 0 (0%) 6 (32%) 
Type of HSCT autologous allogeneic 
HDM was given intravenously (iv.) at a dose of 100 mg/m2 for two consecutive days (day 1 and 2), 
followed by an autologous transplant on day 4. All recipients of this regimen were managed 
with a triple-lumen central venous catheter (CVC).  The patients who received the NMA regimen 
were given Cyclophosphamide (Cyclo) at a dose of 1200 mg/m2 and Fludarabine (Flu) at a 
dose of 30 mg/m2, both given i.v. for 4 consecutive days (day 1 to 4), followed by an allogeneic 
stem cell transplant from a matched related donor on day 7. Only one of these patients had a 
CVC.
Antimicrobial prophylaxis consisted only of ciprofloxacin and valaciclovir which were given from 
admission onwards. Fluconazole was only given to patients who were shown to be colonized 
by Candida	 albicans.12 Ceftazidime was given empirically for fever that occurred during 
neutropenia.13 No hematopoietic growth factors or keratinocyte growth factors were used. 
The course of neutropenia, axillary temperature, citrulline and C-reactive protein levels and 
the occurrence of bacteraemia were monitored. 
NEUTROPHIL COUNT 
The absolute neutrophil count (ANC) was determined daily and neutropenia was defined as 
an ANC ≤ 0.5 x 109 /L.  The duration and the depth of neutropenia was recorded for each patient. 
CITRULLINE ANALYSIS 
The protocol required plasma to be obtained daily for citrulline assay but, in practice, this was 
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not always done though it was collected at least three times a week. Plasma was prepared and 
stored at –80°C for later analysis. Citrulline concentrations were measured by a standard proce-
dure for determining amino acids using high-performance liquid chromatography (Shumadzu© 
Kyoto, Japan)14 and levels below 10 μmol/L were designated hypocitrullinaemia and considered 
to represent severe intestinal damage.7
TEMPERATURE 
The axillary temperature was measured 4-5 times a day and fever was defined by a single 
temperature of ≥ 38.5 °C. The maximum daily temperature was used for analysis.
C-REACTIVE PROTEIN (CRP)
CRP levels were determined every day until discharge using turbidimetric immunoassay 
(Aeroset©, Abbott). The day of maximum CRP and the highest level of CRP (CRP max) were 
recorded.
INFECTIOUS COMPLICATIONS, BLOOD CULTURES AND BACTERAEMIA
Infections were defined according to the Consensus definitions of Immunocompromised Host 
Society.15 The study protocol recommended blood cultures be obtained daily but, in practice, 
they were taken at least three times a week in every case. When a central venous catheter 
(CVC) was present, 10 mL of blood from each lumen was drawn into an aerobic blood culture 
bottle. When there was no CVC, 10 mL of peripheral blood was drawn into an aerobic culture 
bottle.
At the onset of fever, an extra of 40 mL of blood was obtained for culture from a peripheral vein 
together with 10 ml from each lumen of the CVC when present (same protocol as described 
earlier10). 
Bacteraemia was defined by a single blood culture yielding any bacterial species except for 
coagulase-negative staphylococci (CoNS) which required the same isolate to be recovered from 
two separate blood cultures.13 
DATA-ANALYSIS
We used descriptive statistics for each time point from the day of starting conditioning 
regime. Continuous variables are expressed as mean values together with a 95% confidence 
interval (CI). The categorical variables are displayed as absolute number and percentage. 
Results from different regimens in the same patient were considered statistically independent. 
As citrulline was not measured daily, the real nadir might occur between two measurements 
and hence could be missed. To overcome this problem and to be able to estimate the length 
of time citrulline levels were < 10 µmol/L, we transformed the values to their logarithms and 
modelled the course of citrulline as a function of time using a linear mixed model treating the 
‘patient’ as a random factor, and the interaction ‘treatment’ by ‘day  after start of conditioning’ 
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as fixed factors. This modelling approach allowed us to deal adequately with missing values. 
The t-test or Wilcoxon test was used to compare the two treatment regimens with respect to 
continuous variables.  Fisher’s exact test was used to compare the two regimens with respect 
to frequencies.  To estimate the 95% CI for the median a distribution free method was used. 
A P-value of < 0.05 was considered to indicate significance.  SAS version 9.2 software (SAS, Inc. 
Cary, NC, USA) was used for statistical analysis. 
RESULTS
THE COURSE OF NEUTROPENIA
Patients in both groups developed profound neutropenia which was significantly longer (3 
days) among those who had received the NMA regimen than for the MA regimen (see Table 
1B; Figure 1). 
Table 1B. General outcome measure of neutrophils, citrulline, inflammation and 
bacteraemia
Conditioning HDM 
N=18
Cyclo-Flu 
N=19
P-value
Neutrophils Length of neutropenia in days, mean (95%CI) 11 (8-13) 14 (12-15) 0.0048
Citrulline Length of citrulline <10 µmol/L in days, mean 
(95%CI) 
10 (5-12)  0 <0.001
Citrulline nadir (µmol/L): mean (95%CI) 5.6 (5.0-6.2) 16.6 (15.1-18.3) <0.001
CRP CRPmax (mg/L):  mean  (95%CI) 119 (99-156) 60 (38-94) 0.01
Inflammation Fever, N (%) 16 (89%) 13 (68%) 0.02
Fever, day of start conditioning, mean (95%CI) 12.2 (11.1-13) 14.4 (13.2-15.9) 0.02
Bacteraemia Bacteraemia, N (%) 8 (44%) 2 (11%) <0.001
Oral viridans staphylococci, N 5 0
Coagulase-negative staphylococci, N 3 1
Other: Eschericha	coli, N 0 1
THE COURSE OF CITRULLINE
The patients who had received the MA regimen developed hypocitrullinaemia with a rapid 
decline of citrulline levels to <10 µmol/L a mean of 10 days after starting chemotherapy. The 
mean nadir of citrulline was 5.6 (95% CI:  5.0-6.2) µmol/L and hypocitrullinaemia lasted for 10 
(95% CI: 5-12) days. 
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By contrast, no hypocitrullinaemia was evident among those who had received the NMA regimen 
and no real decline in citrulline was seen. The mean nadir of citrulline for this group was 16.6 
(95% CI: 15.1-18.3) µmol/L (figure 1).  
Figure 1. Total days of hypocitrullinaemia and neutropenia for each patient either
treated with the myeloablative regimen (HDM) or non-myeloablative regimen 
(Cyclo-Flu) 
(Thick grey horizontal line indicates the mean and thinner grey vertical line the 95% CI).    
The MA regimen induced severe intestinal MBI manifest by citrullinaemia < 10 μmol/L, whereas no severe 
intestinal MBI was observed in those treated with the NMA regimen. Both groups experienced profound 
neutropenia and its duration was significantly longer for those receiving the NMA regimen (P=0.0048).    
INFLAMMATORY RESPONSE MEASURED BY CRP AND FEVER
Significantly higher CRP values were seen for the cohort who had been given the MA regimen 
with a mean CRPmax of 119 mg/L versus 60 mg/L for the cohort who had received the NMA 
regimen. The course of CRP also reflected the course of citrulline, whereas only a moderate 
inflammatory response was seen among those treated with the NMA regimen. 
Most patients developed fever, which affected 16 (89%) of the patients given the MA regimen 
and 13 (68%) of those given the NMA regimen. The mean duration of fever was 2.5 days for 
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both groups. In the MA group fever occurred two days after the occurrence of hypocitrul-
linaemia approximately 12 days after starting chemotherapy, compared with approximately 
15 days for those given the NMA regimen. The two patients in the NMA group who had the 
longest duration of fever during neutropenia, respectively 7 and 8 days, had infiltrative changes 
on their chest X-ray; one of which was associated with probable aspergillosis. The length of 
neutropenia until fever occurred was also significantly longer in the NMA regimen (respectively 
a mean of 5 days in the MA group versus 11 days in the NMA group (P=0.02).  
BACTERAEMIA
Figure 2. Relationship for patients receiving HDM between citrulline, neutropenia,
bacteraemia and the day after starting conditioning
All patients who developed bacteraemia (inner figure) had hypocitrullinaemia at that moment. Positive 
blood cultures are shown as percentage of all blood cultures taken that day. Four patients had repeat-
ed positive blood cultures - respectively 3 patients had positive blood cultures on two consecutive days 
(2 with viridans streptococci, 1 with coagulase-negative staphylococci) and 1 patient had positive blood 
cultures with coagulase-negative staphylococci on three consecutive days. 
Bacteraemia was experienced by 8 (44%) of those in the MA group (5 cases due to oral viridans 
streptococci (OVS), and 3 cases due to CoNS) compared with 2 (11%) in the NMA treated group 
(P<0.001). None of the patients experiencing a bacteraemia with coagulase negative staphylo-
cocci had any clinical or radiological signs of a CVC related tunnel infection or thrombophlebitis. 
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Moreover, all patients treated with the MA regimen who experienced bacteraemia had hypoci-
trullinaemia (Figure 2) although the course and duration of hypocitrullinaemia was similar 
whether or not bacteraemia had occurred. Bacteraemia developed a day before fever in two 
cases. In six cases it was detected in blood cultures obtained on the same day fever developed. 
One of the patients who had received the NMA regimen had bacteraemia due to Escherichia	
coli that was resistant to ciprofloxacin, but responded well to ceftazidime. The other patient 
developed bacteraemia due to coagulase negative staphylococci which was associated with 
thrombophlebitis in his right arm. Both patients developed fever on the same day that bacterae-
mia was discovered.  
DISCUSSION
In this study, the MA regimen HDM induced severe intestinal MBI which was an important 
determinant of the inflammatory response and bacteraemia. All episodes of bacteraemia in 
the MA treated group were due to either CoNS or OVS most likely as a direct consequence of 
our use of ciprofloxacin, which prevents bacteraemia due to enteric Gram-negative bacilli but 
provides a selective advantage to these Gram positive bacteria as they are less susceptible to 
the quinolone.12 These bacteria almost certainly originated from the gastrointestinal tract as 
has been shown by molecular analysis and clinical observations.10,17-20 
The patients who had been treated with the NMA regimen did not develop severe intestinal MBI, 
had only a moderate inflammatory response and experienced significantly fewer bacteraemic 
episodes even though they experienced profound neutropenia for a significantly longer duration 
than that resulting from the MA regimen. Also, the time from the start of neutropenia to the 
development of fever was significantly longer being around 5 days.  
These results indicate that hypocitrullinaemia identifies severe intestinal MBI induced by MA 
regimens and better defines the risk period for developing an inflammatory response as well as 
bacteraemia than does neutropenia. This might also explain why giving antibiotics pre-emptively 
to reduce the occurrence of fever usually fails, as there will be little or no impact on MBI.21 
Rather, we should reconsider our current approach towards infectious complications among 
HSCT recipients.  Typically, antimicrobial prophylaxis is given for as long as the patient remains 
neutropenic. Empirical antibiotic therapy is then started promptly once fever develops and 
after blood cultures have been obtained. In our study, bacteraemia could be detected even 
before fever occurred and may not have been registered at all later on. Moreover, fever is often 
an expression of inflammation that is unrelated to the occurrence of bacteraemia or any other 
manifest infection.  
Antimicrobial consumption could also be reduced by half if only those with the severe mucositis 
are treated. Citrulline could be useful in this regard22 to explore whether knowing the levels 
might indeed help to determine which patient requires antimicrobial prophylaxis, hospital 
admission or empirical antimicrobial therapy.
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Furthermore the results of our study suggest patients given an NMA regimen may not require 
antimicrobial prophylaxis provided empirical antibiotic therapy is started promptly at the onset 
of fever. Therapy could then be stopped after 2-3 days if there is no evidence of bacteraemia 
or other infectious complications.  
These differentiated approaches would also help to lower the risk for side effects to antimicro-
bial agents, and help reduce emergent resistance and health care costs. 
However to confirm our observations a large prospective trial is needed to investigate this 
more thoroughly before a change in our common approach can be recommended.
In conclusion, our results show that the period of severe intestinal MBI following treatment 
with a MA regimen is manifest by hypocitrullinaemia and that this, rather than neutropenia, 
defines the period of risk of bacteraemia. A more tailored approach to HSCT related infectious 
complications that also focuses on the occurrence of intestinal MBI would benefit patients 
in particular and health care in general not least by reducing costs and lowering the risk of 
antimicrobial resistance.
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 ABSTRACT
INTRODUCTION 
Mucosal barrier injury (MBI) plays an important role in the inflammatory and infectious com-
plications seen in HSCT recipients after intensive chemotherapy and radiotherapy. Palifermin, 
a recombinant human keratinocyte growth factor, is registered for reduction of oral MBI. Less is 
known about intestinal MBI, mainly due to the inaccessibility of the gut. Recently, the aminoacid 
citrulline has been shown to be an useful marker of intestinal MBI. 
In the present single centre matched-control study, we examined the efficacy of palifermin 
for the prevention and reduction of MBI induced by cytotoxic therapy and its impact on the 
inflammatory response and the occurrence of fever and bacteraemia.   
PATIENTS AND METHODS
Between January 2007 and November 2008, 23 autologous HSCT patients conditioned with 
BEAM were enrolled to receive palifermin and compared to matched historic controls. 
RESULTS
Palifermin reduced oral MBI but had no relevant impact on intestinal MBI. 16 of the 21 (76%) 
patients that did not receive palifermin developed fever during neutropenia compared to 13 
(57%) patients of those who were treated with palifermin. There was no impact on the occur-
rence of bacteraemia. Lower levels of CRP were seen in the palifermin group. This difference 
in CRP course was attributable to those without bacteraemia. 
CONCLUSION
The matched-control study failed to show a clinical relevant impact of palifermin on intestinal 
MBI, though there was a reduced inflammatory response and less fever during neutropenia 
among patients who had no bacteraemia.
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INTRODUCTION
Mucositis is the clinical manifestation of mucosal barrier injury (MBI) which plays an important 
role in the inflammatory and infectious complications seen during the leucopenic phase 
following hematopoietic stem cell transplantation (HSCT).1 Palifermin is a recombinant human 
keratinocyte growth factor found to reduce oral MBI after TBI-containing regimens to prepare 
for autologous HSCT but not in other regimens.2-4 Much less is known about palifermin’s 
impact on intestinal MBI, mainly due to difficulties in examining the gut. Johannson et	 al. 
suggested a protective effect of palifermin measured by permeability tests on the intestinal 
barrier in BEAM treated HSCT recipients.5 The amino acid citrulline appears more useful as 
marker of intestinal MBI than do permeability tests.6 So the aim of this single-centre matched-
control study was to explore the efficacy of palifermin in reducing intestinal MBI, measured by 
plasma citrulline after BEAM therapy. Other objectives were to evaluate the effect, if any, of 
palifermin on the inflammatory response using C-reactive protein (CRP) as a marker, on the 
incidence of fever during neutropenia and the occurrence of bacteraemia. 
PATIENTS AND METHODS
Between January 2007 and November 2008, a cohort of 23 patients suffering from malignant 
lymphoma underwent an autologous HSCT after BEAM (carmustine (300mg/m2 day 1 (HSCT-
day -6), etoposide (200mg/m2/day from day 2 till 5 (HSCT day: -5 till -2)), cytarabine (200mg/
m2/day from 2 till day 5 (HSCT day: -5 till -2)) and melphalan (140 mg/m2 day 6 (HSCT day -1)) 
and was treated with palifermin. Palifermin was administered once daily at the standard dose of 
60 μg/kg/day intravenously for 3 days before starting BEAM (day -2 till 0 (HSCT day: -9 until 
-7) and again for 3 days after autologous HSCT (day 7 till 9 after start of BEAM or HSCT day: 0 
until +2).2 
The matched-controlled cohort consisted of patients with malignant lymphoma and were all 
transplanted after BEAM from July 2004 to December 2006. None of these patients received 
glutamine or any other agent with a potential protective influence on MBI. 
Every patient received a stem cell graft with at least 2.0 x 106 CD34+ cells/kg without colony 
stimulating growth factors and remained in hospital until neutrophil recovery. All were managed 
with a central venous catheter (CVC) and antimicrobial prophylaxis consisted of ciprofloxacin 
and valaciclovir. At the onset of fever (defined by a single axillary temperature of ≥ 38.5 °C) 
during neutropenia (absolute neutrophil count ≤ 0.5 x 109/L) 40 mL of peripheral blood was 
obtained for culture together with 10 mL from each lumen of the CVC, appropriate specimens 
were obtained from any site of suspected local infection including a chest radiograph, and 
empirical therapy with ceftazidime was started.7 The following were done prospectively from 
the day before chemotherapy was started (day 0) until discharge: absolute neutrophil count, 
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CRP levels, citrulline levels, oral mucositis scores (daily mucositis score (DMS), WHO toxicity 
score, daily gastrointestinal mucositis score (DGS) and any event according to the CTC-AE v3.0 
including fever, bacteraemia, and adverse drug reactions.8
RESULTS AND DISCUSSION
Patient characteristics were well balanced between the two groups (Table 1a). 
Table 1A. General characteristics
Palifermin Control
Total of patients (N) 23 21
Age in years: mean (range) 46 (18-65) 49 (23-64)
Gender: male/female 17/6 17/4
Diagnoses B-cell Non-Hodgkin’s lymphoma 15 13
T-cell Non-Hodgkin’s lymphoma 2 2
Hodgkin’s lymphoma 6 6
Type of HSCT autologous autologous
The administration of palifermin was generally safe though every patient experienced a 
degree of skin toxicity typically a rash scored as CTC grade 1 for 11 patients and grade 2 for 
the remaining 12 patients. None of the patients developed pancreatitis or arthralgia.
Although there was a statistically significant difference in the peak DGS and nadir of citrulline 
levels palifermin had no discernible clinical effect on intestinal MBI as all patients developed 
severe enterocyte damage reflected by the presence of hypocitrullinaemia (i.e. citrulline below 
10 μmol/L) and the DGS was in the range that corresponds to mild toxicity in both study 
groups. Nevertheless, the duration of hypocitrullinaemia was 2 days shorter and the nadir 
was less pronounced (Table 1b, 1c) among patients treated with palifermin. 
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Table 1B. General outcome measure of neutrophils, citrulline, inflammation and bacteraemia
Number of patients (%) Palifermin
N=23  (100%)
Control 
N=21  (100%)
P-value
Neutrophils Duration  neutrophils ≤ 0.5 x 109/L, days, 
mean (95%CI)
10 (8-10) 9 (8-10) ns
Citrulline First day of citrulline < 10 µmol/L, 
mean (95%CI)
9.2 (8.1-10.3) 8.0 (7.8-8.7) ns
Duration Citrulline < 10 µmol/L, days, 
mean (95%CI) 
10 (8-13)  12 (11-14) 0.02
Nadir (µmol/L):  mean (95%CI) 5.2 (4.6-5.9) 4.1 (3.6-4.6) 0.03
Time of nadir, days from start BEAM, mean 14 15 ns
Inflammation CRPmax (mg/L): mean (95%CI) 86 (68-108) 130 (100-169) 0.02
number of patients (%) with fever  13 (56.5%) 16 (76.2%) 0.02
Time of onset fever, days from start BEAM, 
mean (95%CI)
12 (11.1-13) 11 (10.2-11.9) ns
Bacteraemia number of patients (%) 11 (47.8%) 10 (47.6%) ns
Time of onset of bacteraemia in days from 
start BEAM, mean (95%CI)
13 (11-14) 12 (10-13) ns
Table 1C. General outcome measure of oral mucositis and daily gut score    
Number of patients (%) Palifermin
N=17 (73.9%)
Control
N=14  (66.7%)
P-value
Oral mucositis 
scores
DMSmax: mean (95%CI) 5.1 (4.3-5.8) 6.6 (5.7-7.4) 0.0071
number of patients (%) with DMS Grade II or 
higher
1 (5.9%) 3 (21.4%) ns
WHOmax: mean (95%CI) 1.5 (1.3-1.8) 2.3 (2.1-2.6) <0.0001
number of patients (%) with WHO grade II or 
higher
8 (47.1%) 14 (100%) 0.0013
Daily gut score DGSmax: mean (95%CI) 3.7 (3.5-3.9) 4.2 (3.7-4.7) 0.041
number of patients (%) with DGS Grade II or 
higher
0 (0%) 1 (7.1%) ns
Significantly higher oral mucositis scores were seen in the control group, with the peak DMS 
being seen on day 10 and the peak WHO toxicity score being seen on day 12 in the control 
group, and later on day 13 and 14 respectively in the palifermin group, but there were no 
differences in the incidence. 
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Ten control patients and 11 palifermin patients developed bacteraemia, with 4 and 5 cases 
respectively being due to viridans streptococci and 6 cases in each group being due to coagulase-
negative staphylococci without there being any clinical signs of a catheter-related infection. 
Although both the oral cavity and gut could be the origin of these bacteraemias our data favour 
the latter as we found that every patient developing bacteraemia had hypocitrullinaemia. 
Moreover, patients treated with palifermin had significantly less oral mucositis yet the rate of 
bacteraemia was not lower.9-12 Hence, the onset of hypocitrullinaemia appears to delineate the 
period of highest risk for bacteraemia irrespective of neutropenia, at least among autologous 
HSCT recipients.12 
Lower levels of CRP were seen in the palifermin group and less febrile neutropenia (Table 1B). 
The difference in CRP course was attributable to those without bacteraemia (Figure 1). As mu-
cositis is the main driver of inflammation after myeloablative therapy our results suggest that 
palifermin exerted some effect on the severity of oral and intestinal MBI leading to a reduction 
in inflammation.13 Furthermore, there are reports that palifermin mediates immuneregulation 
by shifting the balance between Th1-cell towards Th2, thereby down-regulating proinflammatory 
cytokines and up-regulating interleukin(IL)-4 and IL-13.14,15 Palifermin might also have a protective 
action on endothelium and fibroblasts.16,17 
Figure 1. Course of mean CRP in patients without bacteraemia after the start of BEAM
In the patients without bacteraemia there is an overall significant palifermin*day interaction: 
P <0.0001. Between day 12 and 17: mean C-reactive protein (CRP) is significanty lower in 
palifermin-treated group (P <0.05).
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CONCLUSION
This study failed to detect any clinically relevant impact of palifermin on intestinal MBI. 
However, the reduction in the inflammatory response and febrile neutropenia in patients who 
had no bacteraemia is intriguing and merits further investigation. Spielberger et	al., also found 
a lower incidence of febrile neutropenia among patients treated with palifermin.2 If fever is, 
in fact, induced by the inflammatory response to cytotoxic induced therapy rather than infection 
per se it might have important consequences for clinical practice by reducing the consumption 
of antimicrobials given empirically to HSCT recipients for the treatment of persistent unexplained 
fever  thereby lowering the risk of side-effects and the induction of microbial resistance.
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 ABSTRACT
INTRODUCTION
Infection is a major cause of treatment-related morbidity and mortality of patients receiving 
hematopoietic stem cell transplantation (HSCT) to treat cancer. The immunosuppressive state 
that accompanies HSCT means that the signs and symptoms of an overt infection are often 
rather subtle. Therefore, optimal care can be delivered only by closely monitoring the patient. 
With less experienced physicians on call, fewer nurses on duty and limited time for consultation 
the care of a HSCT recipient during the weekends is seldom up to the usual standard of care 
and may actually expose the patient to decisions based more on a “gut feeling” rather than on 
objective criteria. 
PATIENTS AND METHODS
To explore this notion we analyzed retrospectively a relatively uniform cohort of 24 patients 
undergoing a HSCT for multiple myeloma to determine whether the day of starting conditioning 
with high dose melphalan (HDM) might predict whether fever or bacteraemia would occur in 
the weekend. 
RESULTS
Of the 24 patients, 18 (75%) developed fever and 12 (50%) developed bacteraemia. Patients 
who started HDM on a Tuesday had fever during the weekend following HSCT, and those who 
developed bacteraemia, also did so in the same weekend.  By contrast, none of the patients 
who started HDM on a Friday, Saturday or Sunday developed fever during the weekend 
(p<0.001). 
CONCLUSION
Better planning of conditioning therapy will reduce the chances that fever and bacteraemia 
will occur during the weekend. This would help limit unwarranted use of antibiotics and the 
unnecessary ordering of diagnostic tests hence reducing health care-related costs.
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INTRODUCTION
Patients who receive a HSCT are vulnerable to infections because of intensive conditioning 
regimens that disintegrate their natural host defences.1 The resultant absence of granulocytes 
and mucosal barrier injury (MBI) allow resident micro-organisms ready access to the blood-
stream. Under these circumstances, a relatively small number of bacteria can cause a serious 
disease, including sepsis and shock. The absence of granulocytes mutes the symptoms of an 
emerging infection with fever often being the only warning sign.2 
Therefore optimal care of the HSCT recipient requires close monitoring paying particular 
attention to the emergence of infectious complications, to allow timely therapeutic interventions 
to be initiated to increase the chances of success in terms of quick recovery and survival.3 
To achieve this, haematologists have to coordinate information from different sources besides 
their own e.g. the patient and his or her visitors as well as the professional carers including 
nurses, microbiologists, radiologists and other specialists. This can contribute to the timely 
discovery of a developing or progressive infection. 
However, in most hospitals, few of these people are present during the weekends and those 
that are, are often less experienced.4 This leads to breaches in the flow of information, and 
even to a lack of trust in the information given.5 As was shown in a survey on the treatment 
of neutropenic sepsis, this results in a delay in antibiotic administration, and hence, suboptimal 
care.6 Moreover, although unintended, patients may be placed at risk since diagnostic tests 
may be ordered out of anxiety rather than need and decisions may be based more on “gut 
feelings” than on objective criteria. This is potentially harmful to the patient as well as to the 
hospital ecology.
Keuhlein et	al. found fever during neutropenia will lead to a higher prescribing rate of antibiotics 
since the uncertainty was experienced as loss of control.7  De Pauw et	al.	showed that outside 
hospital hours, 3 out of every 4 decisions to modify antibiotic therapy during the first few days 
of fever in neutropenic patients were made without a reasonable explanation while 93% of 
similar decisions to change therapy during the normal working hours were made for objective 
reasons. Not only were these out-of-hours changes unnecessary, but they increased the risk 
of drug-related adverse events and led to unwarranted use of antibiotics.8 
The so-called “weekend effect” poses an important problem when timing is crucial such as 
dealing with an acute pulmonary embolism or acute myocardial infarction9-11 since patients 
who are admitted during weekends have a significantly higher mortality in the short-term than 
do those admitted on weekdays.10,11 Since a HSCT can be planned and fever and infections can 
be predicted to a large extent as they tend to occur during the period of severe intestinal MBI 
that accompanies neutropenia following myeloablative conditioning it might be possible to 
avoid their occurrence altogether during weekends by clever planning.12,13 
To explore this we undertook a retrospective analysis of patients with multiple myeloma (MM) 
who had been given high dose melphalan (HDM) in our department during 2008 to prepare 
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for an autologous HSCT as there were various supportive care trials running at the time which 
led to different days for starting HDM. 
PATIENTS AND METHODS
Between January and December 2008 24 patients had been treated for MM with HDM. All 
had given their informed consent to the collection of data and plasma samples by participating 
in studies that had been approved by the local ethics committee (CMO Regio-Arnhem-Nijmegen).
Each patient was managed with a 3 or 4 lumen central venous catheter (CVC) and received 
melphalan at a dose of 100 mg/m2/day on days -3 and -2 before transplant. Antimicrobial 
prophylaxis consisted of ciprofloxacin and valaciclovir. Each patient received a stem cell graft 
containing at least 2.0 x 106 CD 34+ cells per kg on the day planned for transplantation. Patients 
received parental nutrition from the day of transplant onwards, but were not given any 
growth factors.
At the onset of fever, blood cultures were obtained, patients were examined for any sign of 
local infection, and empirical therapy with ceftazidime was started.14 Infections were defined 
according to the Consensus definitions of Immunocompromised Host Society.15
Data on neutropenia, intestinal MBI, inflammation and clinical and microbiological infections 
had been prospectively gathered from the day of starting chemotherapy until discharge. 
NEUTROPHIL COUNT 
The absolute neutrophil count (ANC) was determined daily and neutropenia was defined as 
an ANC ≤ 0.5 x 109 /L. 
INTESTINAL MUCOSAL DAMAGE 
Plasma samples had been collected from 21 of the 24 patients to determine citrulline, an amino 
acid which blood concentrations directly reflect the functioning intestinal cell mass. This plasma 
was prepared and stored at –80°C for later analysis. Citrulline concentrations were measured 
by a standard procedure for determining amino acids using high-performance liquid chromato-
graphy (Shumadzu© Kyoto, Japan) and levels below 10 μmol/L were designated hypocitrul-
linaemia and considered to represent severe intestinal MBI.16
C-REACTIVE PROTEIN (CRP)
CRP levels were determined every day until discharge using turbidimetric immunoassay 
(Aeroset©, Abbott). The day of maximum CRP and the highest level of CRP (CRP max) were 
recorded.
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TEMPERATURE 
The axillary temperature was measured 4-5 times a day and fever was defined by a single 
temperature of ≥ 38.5 °C. The maximum daily temperature was used for analysis.
BACTERAEMIA
Blood (10 ml) was drawn for aerobic culture each Monday and Thursday from each lumen 
of the CVC for surveillance. At the onset of fever, 40 ml of peripheral blood was obtained for 
culture together with 10 ml from each lumen of the CVC. Bacteraemia was defined by a single 
blood culture yielding any bacterial species except for coagulase-negative staphylococci 
which required the same isolate to be recovered from two separate blood cultures.14 
DATA-ANALYSIS
We used descriptive statistics for each time point from the day of starting conditioning regime. 
Continuous variables are expressed as mean or median values together with a 95% confidence 
interval (CI). The categorical variables are displayed as absolute number and percentage. SAS 
version 9.2 software (SAS, Inc. Cary, NC, USA) was used for statistical analysis. 
RESULTS
All 24 patients survived the first 6 weeks after transplant and none developed an invasive 
fungal disease. All patients had received melphalan at a dose of 200 mg/m2 except for one 
individual who had received only 100 mg/m2 because of kidney failure (this patient started 
with melphalan on a Tuesday and there were no samples collected for citrulline). Neutropenia 
started an average of 9 days (95% CI 8-10) after starting HDM and its mean duration was 9.5 
(95% CI 7-10) days.  All patients had elevated CRP levels exceeding 50 mg/L and the average 
peak value was 115 (95% CI 94-186) mg/L seen on average on day 15 (95% CI: 14-16). Eighteen 
(75%) of the 24 patients developed fever with a median day of onset of day 13 (95% CI 12-19). 
The mean duration of admission was 23.3 days (95% CI 21.7-24.8). 
5 patients started with HDM on Tuesday, 8 started on Friday, 9 on Saturday and 2 on Sunday. 
All patients that started with HDM on a Tuesday developed fever at a weekend whereas none 
of those that started on Friday, Saturday or Sunday did so (Fisher’s exact test, P<0.001) (table 1). 
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Table 1. Occurence of fever and bacteraemia in HSCT recipients that started with high 
dose melphalan on different days 
Day of start
conditioning
Total of 
pts
Pts with 
fever
Fever Pts with  
bacter-
aemia
Bacteraemia type
Week-
day
Week-
end
CoNS OVS CoNS & 
OVS
N N 
(%)
N 
(%)
N 
(%)
N 
(%)
N 
(%)
N 
(%)
N 
(%)
Tuesday 5 5 
(100%)
0 
(0%)
5 
(100%)
3
(60%)
2 
(40%)
1 
(20%)
0 
(0%)
Friday 8 6 
(75%)
6 
(75%)
0 
(0%)
2
(25%)
0
(0%)
2
(25%)
0
(0%)
Saturday 9 6 
(67%)
6 
(67%)
0 
(0%)
5
(56%)
4
(44%)
1
(11%)
0
(0%)
Sunday 2 1 
(50%)
1 
(50%)
0 
(0%)
2
(100%)
0
(0%)
1
(50%)
1
(50%)
Total  (N) 24 18 13 5 12 6 5 1
12 (50%) patients developed bacteraemia, 5 due to oral viridans streptococci (OVS), 6 due to 
coagulase-negative staphylococci (CoNS) and 1 due to both bacteria. Of the patients with 
known citrulline values, those who developed bacteraemia also had hypocitrullinaemia at 
that time. 3 (60%) of the 5 patients who started HDM on Tuesday developed bacteraemia at 
the weekend (Table 1). The length of stay was the slightly longer for these patients, although 
the difference was not statistically significant (Table 2). 
Table 2. Length of stay for HSCT recipients after high dose melphalan started on different days  
Day of start
conditioning
Total patients Length of stay 
Minimum stay Maximum stay Mean (95% CI)
N days days days
Tuesday 5 21 29 24.6
(20.6-28.6)
Friday 8 20 27 22.1
(20.1-24.1)
Saturday 9 20 35 24.2
(20.5-27.9)
Sunday 2 20 21 20.5
(14.1-26.9)
Total population 24 20 35 23.3
( 21.7-24.8)
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DISCUSSION
This study shows that the day of starting conditioning has implications for the occurrence of 
infections and inflammatory complications during the weekend as patients who started HDM 
on a Tuesday developed fever and bacteraemia more often during the weekend than did 
those starting on a Friday, Saturday or Sunday. 
The 24 patients studied showed a very similar pattern regarding the occurrence of neutropenia, 
inflammation (course of CRP and occurrence of fever) and bacteraemia which is comparable 
with other reports.17-20 Since these studies investigated different patient cohorts who had 
received an autologous HSCT after conditioning with HDM in different hospitals, the only 
plausible explanation for the consistent pattern is that it is determined by the regimen given. 
Indeed, on average, these studies reported that fever occurred 12-13 days after starting 
HDM. Therefore it is not surprising that starting with HDM on a Tuesday is inviting trouble, 
since fever and infection will both occur during the weekend. 
Fever occurred in 75% of our patients which is also in accordance with other studies17-19 and 
was accompanied by bacteraemia in about half of cases during hypocitrullinaemia as has been 
reported before in two other cohorts.18-19 The only bacteria recovered from blood cultures 
were CoNS and OVS which are residents of the alimentary tract especially the oral cavity and 
gut.21,22 This supports the contention that the GI MBI induced by the conditioning regimen 
provides a portal of entry to the systemic circulation by commensal flora.13 The use of cipro-
floxacin as prophylaxis most likely gives a selective advantage to these Gram-positive cocci 
which are much less susceptible to the quinolone than are the enteric gram-negative bacilli 
associated with bacteraemia. 
The period of increased risk of inflammatory and infectious problems can be predicted since 
every conditioning regimen appears to create its own pattern of occurrence of neutropenia 
and mucositis (Table 3).19,23 This suggests that similar predictions might be made for other 
conditioning regimens to select the best day for starting chemotherapy so as to have the best 
chance of avoiding infectious complications during the weekend.
If this is so, haematologists will have to change their current practice. At present, the day for 
starting treatment is dictated by many things including the wishes of the patients, nursing 
personnel, other specialists, or for logistic reasons. This study shows that since the haematologist 
can anticipate the occurrence of infectious complications they should decide the best day to 
start conditioning therapy for a HSCT. By reducing the risk for inflammatory and infectious 
problems during the weekend, HSCT recipients will be less exposed to the vagaries care during 
the weekends, which may, in turn,  translate into better outcomes if, for example, antimicrobial 
therapy is started on time.6,24 In many cases unnecessary ordering of diagnostic tests may be 
reduced as can the unwarranted antibiotic use that exposes patients to side-effects and 
increases the risk of microbial resistance development.25 Furthermore, knowing infectious 
problems are likely to occur during the week makes managing HSCT recipients outside the 
hospital feasible and safe if accompanied by regular outpatient visits.26
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Table 3. Occurrence of fever (with or without bacteraemia) for different conditioning regimens 
 
Conditioning Total pts Type of 
cond.
Type of HSCT Pts with fever  Fever, day Bacterae-
mia on 
day fever
N N (%) Mean (95% CI) N (%)
HDM 56 MA Autologous 49 (88 %) 11.8 (11.4-12.2) 29 (52 %)
BEAM 21 MA Autologous 19 (90 %) 13.0 (12.2-13.9) 10 (48 %)
Ida-Cyclo-TBI 28 MA Matched sibling
allogeneic
28 (100 %) 12.9 (12.2-13.6) 18 (64 %)
Cyclo-ATG-TBI 34 MA Matched sibling
allogeneic
Early: 25 (73.5 %)
Late: 34 (100 %)
4.1 (3.7-4.5)
14.1 (13.0-15.1
29 (85 %)
Cyclo-TBI 10 MA Matched sibling
allogeneic
10 (100 %) 13.4 (12.0-14.8) 6 (60 %)
Cyclo-Flu 14 NMA Matched sibling
allogeneic
Early: 4 (28.6 %)
Late: 11 (78.6 %)
3.0 (1.7-4.3)
16.0 (14.4-17.5)
0 (0 %)
Adapted, with permission, from Van der Velden et al.19
Every conditioning regimen has its own pattern of occurrence of fever. In some of the patients treated with 
Cyclo-ATG-TBI and Cyclo-Flu there were two episodes of fever (early and late episode). Not all patients that 
develop fever have also bacteraemia. 
CONCLUSION
Better planning of the HSCT will improve the chances of avoiding fever and bacteraemia during 
the weekend. This would help limit unwarranted use of antibiotics and the unnecessary 
ordering of diagnostic tests thereby lowering the risk of adverse events related to drugs or 
unnecessary diagnostic tests, the selective pressure for antibiotic resistance, as well as reducing 
health care-related costs. 
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ABSTRACT
Infection remains one of the most prominent complications after cytotoxic treatment for cancer. 
The connection between neutropenia and both infections and fever has been designated 
“febrile neutropenia” decades ago. However, treatment with antimicrobial agents and hema-
topoietic growth factors has failed to significantly reduce the incidence of febrile neutropenia. 
Moreover, emerging antimicrobial resistance is becoming a concern which necessitates the 
judicious use of available antimicrobial agents. Besides neutropenia, patients who receive cyto-
toxic therapy experience mucosal barrier injury (MBI) or “mucositis”. MBI creates a port-de-entrée 
for resident micro-organisms to cause blood stream infections, and contributes directly to the 
occurrence of fever by disrupting the highly regulated host-microbe interactions, which, even 
in the absence of an infection, can result in strong inflammatory reactions. Indeed, MBI has been 
shown to be a pivotal factor in the occurrence of inflammatory complications after cytotoxic 
therapy. Hence, the paradigm “febrile neutropenia” alone may no longer suffice and the new 
paradigm “febrile mucositis” is more appreciated as the two paradigms are complementary. In 
this review we summarise the existing evidence for both paradigms and propose new therapeutic 
approaches to tackle the perturbed host-microbe interactions arising from cytotoxic therapy-
induced tissue damage in order to reduce fever in neutropenic patients with cancer.
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INTRODUCTION
Infection is a common complication during the neutropenia that accompanies cytotoxic therapy 
used to treat patients with solid and hematological malignancies.1 Fever is often the first and 
only sign of infection and represents a signal to start empirical antibacterial therapy promptly, 
so as to reduce the chance of fulminant sepsis due to gram-negative bacillary infection and 
death.2-5 Additional empirical antifungal therapy is often initiated in case of persistent fever, 
but invasive fungal infection comprise at most 5-10% of febrile episodes.6-8 However, fever 
remains unexplained in 30-50% of neutropenic patients, as there is no evidence found of a 
clinically or microbiologically defined infection.9 Furthermore, irrespective of the aetiology, 
fever persists for 4-5 days or even longer in a substantial number of cases (approximately 
30%) despite adequate antimicrobial therapy directed at bacteria and fungi.10-12 This suggests 
that fever is not necessarily related to infection. Indeed, it is often not appreciated that fever is 
a nonspecific response to a variety of insults of which infection is only one. Living micro-or-
ganisms and the microbial wall motifs (pathogen-associated molecular patterns (PAMPs)) are 
powerful inducers of cytokine release.13,14 A similar role has been proposed for the danger-
associated molecular patterns (DAMPs) that are released from damaged tissues.15 Indeed 
there are many inflammatory diseases that are, in essence, a manifestation of a perturbed 
host-response in the face of “damage”.16 Most of these diseases occur at the integument 
where epithelial and mucosal barriers are inhabited by micro-organisms. At the mucosal level, 
there is strict control and regulation of host responses especially when confronted with tissue 
damage, in order to prevent infection on the one hand, and overwhelming inflammation on 
the other hand.17,18 
Patients who become neutropenic after cytotoxic therapy also suffer simultaneous disruption of 
the integument along the entire alimentary tract including the oral cavity.19 The “mucosal barrier 
injury (MBI)” itself plays a major role in the occurrence of infection and fever. Perturbation of 
the mucosal barrier results in a port-de-entrée for certain micro-organisms to invade the body 
and cause local infection and bacteraemia. Moreover, various DAMPs and PAMPs are released, 
all of which are able to elicit a powerful inflammatory response that results in fever. Indeed 
several studies have suggested MBI to be more important than neutropenia in causing infectious 
complications after chemotherapy and haematopoeitic stem cell transplantation (HSCT).20,21 
Therefore, the paradigm “febrile neutropenia” alone no longer suffices as fever may well be a 
response to MBI whether or not infection is involved. 
This led us to critically appraise the concept of “febrile neutropenia” and review the evidence 
that MBI plays a more important role than does neutropenia per	se in the aetiology of fever 
and infection. Important consequences may arise from this paradigm shift because therapeutic 
approaches other than the use of antimicrobial agents may prove efficacious and enable 
restrictive use of antimicrobial agents in a time of emerging antimicrobial resistance.
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FEBRILE NEUTROPENIA
1. THE CONCEPT OF FEBRILE NEUTROPENIA
In 1966, Bodey et	al. published a landmark article on the quantitative relationship between 
neutrophils and infection in patients given chemotherapy to treat acute leukaemia.1 This 
relationship held for a variety of proven infections ranging from local infection, e.g. pneumonia, 
to disseminated infection, e.g. bacteraemia, hence introduction of the paradigm “febrile 
neutropenia”. However, the occurrence of fever of unknown origin (FUO) appeared not to be 
closely related to neutropenia suggesting that the lack of neutrophils was not the sole deter-
minant of fever. 
Fever that occurs during neutropenia probably results from the release of cytokines by residual 
immune cells and stromal cells, e.g. epithelial cells, that sense micro-organisms and molecular 
motifs through their pattern-recognition receptors (PRRs). Also other pathophysiological 
mechanisms have been proposed to mediate the occurrence of “febrile neutropenia”. One of 
these hypotheses suggests that a subset of neutrophils are anti-inflammatory as they elaborate 
IL-10,22 whereas other neutrophils normally produce powerful anti-inflammatory molecules like 
antimicrobial peptides and cytokine antagonists, including IL-1 receptor antagonist (IL-1Ra), 
that can attenuate inflammation.23 Lower levels of these molecules will prevent negative-
feedback to inflammation which is a natural protective mechanism from damage.24 Another 
possible explanation might be the increased levels of uric acid during neutropenia, which 
leads to increased responsiveness of innate immune cells to microbial stimulation.25 
2. ORIGIN OF INFECTIONS DURING NEUTROPENIA 
The host defences are profoundly affected and mucosal barriers are damaged as a result of 
the treatment of cancer using chemotherapy and radiotherapy. Consequently, infections are 
typically due to those opportunistic pathogens that inhabit the skin and oral and gastrointestinal 
tract rather than professional pathogens such as Streptococcus	pneumonia.26-28 
By contrast, the incidence of infection is much lower in chronic idiopathic neutropenia and 
untreated hematological malignancies and infections are predominantly due to the professional 
pathogens that affect the respiratory tract and skin.29,30 The incidence of FUO and bacteraemia 
is low which can partly be explained by the absence of chemotherapy-induced MBI.29 
2.1	 Prophylactic	antimicrobial	therapy	for	afebrile	neutropenic	patients
Antimicrobial chemoprophylaxis is commonly given to patients receiving intensive cytotoxic 
therapy and recipients of a HSCT who are expected to suffer from profound neutropenia.31 
Indeed, the use of certain fluoroquinolones for this purpose improves overall survival.32-34 
The evolution of antimicrobial prophylaxis began with the simple aim of decontaminating 
the gut to prevent the translocation of gram-negative bacilli that resided in the intestinal tract 
such as Escherichia	 coli	 that most often caused infection.11 Fluoroquinolones, particularly 
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ciprofloxacin and levofloxacin, are ideally suited to this purpose as they prevent the occurrence 
of gram-negative bacilliary bacteraemia,10 although their clinical use has been increasingly 
questioned because of the emergence of resistance and concerns regarding increased risk for 
infections with Clostridium	difficile. Moreover, most patients on prophylaxis still become febrile 
with only about 1 in 3 being explained by documented infections.
 
2.2	 Empirical	antimicrobial	therapy	for	febrile	neutropenia
Empirical use of broad-spectrum antimicrobial agents to manage febrile neutropenia has become 
the standard of care and has resulted in improved survival in cancer patients.3,5,32,33 However, the 
rate of FUO has not been reduced substantially and a large minority of patients remain febrile 
despite broad-spectrum antimicrobial therapy.35,36 Almost 2 in 3 patients and 1 in 3 patients 
are still febrile 2 respectively 4 days after the onset of fever.12,35 Many clinicians assume the 
presence of cryptic infection and change the antimicrobial regimen empirically,37 but to little 
avail as more than half of patients who respond to antibiotics are still febrile after 3 days.38
3. COLONY-STIMULATING FACTORS AND GRANULOCYTE TRANSFUSION
The relationship between neutropenia and infections drove the development of hematopoietic 
growth-factors such as granulocyte (monocyte) colony-stimulating factor (G(M)-CSF), and 
granulocyte transfusions, with the expectation of lowering the incidence of infections by 
reducing the duration and depth of neutropenia. Indeed CSFs were shown to marginally reduce 
infection-related mortality, as well as shorten the duration of neutropenia.39,40 However, their 
use is not favoured for patients with protracted neutropenia following intensive chemotherapy 
as the duration of neutropenia is only abridged by a few days, and the modest clinical benefit 
in reducing infections and the marginal reduction in mortality does not outweigh the costs 
and adverse effects.33,40,41 In addition, there is little if any clinical benefit for granulocyte 
transfusions and there are even reports suggesting a detrimental impact on the outcome of 
infection.42,43  
Therefore, it would seem reasonable to seek an alternative explanation for fever as it occurs 
despite effective suppression of bacterial infections using prophylaxis, it persists despite 
broad-spectrum antimicrobial therapy, an infectious aetiology is seldom identified and the 
use of growth factors fails to reduce fever and infections significantly.
FEVER RELATED TO MUCOSAL BARRIER INJURY
Several diseases besides infections are accompanied by fever, including the cancer itself and 
drug reactions. In 1984 it was already suggested that intestinal damage caused by chemotherapy 
might result in endotoxinaemia leading to fever.44 This hypothesis is in line with the fact that 
most bacteria found in blood cultures originated from the gut flora that translocated through 
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ulcerated barriers.45 Moreover it was generally believed that oral mucositis coincided with 
neutropenia and fever but had no causal relationship. This belief changed as what became 
known as MBI began better understood. 
1. PATHOGENESIS OF MBI AND RELATED FEVER
The pathogenesis of MBI is thought to consist of five phases19: 1) the activation of nuclear factor-
kappa B directly by chemotherapy and radiotherapy and indirectly from formation of reactive 
oxygen species, DNA, and non-DNA damage46, 2) production and release of cytokines and 
chemokines (IL-1β, IL-6, IL-8, TNFα, IL-23, interferon-gamma (IFNγ) by tissue macrophages, 
dendritic cells, and epithelial cells47,48, 3) positive feedback loop of TNFα, epithelial cell apoptosis 
and increased mucosal permeability49, 4) translocation of microbes and PAMPs aggravating 
inflammation50-52, and 5) repair and healing. Most data on the pathogenesis of MBI come from 
animal studies, but it is likely that the model also explains human complications. Although 
developed to explain oral mucositis, the model can probably be extended to gastrointestinal 
mucositis.53
It is thought that MBI is essentially an inflammatory disorder that results from perturbation of 
the normal innate immune system at the mucosal barriers, leading to distorted host-microbe 
interactions (Figure 1).16 The sequence of events in the gut of mice show that chemotherapy 
induces an initially sterile inflammatory response at the mucosal level of the gut, which is then 
followed by changes in the epithelium, apoptosis resulting in crypt hypoplasia, and villous 
blunting which, in turn, leads to a breach in the barrier.48,52,53 MBI is established before trans-
location of bacteria and PAMPs occurs, which, in turn, enhance the response of the already 
primed innate immune cells that reside in the tissue. This culminates in a systemic inflammatory 
response syndrome that manifests itself primarily as fever and is associated with other 
complications such as the non-cardiogenic pulmonary oedema, idiopathic pneumonia syndrome, 
engraftment syndrome, and graft-versus-host disease (GvHD).54 Therefore, what is known as 
“febrile neutropenia” can better be described as “MBI-related fever” as it summarizes better 
the pathological connection between MBI and fever, whether or not infection occurs. 
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Figure 1. Concept of fever due to mucosal barrier injury and disrupted innate immunity 
In health there is a tightly controlled immune balance at the mucosal barriers with tolerance to com-
mensal flora, and absence of tissue damage. PRRs sensing PAMPs play an import role in maintaining 
this homeostasis. The microbial flora is kept in check, for instance through the release of antimicrobial 
peptides (AMPs), and immune responses are dampened by preservation of the physical barrier, selective 
expression of PRRs, and beneficial properties of commensal microorganisms. There is a low state of  
immune activation and inflammation (‘physiological inflammation’) that contributes to the development 
of a healthy local and systemic immune system and keeps the immune system on stand-by (left panel). 
During health, innate immune responses modulate the acquired immune responses towards a tolero-
genic profile contributing to the homeostasis.  
Due to MBI resulting from cytotoxic therapy and mucosal damage resulting from GvHD the mucosal 
barriers and immune homeostasis are perturbed. Microorganisms and PAMPs are able to translocate 
and induce inflammation by activating PRRs. This is aggravated by the release of DAMPs released on 
the occurrence of tissue damage. The microbial flora is not kept in check with an increase in pathogenic 
microorganisms (dysbiosis) (right panel). Deregulated innate immune responses contribute to the  
development of inflammatory complications by eliciting pro-inflammatory acquired immune responses 
which can further damage the mucosal barriers.  Tine Thörig scientific illustrations.
TSLP = thymic stromal lymphopoietin, TGFβ = transforming growth factor beta, HMGB-1 = high mobility 
group box 1, HSP = heat shock protein, LPS = lipopolysaccharide, LTA = lipoteichoic acid, MDP = 
muramyl dipeptide and AMP = antimicrobial peptide.
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1.1	 Innate	immunity	and	MBI
During MBI, the stimulation of PRRs by invading micro-organisms and PAMPS that have trans-
located through the disrupted mucosal barrier appear to aggravate inflammation and fever. 
However, data on the role of perturbed innate host-microbe interactions during MBI come 
mainly from GvHD studies.55 The tissue damage following conditioning therapy for allogeneic 
HSCT that constitutes the initiation phase of acute GvHD mostly involves gastro-intestinal 
MBI.56 The inflammation that ensues causes activation of host antigen-presenting cells that 
enables them to initiate and perpetuate the allo-immune responses that account for acute 
GvHD. The role of endotoxins translocating from the gut in activating the immune system 
through Toll-like receptor (TLR)-4 in GvHD was postulated 20 years ago.57 TLR9 activation may 
also play a pivotal role in GvHD, mainly through intestinal epithelial cells being activated by 
microbial DNA.50 
In addition, during MBI the innate immune system is activated by DAMPs in a similar fashion 
as PAMPs. DAMPs are released by cells that are killed by chemotherapy and radiotherapy and 
include ATP, high-mobility box group-1 (HMGB-1) and heat-shock proteins.15 The process is 
designated ‘immunogenic cell death’ because these molecules mediate immune responses. 
Among cytotoxic therapies, anthracyclines, cyclophosphamide and radiotherapy are strong 
inducers of immunogenic cell death by inducing apoptosis and necrosis of epithelial, endothelial 
and other cells (Figure 1).58 Subsequently, they activate tissue macrophages, and stromal 
cells, through the activation of PRRs, including TLR4 and the P2X7 receptor. DAMPs have also 
been suggested to be involved in mucosal damage-related inflammation in HSCT.59
Single nucleotide polymorphisms (SNPs) in innate immune genes in the setting of HSCT also 
suggest a role for innate immunity in MBI.60 The best-known examples are the SNPs of the 
nucleotide-oligomerization domain peptide (NOD)-2, a PRR that plays a pivotal role in mucosal 
barrier defences. NOD2 SNPs result in reduced microbial clearance, increased gut permeability, 
and uncontrolled inflammation.61-63 NOD2 SNPs have been associated with the occurrence of 
Crohn’s disease as well as severe acute GvHD.64 This effect is related to the severity of intestinal 
MBI and the use of T cell-depletion.65 
Innate immune signalling induced by changes in the gut microbial flora (microbiota) during 
conditioning-induced MBI influences GvHD.66 Modification of the gut microbiota also alters 
the course of acute GvHD in mice indicating a clear role for bacterial communities in GvHD.67 
Clinical studies of HSCT recipients have also shown that the use of ciprofloxacin and metronida-
zole markedly reduced the incidence and severity of GvHD.68 More recently, the role of the 
microbiota has also been shown of importance in MBI outside the setting of allogeneic HSCT.69
 
1.2	 Anti-inflammatory	properties	of	epithelial	cells
Besides preventing the invasion of micro-organisms by forming a physical barrier, epithelial 
cells have other ways of preventing inflammation in the presence of overwhelming numbers 
of microbial residents. These comprise three major groups of molecules; 1) antimicrobial 
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peptides, 2) anti-inflammatory cytokines including IL-10, and transforming growth factor β 
(TGFβ), and 3) cytokine receptor antagonists, including IL-1Ra.70 Damage inflicted on epithelial 
cells can therefore disrupt tightly regulated anti-inflammatory mechanisms in addition to the 
loss of the barrier function. Losing the ability to resolve an inflammatory response by deficien-
cies in these molecules will eventually contribute to aggravated tissue damage, inflammation 
and fever.
 
2. CLINICAL CONSEQUENCES OF MBI
2.1	 MBI,	infection,	inflammation	and	fever
Several studies have shown the occurrence of MBI to have a major impact on complications 
of cancer therapy and, albeit indirectly, illustrated the influence of MBI on fever. The report of 
Sonis et	al. in 2001 showed that the number of days with fever and early infections in HSCT 
recipients increased proportionally with the highest mucositis score.71 Similar results were found 
among patients with solid tumours and lymphoma with MBI being independently associated 
with FUO and infection.72 MBI is also associated significantly with greater use of total parental 
nutrition and opioid analgesics, as well as increased costs, length of hospital stay, and mortality.71 
The more recent Prospective Oral Mucositis Audit found that a high incidence of oral MBI 
corresponded to different clinical and economic outcomes in autologous HSCT recipients.73 
Chemotherapy-induced MBI is associated with early onset bacteraemia. Before the introduction 
of antimicrobial prophylaxis, gram-negative enteric bacilli predominated as causes of infection.45 
Later on, the gram-positive cocci particularly the oral viridans streptococci (OVS), and coagulase-
negative staphylococci (CoNS) prevailed.74,75 The streptococci reside on the mucosal barriers 
and their numbers increase as a result of antimicrobial prophylaxis.76 It is widely assumed that 
the CoNS bacteraemia results from this skin commensal invading the bloodstream via central 
venous catheters, but this assumption has been challenged as CoNS also reside on mucosal 
barriers. Indeed Costa et	al. typed CoNS isolates retrieved from skin, gut and the bloodstream 
and found that the gut mucosa was the most likely source of these bacteria.77 
Gut microbes reach the bloodstream by traversing the mucosa of the gut which shows signs 
of hyperpermeability among these patients. Other factors, including the composition of the 
microbial flora, bacterial overgrowth, and concomitant immune dysfunction, seem also to be 
required.78,79 However, following cytotoxic therapy the relationship between gut permeability 
and bacterial translocation is fairly consistent, probably because most patients are neutropenic 
the moment MBI occurs, and therefore the second line of defence consisting of phagocytic 
cells is no longer able to prevent translocation.52,80 The peak of permeability of the gut has 
been shown to occur 10-14 days after starting the intensive chemotherapy.81,82  Bow et	al. 
found a direct relationship between D-xylose malabsorption and invasive bacterial and fungal 
infections of patients with acute myeloid leukaemia with the highest incidence occurring in the 
second week after starting chemotherapy when there was marked malabsorption.82 Similarly, 
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several studies have shown that bacteraemia occurs on average 12-14 days following high-dose 
chemotherapy (Figure 2).21,83,84 The timing also correlates with the development of severe 
intestinal MBI as determined by sugar malabsorption and low citrulline levels.20 
Figure 2. Pattern of events following chemotherapy 
In patients receiving intensive chemotherapy and radiotherapy for the treatment of acute leukaemia or 
in the preparation of an autologous or allogeneic HSCT there is a striking pattern of inflammation (C-
reactive protein, red line) that in time correlates with the occurrence of intestinal mucositis (citrulline 
levels, blue line).  Fever and bacteraemia occurs at a median of 12-14 days after the start of therapy 
and coincides with the presence of severe intestinal damage, designated by a citrulline level below 10 
µmol/L.20,21,83
The relationship between MBI and the inflammatory response and fever among patients 
receiving an autologous HSCT showed inflammation clearly coincided with the occurrence 
and progression of oral and intestinal MBI (Figure 2).84 Fever occurred 12 days after the start 
of conditioning treatment and coincided with the presence of severe intestinal damage 
regardless the presence or absence of bacteraemia. This pattern was similar to that seen 
among patients receiving chemotherapy for acute myeloid leukaemia.85 These observations 
were confirmed in a subsequent study of 6 different conditioning regimens.21 Once again a 
clear pattern of inflammation and fever was observed that coincided with the progression of 
MBI. There was a strong correlation between the extent of intestinal MBI and the evolution of 
C-reactive protein; a biomarker of inflammation that correlates with pro-inflammatory cytokines 
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such as IL-8.86 Comparing patients who had received a non-myeloablative conditioning versus 
patients treated with a myeloablative regimen showed that in the non-myeloablative condi-
tioning very little intestinal mucositis was accompanied with limited inflammation and a lack 
of bacteraemia, despite profound neutropenia.20,21 This provides evidence that the presence 
or absence of MBI determines to a large extent the early complications seen after HSCT. 
Moreover the occurrence of the so-called “alpha-streptococci syndrome” which is characterised 
by bacteraemia due to OVS, and septic shock or non-cardiogenic pulmonary oedema, was related 
to the degree of underlying MBI.21 Interestingly, it was already noted decades ago that severe 
oral mucositis rather than infection appeared to induce an acute-phase response with fever 
suggesting bacteraemia due to these OVS to have only been a consequence of mucosal damage 
and not the primary initiator of the inflammatory response.11 This is consistent with the 
observation that the occurrence of pulmonary oedema correlated strongly with cytarabine-
induced intestinal lesions.87 Hence it would appear that the host-microbe interaction defines 
the outcome of OVS bacteraemia rather than the opportunistic pathogen alone, as it exhibits 
low virulence. Therefore, restoring the balance by ameliorating the inappropriate host response 
might prove beneficial and improve the outcome of these patients.88
2.2	 Mucosal	barrier	preservation	ameliorates	complications
The concept of “MBI-related fever” is supported by the consistent observation that reducing 
mucosal damage attenuates fever and infection. The pioneering study of Spielberger et	al. 
showed that recombinant human keratinocyte growth factor (rh-KGF, Palifermin®) significantly 
reduced the incidence of oral mucositis in patients receiving a HSCT after conditioning 
containing total body irradiation.89 The incidence of febrile neutropenia was also significantly 
decreased, by almost 20%, although the drug had no effect on the duration of neutropenia. 
Exploratory analysis also showed a trend towards a lower incidence of bacteraemia in the KGF 
group than in the placebo group (15 versus 25 percent). Similarly, the use of recombinant 
human IL-11 preserved the gut barrier after cytotoxic therapy and resulted in a decrease in 
bacteraemia.80 Comparable results have been shown with the use of less mucotoxic therapies 
such as the so-called reduced-intensity conditioning regimens, which result in fewer days of 
fever and less gram-positive coccal bacteraemia.90 
The association between chemotherapy-induced MBI of the gut and the occurrence of acute 
GvHD, which frequently involves the gut is compelling.91 Not surprisingly, by preserving the 
mucosal barrier using less mucotoxic non-myeloablative conditioning regimens and drugs 
including rh-KGF and Wnt signalling agonist R-spondin-1, has been shown to ameliorate or 
delay acute GvHD, although thus far only in animal studies.92,93 In humans rh-KGF seemed 
not protective for GvHD, despite the reduced incidence of oral mucositis, but this is probably 
explained by a virtual lack of effect of the growth factor on intestinal mucositis.94,95
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3. CONTEXT DEPENDENT ROLE FOR MBI?
It is important to realise that the extent of MBI differs strongly among patient categories, cancer 
subtypes and mostly the cytotoxic therapies that are employed. Intensive cytotoxic therapies 
that are used for hematological malignancies bear the highest risk for MBI and related inflam-
matory complications. The exact role for MBI in the treatment of solid tumours is less clear 
and warrant further investigation. Nevertheless, most chemotherapy schemes accompanied 
by a 20% or higher incidence of febrile neutropenia are associated with the occurrence of 
mucositis and also in these setting MBI may contribute to the occurrence of fever.96,97
RESEARCH QUESTIONS
1. NEW WAYS OF TREATING FEVER IN CANCER PATIENTS?
The concepts of febrile neutropenia and MBI-related fever are at least complementary and have 
implications for the care of neutropenic patients at risk for developing fever and infection, not 
least in reassessing the role of antimicrobial strategies (Figure 3). Antibacterial prophylaxis 
may be most beneficial to patients who develop MBI. When fever develops, switching to 
parenteral antibiotics empirically is common practice although this may not always be effective 
or even necessary in all patients. However, it cannot be predicted who is to benefit and who 
is not and therefore empirical antibiotics cannot be discarded. Nevertheless, simply switching 
or adding antimicrobial agents for persisting FUO should be discouraged, although in the absence 
of diagnostic tools or a high background incidence of fungal infections empirical antifungal 
therapy might be considered. Instead, especially because of the growing armamentarium of 
diagnostic tools, an attempt should be made to diagnose microbiologically and clinically defined 
infections. Further therapy could then be directed by the findings. This would limit antimicrobial 
therapy to those most at risk (Figure 3) and would help limit the emergence of antimicrobial 
resistance, reduce the risk of inducing dysbiosis and help contain health costs. The modest 
effects of hematopoietic growth factors should also be carefully balanced against the potential 
side effects and high costs. 
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Figure 3. Inflammatory response and the response to antibiotics 
Patients treated with chemotherapy for cancer can mount a sustained inflammatory response with fever 
irrespective of whether an infection is involved. This is partly the result of MBI of the oral cavity and gut. 
The innate immune responses during this process are not necessarily directed at any particular microbial 
pathogen, but can be initiated by microbial motifs (PAMPs) and tissue damage (DAMPs) alone. The  
resulting fever leads to therapy with antimicrobial agents, which in a substantial proportion of patients 
will have no effect on the persisting fever and inflammation. Therefore other approaches should be  
explored, including the use of mucosal growth factors, PRR agonists and antagonists, and pre- and pro-
biotics, in order to restore the perturbed host microbe responses at the integument so the outcome of 
cancer patients can be improved.
Other approaches might be more appropriate for dealing with protracted inflammation and 
fever given the role of MBI and innate immune perturbations. For instance, restoring mucosal 
health or at least preventing mucosal damage of the oral cavity and gut can avert microbial 
translocation, bacteraemia, and innate immune activation by PAMPs.  However, there are few 
remedies available to ameliorate MBI.98 Borrowing ideas from other areas with knowledge of 
MBI and deregulated immunity, for instance gastroenterology (inflammatory bowel diseases) 
and hematology (GvHD), may help. Promising approaches include the use of growth factors to 
stimulate intestinal stem cells, e.g. R-spondin-1, IL-22 and glucagon-like peptide,99 modulation 
of PRR activation by agonist and antagonists,100 and modulation of the gut microbiota.101 The 
microbiota can also be modulated by employing pre- and probiotics and has been shown 
effective in treating antibiotic-associated diarrhoea caused by Clostridium	 difficile and gut 
inflammation.102 Guidelines for managing intestinal mucositis already suggest that probiotic 
treatment containing Lactobacillus species may prevent chemotherapy and radiotherapy- 
induced diarrhoea in patients with pelvic malignancies.98 
Exploiting the existing negative feedback and anti-inflammatory pathways that facilitate tissue 
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repair and resolution of inflammation might offer another approach.103 This can be achieved 
by correcting deficiencies in antimicrobial peptides, e.g. lactoferrin and defensins,104 using 
anti-inflammatory cytokines e.g. IL-10 , and with the use of cytokine inhibitors, e.g. IL-1Ra.105 
Similarly, scavengers of PAMPs and DAMPs may prove productive to study with candidate 
molecules consisting of antimicrobial peptides, innate defence regulators, and recombinant 
antibodies, for example anti-HMGB-1.106 
2. RISK PREDICTION AND INDIVIDUALIZED RISK?
It would be very helpful if the risk of complications could be estimated before starting treatment 
of malignancies. This would require the integration of patient characteristics (age, gender), 
treatment characteristics (type of chemotherapy, schedule, intensity), and genetic predisposi-
tion. Genes related to drug metabolism, organ function, host immunity, tissue repair and stem 
cell recovery are all likely to be involved in the development of neutropenia, MBI, and infection. 
For instance, relationships have been shown between TLR4 polymorphisms and neutropenia 
in children with acute lymphoblastic leukaemia,107 polymorphisms in mannose binding lectin, 
TLR4 and dectin-1 and an increased risk of bacterial and fungal infections108,109  and NOD2 
polymorphisms have been associated with Crohn’s disease and GvHD.64 
Citrulline has been shown to be a good marker of gut damage and permeability with low levels 
being associated with the occurrence of bacteraemia and inflammation.21,83 Other potential 
biomarkers include regenerating islet-derived 3-alfa, as it correlates well with the severity of 
intestinal GvHD,110 and intestinal fatty acid-binding protein and ileal bile acid-binding protein, 
both proteins being released by dying mature enterocytes.111 
The old idea of preserving the gut ecology has been given a new impulse with recent advances 
in molecular biology that allow the identification of the composition of the patients own 
gut microbiota. Hence we now know that there are three different enterotypes112  and that 
dysbiosis has important impact on auto-immunity, allergy and auto-inflammatory diseases. 
There are also strong indications that the microbiota varies amongst patients with cancer and 
has an impact on the occurrence of MBI and the related inflammatory response.66,69 Moreover, 
oral and colonization with Candida species have been related to the occurrence of GvHD, 
especially of the gut.113 This knowledge might be used in the future to better predict which 
patients are at most risk for developing chemotherapy-induced MBI and related complications.
CONCLUSION
Patients treated with chemotherapy for cancer can mount a sustained inflammatory response 
with fever irrespective of whether an infection is involved. This is partly the result of MBI of 
the oral cavity and gut. The innate immune responses during this process are not directed at 
any particular microbial pathogen but are initiated by microbial motifs (PAMPs) and tissue 
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damage (DAMPs) and are excessive, inappropriate and propagate tissue damage resulting in 
an increased burden of illness for cancer patients. The resulting fever is currently managed by 
employing antimicrobials for therapy, which in certain sub-categories of patients has little or no 
effect on persisting fever and inflammation. The time seems ripe for considering an alternative 
model that takes MBI and innate immunity into account and complement the paradigm of 
“febrile neutropenia” with that of  “febrile mucositis”. This should provide a new impulse for 
developing drugs and other therapeutic approaches to tackle the principal problem and 
re-establish the balance between the host and the microbiota. 
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SUMMARY
Studying the role of citrulline in HSCT recipients is the focus of this thesis. Citrulline is a marker 
of cytotoxic therapy-induced intestinal mucosal barrier injury (MBI) allowing us to explore the 
role of intestinal MBI in the occurrence of fever and infections. The value that measuring 
citrulline could add to the current care of the HSCT recipient is discussed. 
PART I: BACKGROUND OF MANAGING FEBRILE NEUTROPENIA IN HEMATOLOGY 
PATIENTS
In	this	first	part	it	is	described	how	historical	perspectives	still	determine	the	approach	of	fever	
and	infections	in	the	current	daily	practice	in	patients	with	hematological	malignancies.	
Until 1960’s, most patients with cancer could not be cured but this began to change after the 
early successes of cytotoxic chemotherapy. However it became rapidly clear that the destructive 
effect of chemotherapy was not limited to cancer cells. Haemorrhage and infection emerged 
as the most prominent complications of chemotherapy. Blood transfusion was an effective 
remedy for bleeding but infection proved more intractable as it was difficult to diagnose early 
enough to treat effectively, and such antibiotics as were available were limited in spectrum, had 
to be given in combination, and were only marginally effective. By 1966 a positive correlation 
was shown between the severity and duration of neutropenia (defined as an absolute neutrophil 
count of ≤ 0.5 x 109 granulocytes/L) and the risk of acquiring a life-threatening bacterial infection. 
Since fever in the immunocompromised patient was most often the first and only sign of 
infection, the syndrome became known as “febrile neutropenia” to indicate a life-threatening 
event that, if left untreated, could result in fulminant sepsis and death. A few years later it was 
demonstrated convincingly that lives were saved by administering promptly antimicrobial 
agents that covered the common pathogens. This approach became known as empirical therapy 
which was given at the onset of fever during neutropenia without waiting for the results of 
blood cultures. As a result, it was widely adopted and soon became the standard of care. In the 
years that followed, better antimicrobial agents allowed doctors to intensify their chemotherapy 
regimens. A spiral of subsequent rounds of improved antibiotic cover and further escalations 
of cytotoxic regimens ensued resulting in more remission of hematological malignancies and 
in helping stem cell transplantation to become successful enough to become an accepted 
treatment modality. 
The approach to preventing and treating infectious complications remained essentially the 
same and emphasised neutropenia as the primary risk factor. Hence physicians and nurses 
aligned their monitoring and care to neutropenia to detect infections as early as possible so 
that empirical antibiotic treatment could be started as soon as fever developed. The practice 
of empirically adjusting initial empirical therapy also became widespread with a variety of 
algorithms being adopted for treating febrile neutropenic patients without an evident infectious 
focus. Typically these algorithms dictated that adjustments to the empirical antimicrobial 
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therapy should be made after a fixed duration of fever typically three days after onset, even if 
the patient was stable or recovering. Moreover, antimicrobials were to be given for at least 7 
days or more or until neutropenia resolved. 
This placed a great demand on the antimicrobials that were available leading to the overuse 
of these agents but was justified on the grounds that a broader antimicrobial coverage would 
benefit the patient. The downside was largely ignored but included induction of antimicrobial 
resistance, perturbation of the ecological microbial balance of the gut flora as well as drug- 
induced side effects that might include drug fever, rash or even organ toxicity. 
In fact, antimicrobial resistance and the sharp decline in the development of new antimicrobial 
agents now pose a serious threat to caring for these patients in the future. This is reason 
enough to reconsider our current strategies and revisit the impact of the cytotoxic therapy-
induced damage to other parts of the host defences (chapter	2).  
PART II:  INTRODUCTION OF CITRULLINE AS BIOMARKER FOR INTESTINAL 
MUCOSAL BARRIER INJURY
To	investigate	the	role	of	intestinal	MBI	in	the	development	of	fever	and	infections,	it	is	important	
to	have	a	reliable	biomarker.	The	amino	acid	citrulline	is	one	of	the	new	potential	biomarkers	
of	intestinal	MBI	and	was	studied	in	clinical	studies.
Chapter	3 is a review of the amino acid citrulline and its potential role as a biomarker for MBI. 
Citrulline is not incorporated into proteins which means that circulating citrulline in the blood 
depends only on “de novo” synthesis and absorption of food. In the case of citrulline, it is not 
only not commonly present in food, but it is almost exclusively synthesized and released by 
the intestine (especially the small bowel) into the bloodstream. Hence, irrespective of the cause, 
damage to the intestine will result in lower levels of circulating citrulline. Citrulline is not 
influenced by inflammation, there is no appreciable uptake by the liver and the kidney is the 
major consumer of the amino acid. Accordingly, with normal renal function, the concentration 
of citrulline depends only on the production and release of citrulline by the intestine. Further-
more citrulline can be measured by a simple and relatively inexpensive blood test. The review 
shows that the use of citrulline enables standardized assessment of intestinal MBI which can 
improve the management of intestinal MBI- related complications. 
In chapter	 4 plasma citrulline was assessed as marker for intestinal MBI in a cohort of 94 
recipients of a HSCT who had received different conditioning regimens. It was shown that 
each treatment regimen induced a unique and different course of MBI. Two citrulline-based 
assessment scores were developed; one based on the level of citrulline, using severity thresholds, 
and a second based on the area under the reciprocal (10/citrulline) curve. Both are able to 
delineate between damage induced by different conditioning regimens. However the score 
based on the area under the reciprocal curve of citrulline is probably only appropriate for 
research purposes, though only a few measurements are necessary to estimate this score. For 
206
Chapter 12
clinical purposes, a scoring system based on absolute citrulline concentrations seems more 
practical for determining intestinal MBI. This makes a score based on citrulline more specific 
and sensitive than either one based on signs and symptoms (such as World Health Organization 
and the National Cancer Institute- Common Terminology Criteria for Adverse Event (NCI-CTCAE) 
scales) or on sugar permeability tests. 
In chapter	5 the use of plasma citrulline was compared to albumin concentrations which clini-
cians often rely on to indicate, among other things, intestinal function. The course of citrulline 
and albumin was evaluated in a cohort of 106 patients treated with different conditioning 
regimens (myeloablative and non-myeloablative). It was shown that albumin levels were greatly 
influenced by inflammation, confirming it to be a “negative acute phase protein”. This was not 
the case for citrulline which proved to be a better marker of intestinal MBI.
In conclusion, citrulline has shown to be an objective, reproducible, specific and reliable 
marker for intestinal MBI in patients following a HSCT.
PART III: FEBRILE NEUTROPENIA OR FEBRILE MUCOSITIS?
In	 this	part	by	measuring	citrulline	the	role	of	 intestinal	MBI	 in	 the	occurrence	of	 fever	and	 
infections	is	studied.
In chapter	6 the role of intestinal MBI in the occurrence of bacteraemia was investigated. In a 
retrospective study of autologous HSCT recipients who had been given high-dose melphalan 
as conditioning regimen, we showed that bacteraemia only occurred in those patients with 
fever (defined as a temperature ≥ 38,5 °C) during neutropenia who had hypocitrullinaemia, 
i.e. citrulline below 10 μmol/L. This suggests that the severity of intestinal MBI determines 
whether or not bacteraemia occurs, rather that neutropenia per	se. The extent of MBI deter-
mined the loss of the physical barrier thereby facilitating bacteraemia due to micro-organisms 
originating from the gut. All episodes of bacteraemia were either due to viridans streptococci 
and coagulase negative staphylococci which are known to originate from the gastrointestinal 
(GI) tract in these patients.  
This was followed by a study involving a cohort of 163 patients who were treated with six 
different conditioning regimens for autologous and allogeneic HSCT. There was a striking 
pattern of inflammation (measured by CRP) following myeloablative conditioning with the 
onset of fever coinciding with occurrence of MBI. Furthermore the inflammatory response 
and fever corresponded to the occurrence of MBI whether or not bacteraemia developed 
suggesting that fever is the direct consequence of MBI alone, irrespective of the duration of 
neutropenia, at least for some HSCT recipients. Hence MBI- related fever might be better 
termed “febrile mucositis” instead of “febrile neutropenia”. Moreover, patients with fever 
who developed bacteraemia during neutropenia also had hypocitrullinaemia, reflecting the 
central role of MBI in the triad of MBI, inflammation and bacteraemia (chapter	7).
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To further untangle the relationship between intestinal MBI, neutropenia and the occurrence 
of inflammation, fever and bacteraemia, we performed a study in which a non-myeloablative 
regimen was compared with a myeloablative regimen to prepare for a HSCT with blood cultures 
being obtained for screening at regular intervals from admission onwards as well as at the onset 
of fever to investigate bacteraemia. This study showed that myeloablative treatment induced 
severe intestinal MBI manifested by hypocitrullinaemia, which was accompanied with an 
inflammatory response and bacteraemia in 44% of cases. By contrast, treatment with a non-
myeloablative regimen was accompanied by less MBI, only modest inflammation and no 
bacteraemia. However both groups experienced profound neutropenia and its duration was 
significantly longer for those receiving the non-myeloablative regimen. These results suggest 
that hypocitrullinaemia defines the period of risk for bacteraemia better than does neutropenia 
and that measuring citrulline may prove useful in deciding who needs antimicrobial treatment 
and when (chapter	8). 
PART IV: CONSEQUENCES OF USING CITRULLINE IN CLINICAL PRACTICE  
In	this	last	part	we	investigated	how	we	might	use	the	knowledge	gained	from	studying	MBI	
and	the	kinetics	of	citrulline	to	improve	the	management	of	febrile	episodes	of	patients	who	
received	intensive	cytotoxic	treatment	for	cancer.	
The recombinant human keratinocyte growth factor palifermin was shown to reduce the MBI 
of the oral cavity after TBI-containing regimens to prepare for allogeneic HSCT but not after 
other regimens. A protective effect of palifermin on intestinal MBI was seen when measured 
by permeability tests on the intestinal barrier of HSCT recipients who had been given BEAM 
as conditioning therapy. Therefore we also performed a study in a cohort of HSCT recipients 
given BEAM but used citrulline as a marker for intestinal MBI. While our study failed to detect 
any clinical relevant impact of palifermin on intestinal MBI it illustrated the usefulness of 
measuring citrulline for evaluating new therapies and strategies directed at the preservation 
on enterocyte mass, intestinal integrity and function (chapter	9).
Because of the central role MBI plays, we hypothesized that the onset of hypocitrullinaemia 
might help identify the period when a patient is at highest risk of developing fever and bacterae-
mia. To study this we investigated the occurrence of inflammatory and infectious complications 
of a conditioning regimen that was started on different days in a homologous group of HSCT 
recipients. We showed that by planning the start of the conditioning we could limit the risk of 
patients developing fever and bacteraemia during the weekend. This is important for our usual 
care as it could make managing HSCT recipients outside the hospital feasible and safe if 
accompanied by regular outpatient visits (chapter	10).  
Finally, to gain a better insight into the true cause of fever in the patient with cancer, we 
postulated the new paradigm “febrile mucositis” in a review that also summarized the existing 
evidence for “febrile neutropenia”. We showed that, at least for some HSCT recipients, fever 
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is a direct consequence of MBI alone and that neutropenia plays a minor role or none at all. 
The term “febrile neutropenia” is misleading for these patients, as it does not reflect the true 
nature of fever induced by cytotoxic therapy and we suggest that the term “febrile mucositis” 
may be more appropriate. These patients are unlikely to benefit from adding or changing 
antimicrobials empirically or from treatment with growth factors such as G-CSF but may be 
exposed unnecessarily to the risk of side effects of these agents. Even though patients with 
fever during neutropenia will still need to be treated initially with antimicrobial therapy given 
empirically, switching or adding antimicrobials on the basis of persistent unexplained fever (≥ 
3 days of fever) or “FUO” should be discouraged. Instead, a vigorous attempt should be made 
to diagnose or exclude infection. This approach will reduce the prescription of antimicrobial 
therapy and G-CSF, thereby helping to reduce health care costs, antimicrobial resistance and 
the risk of creating an imbalance between harmful and protective bacteria. Furthermore, the 
paradigm “febrile mucositis” will help open new doors to further improve the supportive care 
of cancer patients (chapter	11).   
 
FUTURE PERSPECTIVES
The following recommendations can be made for the role of citrulline in: 
A) POST-TRANSPLANT PERIOD OF HSCT RECIPIENTS
Several studies over the last decades have shown that MBI is not only one of the most debilitat-
ing side-effects of the intensive treatment prior to a HSCT1, but is also an important determinant 
in the occurrence of post-transplant complications. It is associated with inflammatory and 
infectious complications, occurrence of acute graft versus host of the gut, greater use of total 
parental nutrition and opioids analgesics, as well as increased costs, length of stay and mor-
tality.2-4 Citrulline is a valuable biomarker of intestinal MBI in HSCT recipients and allows for a 
standardized assessment of MBI and can support the management of MBI-related complications. 
Thus the time seems ripe for an alternative approach in HSCT recipients in which MBI plays a 
more important role than it has before.
This can potentially result in the following benefits:
o  Knowledge concerning the course of MBI can be used to limit antimicrobial therapy to 
those most at risk, which can limit the emergence of antimicrobial resistance, reduce the 
risk of inducing dysbiosis and help contain health care costs. As example, antibacterial 
prophylaxis may be most beneficial to patients who develop MBI; and in patients who are 
treated with empirical antibiotics because of fever, simply switching or adding antimicrobials 
for persisting  “FUO” should be discouraged. Currently in the Netherlands a `short versus 
extended  treatment with a carbapenem for high-risk febrile neutropenia in hematology 
patients with “FUO” (SHORT trial)’ has been started to answer the question whether or 
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not it is safe to discontinue the empirical antibiotic therapy of patients with “FUO” after 3 
days.5
o  The workload of nurses can be reduced if the risk period for fever and infections is determined 
by MBI instead of neutropenia. The feasibility of managing at least some of HSCT recipients 
outside the hospital could also be investigated under strict defined circumstances.       
o  MBI is likely to be the main determinant for not only choosing nutritional support but also 
how it is given. Total parenteral nutrition (TPN) is still the only option when there is severe 
malfunction of the gut, GI-fistulae or prolonged ileus, but patients may benefit more from 
enteral support once intestinal reconstitution occurs.6 For instance, TPN is probably only 
necessary for a limited time after myeloablative regimens whereas patients given non-
myeloablative regimens probably benefit more from enteral nutrition. If citrulline levels 
are able to guide the best approach for nutritional support this will most likely lead to a 
reduction of TPN use as well as thrombosis and catheter related infections. Studies are 
eagerly awaited in HSCT recipients to investigate this more thoroughly.  
o  MBI could play a role in determining the optimal route for administering medication, including 
antimicrobial agents. 
Clearly, formal studies are necessary to determine the specific thresholds of citrulline levels 
at which certain actions should be taken or the course of actions changed and to evaluate 
whether actions based on the severity of MBI really do lead to the expected improvements in 
the management of HSCT recipients in terms of reduced morbidity and mortality, better quality 
of life and lower health care costs.
B) GASTRO-INTESTINAL ACUTE GRAFT-VERSUS-HOST DISEASE (GI-GvHD)
Citrulline may also have a role in measuring the intestinal damage associated with GI-GvHD 
and therefore in monitoring the response to treatment thereby allowing timely adjustments 
in case of failure. However the use of citrulline should be compared to other biomarkers, such 
as regenerating islet-derived-3-α (REG3α) and albumin. 
o  REG3α, a C-type lectin (an antimicrobial protein) secreted by Paneth cells, has been iden-
tified as a biomarker of GvHD of the lower GI tract that can differentiate GI-GvHD from 
non-GvHD diarrhoea.7 Moreover, REG3α levels were prognostic with regards to steroid 
responsiveness of GvHD and post-transplant mortality.8,9 
o  Albumin is another organ specific biomarker for GI-GvHD. In allogeneic HSCT recipients 
prepared with reduced intensity regimens, decreases in serum albumin before aGvHD 
onset have substantial predictive value for aGvHD severity and mortality.10 The albumin 
level is also an independent prognostic factor for acute GI-GvHD, in contrast with acute 
GvHD of the skin.11 Albumin levels on day 5 after starting steroid treatment could be used 
as a predictor of GvHD response to steroid treatment.12 
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Such biomarkers can be used in the future to generate a grading system that will allow better 
risk stratification and rapid identification of those patients with severe GI damage in whom 
standard treatment is likely to be insufficient and who need pre-emptive intensification of 
aGvHD therapy.
C) SOLID TUMOURS
Beside HSCT recipients, also other patients treated with cytotoxic therapy for cancer can develop 
intestinal MBI. The exact role for MBI in the treatment of solid tumours is less clear but MBI 
may also contribute to fever and infection. Also severe MBI should lead to a reduction of the 
dose in subsequent treatment cycles to prevent potentially fatal complications. Investigations 
using citrulline are awaited especially for regimens that induce fever during neutropenia in 
more than 20% of the patients. 
D) EXPLORING REMEDIES TO AMELIORATE MBI
We need to find ways of preventing or ameliorating MBI to be able to further intensify our 
treatment in order to cure more patients, since this is an important dose-limiting toxicity. For 
example, restoring mucosal health or at least preventing MBI could prevent inflammation, micro-
bial translocation and bacteraemia. Citrulline can be used to explore remedies to ameliorate 
MBI. 
It may be fruitful to borrow insights and ideas from other medical areas such as inflammatory 
bowel disease and GvHD that are characterized by mucosal barrier damage and dysregulated 
innate immunity. Promising approaches, include the use of growth factors e.q. R-spondin-1, 
Interleukin-22 and glucagon-like peptide to stimulate intestinal stem cells to help restore the ana-
tomical barrier, as well as modulation of pattern-recognition receptors and the gut microbiota.13-16 
Another approach might be to exploit pathways that enable tissue repair and resolution of the 
inflammatory process, by using anti-inflammatory cytokines (such as interleukin 10), or cytokines 
inhibitors (such as IL-1Ra), or scavengers that neutralize the effects of pathogen-associated- 
(PAMPs) and danger-associated- molecular patterns (DAMPs) (like anti-HMGB-1), or by 
correcting deficiencies in antimicrobial peptides (e.g. lactoferrin and defensins).17-20
Success in finding ways to prevent or treat MBI will be an important advance in the care of 
those patients who still need treatment of their cancer with cytotoxic regimens that induce MBI. 
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NEDERLANDSE SAMENVATTING VOOR 
NIET-INGEWIJDEN 
Voor veel patiënten met een hematologische maligniteit (bloedkanker) is het ondergaan van een 
stamceltransplantatie de enige mogelijkheid op genezing. Zo’n stamceltransplantatie traject 
omvat (1) een intensieve cytotoxische (celdodende) behandeling (bestaande uit chemotherapie 
met of zonder radiotherapie (bestraling)) die gericht is op het doden van snel delende kanker-
cellen, gevolgd door (2) het teruggeven van lichaamseigen (autoloog) of lichaamsvreemde 
(allogene) stamcellen. Vanuit deze stamcellen worden in het beenmerg, waar de bloedaanmaak 
plaatsvindt, weer gezonde bloedcellen gevormd. 
Een van de belangrijkste complicaties van deze behandeling is het optreden van koorts en 
infecties. Koorts treedt bij ongeveer 4 op de 5 stamceltransplantatie patiënten op. In 1 op de 
5 patiënten wordt daarbij een klinische infectie, zoals een longontsteking, gevonden en in een 
derde tot de helft van de patiënten is er een microbiologische infectie, zoals een bacteriëmie 
(dat wil zeggen, dat er bacteriën in het bloed aanwezig zijn). Patiënten kunnen hierdoor ernstig 
ziek zijn en ook overlijden. Voor 7% van de patiënten die een autologe stamceltransplantatie 
hebben ondergaan en voor 13-17% van de patiënten die een allogene stamceltransplantatie 
ondergaan, is een infectie de primaire oorzaak waaraan zij overlijden. De reden voor het 
optreden van koorts en infecties is voornamelijk dat cellen van het afweersysteem ook voor 
het overgrote deel snel delend zijn en ernstig beschadigd raken door de intensieve cytotoxische 
behandeling. Omdat patiënten door deze afgenomen afweer erg kwetsbaar zijn voor infecties, 
wordt er zodra een patiënt koorts ontwikkeld direct gestart met zeer breed dekkende antibiotica 
(veelal carbapenems of 3de/4e generatie cefalosporines). Blijft de koorts ook na 3-4 dagen 
aanwezig, zullen hieraan vaak nog andere antimicrobiële middelen worden toegevoegd. Nadien 
wordt gezien de kwetsbaarheid van de patiënt meestal relatief lang gewacht voordat de anti-
microbiële therapie weer gestaakt wordt. 
Dit betekent dat door de koorts en de infecties er een groot beroep gedaan wordt op de on-
dersteunende zorg, patiënten langer opgenomen blijven en kosten voor de zorg flink stijgen. 
Daarnaast zorgt het antibiotica gebruik voor ontregeling van de microbiële flora (ook wel het 
microbioom van de patiënt genoemd), worden patiënten blootgesteld aan de bijwerkingen 
van de antibiotica en zorgt uitgebreid en langdurig gebruik van antibiotica, voor het ontstaan 
van antibiotica resistentie. 
De toenemende antibiotica resistentie en de alsmaar stijgende zorgkosten zijn belangrijke 
factoren die de behandeling van (hematologische) patiënten met kanker in de toekomst 
bedreigen. 
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HET MICROBIOOM EN DE AFWEER 
VAN DE PATIËNT 
Ieder mens bestaat uit 10 miljoen kernhoudende cellen en ter hoogte van de oppervlakken van 
het lichaam, zowel aan de buiten- als de binnenzijde, leven er nog eens 10 x zoveel bacteriën, 
namelijk zo’n 100 miljoen (Figuur 1). 
Figuur 1. Microbioom van de mens
Aantal micro-organismen die leven in onze darmen, op onze huid en andere lichaamsoppervlakken. 
Afkomstig uit: Donnelly JP, Blijlevens NMA, van der Velden WJFM. Infections in the Immunocompromised 
Host: General Principles. Principles and practice of infectious diseases, 8th Edition: 3384-3395. 
Gebruikt en vertaalt naar het Nederlands met toestemming van de auteurs. 
Dit lichaamseigen microbioom speelt een belangrijke rol in het functioneren van de mens en 
helpt, in geval van een intacte anatomische barrière (zoals huid of spijsverteringsstelsel) om 
het lichaam te beschermen tegen pathogene (ziekmakende) micro-organismen. 
Echter bij beschadiging van de anatomische barrière raakt deze interactie met micro-organismen 
ontregeld. Hierdoor kunnen micro-organismen die zich normaal gesproken onschuldig gedragen, 
opeens voor een infectie zorgen. Zodra bacteriën er in slagen om de barrière van bijvoorbeeld 
huid of darm te passeren, zullen specifieke witte bloedcellen, neutrofielen genoemd, gaan 
proberen de bacteriën onschadelijk te maken. Als neutrofielen hier onvoldoende in slagen, 
worden vervolgens andere soorten bloedcellen voor de afweer geactiveerd. 
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GEVOLGEN VAN DE CYTOTOXISCHE 
BEHANDELING OP DE AFWEER
1. NEUTROPENIE (VERLAAGD AANTAL NEUTROFIELEN) 
Van oudsher is gedacht dat de belangrijkste oorzaak voor de afgenomen afweer bij stamcel-
transplantatie patiënten, in de eerste periode na de transplantatie, komt doordat de cytotoxische 
behandeling zorgt voor afname van neutrofielen. Het beenmerg waar bloedcellen worden 
gemaakt, is snel delend en raakt ernstig beschadigd door de cytotoxische behandeling. Daar 
neutrofielen een korte levensduur hebben, zal de schade aan het beenmerg hier het eerste 
zichtbaar worden. Koorts die optreedt bij neutropenie, noemt men “febriele neutropenie” en 
wordt gerelateerd aan de ernstige infecties die optreden. Op basis van neutropenie wordt bij 
stamceltransplantatie patiënten de risicoperiode bepaald waarbinnen infecties kunnen optreden 
en extra controles door verpleegkundig personeel nodig zijn. Op het moment van vaststellen 
van “febriele neutropenie” wordt direct met empirische (dat wil zeggen: op basis van ervaring) 
antibiotica gestart. Deze antibiotica worden op zijn minst 7 dagen gegeven en vaak pas gestaakt 
als de neutropene periode over is. 
2. BESCHADIGING VAN DE ANATOMISCHE BARRIÈRE.
De anatomische barrière (zoals huid en spijsverteringstelsel) is echter ook snel delend en zal als 
gevolg van de cytotoxische behandeling eveneens beschadigen. Vooral de gevolgen ter hoogte 
van de darm zijn hierbij interessant, omdat hier 90% van de blootstelling aan micro-organismen 
plaatsvindt.
Vooralsnog wordt in de zorg van stamceltransplantatie patiënten hieraan echter weinig aandacht 
besteed. 
2.1		Mucositis
De schade die wordt aangericht aan de slijmvliezen van het spijsverteringskanaal wordt mucositis 
of mucosale barrière schade genoemd. 
Vaak wordt mucositis onderverdeeld in orale mucositis (schade aan het mondslijmvlies) en 
intestinale mucositis (schade aan het darmslijmvlies). 
Mucositis wordt over het algemeen gezien als een vervelende bijwerking van de gegeven 
cytotoxische behandeling, die echter ook spontaan weer overgaat. Doordat orale mucositis 
redelijk eenvoudig gezien kan worden door in de mond te kijken, is hier veel meer over bekend 
dan over intestinale mucositis. 
2.1.1. Scoringsmethoden	op	basis	van	symptomatologie 
Orale mucositis is zichtbaar in de mondholte als rood, snel bloedend slijmvlies al dan niet in 
combinatie met zweren. Het geeft pijnklachten waardoor patiënten minder gaan eten en drinken. 
De scoringsmethoden van o.a. de Wereldgezondheidsorganisatie (WHO) baseren zich op deze 
objectieve en functionele gegevens om orale mucositis in kaart te brengen. 
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Dit is echter lastig als het intestinale mucositis betreft. Intestinale mucositis kenmerkt zich 
door misselijkheid, braken, buikpijn en diarree waardoor de eetlust afneemt en gewichtsverlies 
optreedt. Deze symptomen kunnen echter ook directe bijwerkingen zijn van de gegeven cyto-
toxische behandeling of van andere toegediende medicatie. Bijvoorbeeld morfine gebruik, 
gegeven voor de pijn, kan constipatie geven en dus tekenen van intestinale mucositis vertroebe-
len. Bovendien kan intestinale mucositis alleen gezien worden wanneer met behulp van een 
endoscoop (een kijkbuis) in de darm gekeken wordt en er eventueel een darmbiopt (hapje 
slijmvlies) wordt afgenomen. Bij pathologisch onderzoek zal dan atrofie (afsterven) van de villi 
(darmvlokken) gezien worden. Endoscopisch onderzoek is echter ingrijpend en mogelijk ook 
gevaarlijk voor de patiënt vanwege het risico op infectie, bloedingen (omdat ook de bloedplaatjes 
laag zijn door de effecten op het beenmerg) en perforatie (ontstaan van een gaatje in de 
darm). In de praktijk wordt dit onderzoek daarom zeker niet routinematig toegepast. 
2.1.2. Absorptie-	en	permeabiliteittesten
Om toch meer te weten te komen over intestinale mucositis is daarom gekeken naar verande-
ringen in het functioneren van de darm zodra er schade optreedt. De beschadiging van de darm 
veroorzaakt veranderingen in de absorptie (opname) en permeabiliteit (doorlaatbaarheid) 
van verschillende stoffen. Om dit vast te leggen is gebruik gemaakt van verschillende suikers 
en soms ook radioactief gelabelde stoffen. Deze worden oraal (via de mond) ingenomen en later 
in de urine gemeten. De mate waarin bepaalde suikers al dan niet worden opgenomen via het 
darmslijmvlies om nadien vanuit de bloedbaan in de urine te worden uitgescheiden, zegt iets 
over de darmfunctie. Op deze manier wordt direct na toediening van een cytotoxische behandeling, 
die intestinale mucositis veroorzaakt, een afname van de darmfunctie gezien. In de dagen die 
hierop volgen, neemt de functie van de darm steeds verder af, totdat vaak na ongeveer 10-14 
dagen de grootste afname in darmfunctie wordt bereikt. Dit dieptepunt wordt gevolgd door 
een geleidelijk herstel van de darmfunctie. Beperkingen bij deze absorptie- en permeabiliteit-
testen zijn o.a. verschillen in maagledigingssnelheid, darmpassagetijd en nierfunctie. Bovendien 
zijn deze onderzoeken erg belastend voor de patiënt, wat in de praktijk betekent dat de patiënt 
dit onderzoek vaak zal weigeren juist op het moment dat de schade aan de darm het ergst zal zijn. 
Daarom is uitgekeken naar een andere manier om de schade aan de darm, als gevolg van de 
cytotoxische behandeling, vast te leggen. De voorkeur ging hierbij uit naar een marker die 
bepaald zou kunnen worden in het bloed. Dit, daar bij stamceltransplantatie patiënten, al omwille 
van allerlei andere redenen, vrijwel dagelijks bloed wordt afgenomen. Bovendien gebeurt deze 
bloedafname veelal via een centrale lijn, waardoor het weinig belastend is voor de patiënt. 
2.1.3.	 Citrulline   
In 2003 verscheen een artikel over patiënten waarbij darmvlokken afstierven o.a. als gevolg van 
coeliakie (glutenintolerantie). Hierin werd beschreven dat bij deze patiënten de mate van darm-
schade kon worden vastgesteld door het meten van een aminozuur in het bloed. Dit aminozuur 
is citrulline. Citrulline is een interessante marker om de mate van darmschade te meten, omdat 
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alleen het slijmvlies van de darm (om precies te zijn: de enterocyt) dit in aanzienlijke hoeveel-
heden afgeeft aan de bloedbaan. Vervolgens passeert citrulline de lever zonder dat dit een 
significante invloed heeft op de totale citrulline concentratie en wordt het enkel door de nieren 
opgenomen uit de bloedbaan en omgezet in een ander aminozuur namelijk arginine. 
Dit betekent dat de hoeveelheid citrulline bij een normale nierfunctie direct gerelateerd is 
aan het aantal functionerende enterocyten. Bij beschadiging van het darmepitheel zal het ge-
halte aan citrulline in het bloed dalen. 
Citrulline is vervolgens ook onderzocht in andere categorieën van patiënten, onder meer bij 
patiënten met een kortedarmsyndroom (dit syndroom wordt gekenmerkt door een tekort aan 
goed functionerend darmweefsel) en patiënten die een darmtransplantatie hadden ondergaan. 
Ook bij deze patiënten bleek de citrulline concentratie in het bloed een goede weergave van 
het functionerende darmepitheel. Zodanig is in ons ziekenhuis ook onderzocht of citrulline 
een geschikte marker zou kunnen zijn voor de schade aan de darm, die wordt aangericht door 
de intensieve cytotoxische behandeling, bij stamceltransplantatie patiënten. Eerdere studies 
wekken inderdaad deze indruk. 
In dit proefschrift wordt daarom nu de waarde van citrulline in deze patiëntengroep nader 
onderzocht. Allereerst wordt nagegaan in hoeverre citrulline een geschikte marker is voor 
intestinale mucositis bij alle stamceltransplantatie patiënten. Vervolgens wordt gebruik makend 
van citrulline bepalingen de rol van intestinale mucositis op het optreden van koorts en infecties 
onderzocht. De inzichten die hieruit voortvloeien, worden gebruikt om na te gaan in welke mate 
het bepalen van citrulline mogelijkheden biedt om de zorg voor de (hematologische) patiënt 
met kanker verder te verbeteren. 
Dit proefschrift bestaat uit 4 delen.
DEEL I. DE HUIDIGE PRAKTIJK. 
In	dit	eerste	deel	wordt	beschreven	waaruit	onze	huidige	zorg	ten	aanzien	van	een	infectie	bij	
de	neutropene	patiënt	met	een	hematologische	kanker	bestaat	en	hoe	dit	beleid	in	de	loop	der	
jaren	tot	stand	is	gekomen.	
In de 20e eeuw is er namelijk veel veranderd met betrekking tot de zorg voor de (hematologische) 
patiënt met kanker. Zo is het in de eerste helft van de 20e eeuw vrijwel onmogelijk om te 
genezen en overlijden bijna alle patiënten aan de gevolgen van hun ziekte. Dit verandert in 
de 60er jaren met de komst van cytotoxische middelen. Hierdoor blijven sommige patiënten 
leven. Terwijl er ook andere patiënten zijn die juist door de complicaties van deze behandeling 
overlijden. Infectie vormt hierbij één van de belangrijkste doodsoorzaken. 
In 1966 wordt voor het eerst beschreven dat deze ernstige infecties optreden tijdens, door 
cytotoxische behandeling geïnduceerde, neutropenie. Ontdekt wordt dat naarmate de ernst 
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en duur van de neutropenie toeneemt, er ook meer kans is op ernstige en levensbedreigende 
infecties. Kort daarop wordt ook ingezien dat er minder mensen aan een infectie tijdens neu-
tropenie overlijden wanneer er al bij de eerste tekenen daarvan, dat wil zeggen bij het optreden 
van koorts, gestart wordt met antibiotica en niet gewacht wordt tot er uit de bloedkweken 
eindelijk een bacterie wordt gekweekt. Dit leidt tot de introductie van de term “febriele 
neutropenie” (koorts bij neutropenie). De empirische aanpak (aanpak op basis van ervaring), 
waarbij er bij “febriele neutropenie” direct met breedspectrum antibiotica wordt gestart, 
wordt de standaardzorg voor de patiënt met kanker.
In de jaren die volgen zijn er steeds meer patiënten die genezen van kanker. Enerzijds komt 
dit door verbeteringen in de ondersteunende zorg, waaronder de empirische aanpak en de 
ontwikkeling van steeds nieuwere en betere antibiotica. Anderzijds wordt dit bereikt door een 
steeds intensievere cytotoxische behandeling (die ook mogelijk wordt door de betere onder-
steuning) en gaat stamceltransplantatie een onderdeel vormen van het behandelplan bij de 
patiënt met een hematologische kanker. 
Door deze intensievere behandeling raakt de afweer echter op veel meer fronten tegelijk 
beschadigd. Het huidige beleid ten aanzien van koorts en infecties is echter nog steeds gericht 
op het concept van “febriele neutropenie” (hoofdstuk	2). 
DEEL II. INTRODUCTIE VAN CITRULLINE ALS BIOMARKER VAN INTESTINALE 
MUCOSITIS 
Hier	wordt	citrulline	geïntroduceerd	als	marker	voor	darmschade	als	gevolg	van	cytotoxische	
behandeling.	
In hoofdstuk	 3	wordt in een review artikel beschreven welke rol citrulline kan hebben als 
marker van darmschade bij stamceltransplantatie patiënten. Hierbij wordt citrulline als marker 
afgezet ten opzichte van de tot op heden toegepaste methoden. Tevens wordt geïllustreerd 
hoe door het meten van citrulline de zorg voor patiënten (wellicht) verbeterd kan worden, 
namelijk door gerichtere toepassing van medicatie, antibiotica, en nutritionele ondersteuning. 
In hoofdstuk	4 wordt citrulline als marker van intestinale mucositis getest in 94 patiënten die 
een stamceltransplantatie ondergaan en vooraf behandeld worden met verschillende cyto-
toxische schema’s. Hierbij wordt getoond dat met behulp van citrulline het mogelijk is om te 
laten zien dat elk schema zijn eigen patroon van het optreden van intestinale mucositis 
(darmslijmvliesschade) heeft. Vervolgens worden twee scoringsmethoden beschreven, die 
allebei gebruik maken van de citrulline bepaling. De ene methode is meer geschikt voor de 
dagelijkse praktijk en baseert zich op de werkelijke hoogte van het citrulline gehalte in het 
bloed. Citrulline waarden onder de 10 μmol/L  (hypocitrullinemie)  zijn hierbij overeenkomend 
met een beeld van totale villusatrofie, dat wil zeggen de meest ernstige beschadiging van het 
darmslijmvlies. De andere methode baseert zich op het totale verloop van het citrulline gehalte 
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gedurende 30 dagen en kan daardoor beter voor onderzoeksdoeleinden gebruikt worden om 
op deze manier verschillende behandelingsregimes of interventies met elkaar te vergelijken. 
Uit beide methoden wordt echter duidelijk dat bij stamceltransplantatie patiënten citrulline 
een zeer sensitieve en specifieke marker is om intestinale mucositis weer te geven. 
 
Vervolgens wordt citrulline als marker van intestinale mucositis vergeleken met albumine. Dit, 
omdat veel clinici albumine gebruiken als een indicator voor de ernst van mucositis. Uit deze 
studie blijkt dat de waarde van albumine echter in belangrijke mate beïnvloed wordt door 
ontstekingsprocessen, terwijl dit niet voor citrulline geldt (hoofdstuk	5).
Geconcludeerd kan worden dat op basis van de sensitiviteit, specificiteit, de eenvoudige 
methodologie, en de relatief lage kosten citrulline de eerste keuze zou moeten zijn voor het 
objectief meten en monitoren van de door cytotoxische behandeling geïnduceerde intestinale 
mucositis.
DEEL III: FEBRIELE NEUTROPENIE OF FEBRIELE MUCOSITIS? 
In	dit	derde	deel	wordt	gekeken	naar	de	rol	die	intestinale	mucositis	speelt	in	het	optreden	van	
koorts	en	infecties	bij	patiënten	die	een	stamceltransplantatie	ondergaan.	
Figuur 2. Optreden van neutropenie en mucositis in relatie tot koorts en infecties
Deze figuur toont het verloop van de temperatuur, het optreden van infecties, mucositis en neutropenie 
nadat een stamceltransplantatie patiënt gestart is met chemotherapie. In het bovenste deel staat het 
verloop van temperatuur en het optreden van infecties. Het middelste deel toont wanneer mucositis 
optreedt. Het onderste deel laat het neutrofielen aantal per dag zien vanaf het moment dat er gestart 
is met chemotherapie.
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Zoals in figuur 2 wordt getoond treden koorts en infecties op ten tijde van zowel de neutropenie 
als mucositis. 
Met behulp van citrulline is vervolgens uitgezocht wat het belang van intestinale mucositis bij 
het optreden van deze inflammatoire en infectieuze complicaties is.
In hoofdstuk	6 wordt nagegaan wat de rol van intestinale mucositis is bij het ontstaan van een 
bacteriëmie. Dit wordt onderzocht in een uniforme groep van patiënten, die allen behandeld 
zijn voor een multipel myeloom, met hoge dosis melfalan gevolgd door een autologe stamcel-
transplantatie. In deze groep wordt gekeken naar de patiënten die “neutropene koorts” 
ontwikkelen, waarbij er wel of niet sprake is van een bacteriëmie. De citrullinewaarden van 
patiënten met een bacteriëmie worden vervolgens vergeleken met de citrullinewaarden van 
patiënten met enkel koorts. Deze studie toont aan dat de patiënten met een bacteriëmie 
significant meer darmschade hebben op het moment van koorts; alle patiënten met een 
bacteriëmie hebben een citrulline onder de 10 µmol/L. Tevens worden alle bacteriëmieën 
veroorzaakt door ofwel een coagulase negatieve stafylokok ofwel een streptococcus	viridans. 
Eerdere studies hadden al laten zien dat deze typen bacteriën uit het spijsverteringskanaal 
afkomstig kunnen zijn. Dit suggereert dat de ernst van de schade aan de darm bepaalt of er 
een bacteriëmie optreedt en niet de neutropenie.
Dit wordt gevolgd door een studie waaraan 163 stamceltransplantatie patiënten hebben deel-
genomen, die met 6 verschillende cytotoxische schema’s zijn behandeld, gevolgd door ofwel 
een autologe ofwel een allogene stamceltransplantatie. In deze studie is gekeken naar de rol 
die intestinale mucositis speelt bij het optreden van koorts en inflammatie (gemeten door 
CRP). Door de onderlinge verschillen in het ontstaan van intestinale mucositis tussen de 
behandelingsschema’s wordt zichtbaar dat het optreden van ernstige mucositis de belangrijkste 
factor is in het ontstaan van koorts bij patiënten, die behandeld zijn met schema’s die ernstige 
mucositis induceren (myeloablatieve schema’s). Het optreden van koorts en inflammatie 
correspondeert met het ontstaan van ernstige intestinale mucositis, ongeacht of er wel of geen 
sprake is van bacteriëmie. Deze studie veronderstelt dat in een aantal patiënten het ontstaan 
van koorts louter het gevolg is van intestinale mucositis en dat de duur van de neutropenie 
hierin geen rol bij speelt. Bij deze patiënten kan men daarom beter spreken van “febriele 
mucositis” (koorts bij mucositis) in plaats van “febriele neutropenie” (neutropene koorts). 
Overigens hebben ook in deze studie alle patiënten met een bacteriëmie een citrulline onder 
de 10 µmol/L. Intestinale mucositis lijkt daarom een centrale rol te spelen in zowel het optreden 
van koorts als in het ontstaan van een bacteriëmie (hoofdstuk	7). 
Om de relatie tussen intestinale mucositis, neutropenie en het optreden van koorts en 
bacteriëmie verder te ontrafelen, wordt vervolgens een studie uitgevoerd, waarbij stam-
celtransplantatie patiënten die behandeld zijn met een schema dat veel mucositis geeft (een 
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zogenaamd myeloablatief schema), worden vergeleken met stamceltransplantatie patiënten 
die behandeld zijn met een schema dat nauwelijks mucositis maar wel diepe en langdurige 
neutropenie geeft (een non-myeloablatief schema). In deze studie worden frequenter bloed-
kweken dan gewoonlijk afgenomen, namelijk minimaal 3x/ week en ook zonder dat er sprake 
is van koorts. Deze studie laat zien dat ondanks de significant langere diepe neutropenie duur 
in het non-myeloablatieve schema, er significant minder koorts en bacteriëmieën optreden 
ten opzichte van het myeloablatieve behandelregime. 
Kortom, de belangrijkste factor in het ontstaan van koorts en bacteriëmieën bij patiënten die 
een stamceltransplantatie ondergaan is de ernst van de mucositis en niet de neutropenie 
(hoofdstuk	8). 
DEEL IV: KLINISCHE CONSEQUENTIES 
In	dit	laatste	deel	wordt	gekeken	naar	mogelijke	consequenties	die	voortvloeien	uit	de	nieuw	
verworven	kennis	ten	aanzien	van	de	rol	van	intestinale	mucositis,	die	gemeten	kan	worden	
middels	citrulline	in	het	bloed.
Zo wordt met behulp van citrulline bepalingen bij patiënten met een lymfoom (lymfeklierkanker) 
het beschermende effect van palifermine, een humane keratinocyten groeifactor, op het optreden 
van intestinale mucositis getest. Alle patiënten in deze studie zijn behandeld met het cytotoxische 
schema BEAM (waarna een autologe stamceltransplantatie volgde), omdat permeabiliteittesten 
bij dit schema reeds eerder dit beschermende effect van palifermine hadden getoond. Helaas 
kon dit beschermende effect van palifermine op het darmslijmvlies niet geobjectiveerd worden 
door gebruik te maken van citrulline bepalingen. Wel toont deze studie het belang van citrulline 
aan in de beoordeling van de effectiviteit van een interventie voor intestinale mucositis 
(hoofdstuk	9).
Gebruik makend van eerdere observaties dat 1) het behandelingsschema het optreden van inte-
stinale mucositis bepaald en dat 2) intestinale mucositis de belangrijkste factor in het ontstaan 
en optreden van koorts en bacteriëmieën is, wordt vervolgens onderzocht of door het beter 
plannen van een stamceltransplantatie het risico op inflammatoire en infectieuze problemen 
in het weekend beperkt kan worden. Dit is van belang omdat dit wellicht mogelijkheden biedt 
om, na de infusie van autologe stamcellen, (een deel van) het stamceltransplantatietraject op 
een veilige manier met frequente poliklinische controles buiten het ziekenhuis te laten verlopen. 
Hiervoor wordt retrospectief gekeken naar patiënten met een multipel myeloom die behandeld 
zijn met hoge dosis melfalan voorafgaande aan een autologe stamceltransplantatie. De melfalan 
is bij deze patiënten op verschillende dagen in de week gestart. Deze studie laat zien dat, op 
grond van het verwachte beloop van intestinale mucositis, de dag waarop de chemotherapie 
start van invloed is op het al dan niet optreden van infecties in het weekend (hoofdstuk	10). 
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Tot slot wordt, in een review artikel, het concept “febriele mucositis” geïntroduceerd, waarmee 
wordt weergegeven dat koorts als gevolg van mucositis kan optreden. Deze koorts is het gevolg 
van het ontstekingsproces geïnduceerd in het slijmvlies door de cytotoxische therapie. Omdat 
het om een ontsteking gaat en niet om een infectie is het toedienen van antibiotica minder 
logisch. Het doel van de introductie van de term “febriele mucositis” is om dokters bewust te 
laten worden van de invloed van mucositis op het ontstaan van koorts, waardoor er kritischer 
met antibiotica kan worden omgegaan. Dit is van belang omdat minder en dus ook korter 
antibiotica gebruik zal leiden tot minder ontregeling van het microbioom, minder ontwikkeling 
van antibiotica resistentie en meest waarschijnlijk ook een kortere opnameduur; dit zal uitein-
delijk ook de kosten van de zorg voor de stamceltransplantatie patiënt doen afnemen. Nader 
onderzoek is echter nodig om de klinische implicaties die uit deze nieuwe inzichten kunnen 
voortvloeien, verder te bestuderen. Ook dient meer geld en mankracht beschikbaar te komen 
voor studies naar interventies met middelen, die een beschermend effect op de darmmucosa 
kunnen hebben. Immers, indien het lukt om het optreden van mucositis te beperken of te 
voorkomen zal dit een aanzienlijke verbetering betekenen in de zorg voor de patiënt met kanker 
(hoofdstuk	11). 
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LIST OF ABBREVIATIONS 
aGvHD      acute graft-versus-host disease 
ALL        acute  lymphatic leukemia
ALI        acute lung injury 
AML       acute myeloid leukemia
AMP       antimicrobial peptide
ARG        arginine 
ARGase      arginase 
ASL        argininosuccinate lyase
ASS         argininosuccinate synthetase 
ATG        anti-thymocyte globulin
AUC         area under the curve 
BEAM       carmustine, etoposide, cytarabine and melphalan 
Bu        busulfan
CLL         chronic lymphatic leukemia
CML         chronic myeloid leukemia
CoNS       coagulase-negative staphylococci 
CRP        c-reactive protein 
CT-scan      computer-assisted tomography-scan
CTCAE       common terminology criteria for adverse event
CVC        central venous catheter
Cyclo       cyclophosphamide 
DAMP       danger-associated molecular pattern
DGS        daily gut score 
DMS       daily oral mucositis score 
G-CSF       granulocyte-colony stimulating factor
GFR        glomerular filtration rate
Glu        glutamate 
GLN        glutamine 
GLN-ase      glutaminase 
Gy        gray
HDM       high dose melphalan 
HMGB-1       high mobility group box 1 
HSCT       hematopoietic stem cell transplantation 
HSP        heat shock protein 
HPLC       high-performance liquid chromatography
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List of abbreviations
Ida         idarubicin
IL         interleukin
IFNγ        interferon gamma
ISOO       International Society for Oral Oncology 
LPS         lipopolysaccharide 
NCI        National Cancer Institute
NFkB       nuclear factor-kappaB 
NHL        non-Hodgkin lymphoma 
NMA regimen   non-myeloablative regimen
MA regimen    myeloablative regimen 
MASCC      Multinational Association of Supportive Care in Cancer 
MBI        mucosal barrier injury
MDS        myelodysplastic syndrome
MM        multiple myeloma 
MPD        myeloproliferative disease 
MUD       matched unrelated donor
OAT        ornithine aminotransferase 
OCT        ornithine carbamoyl transferase 
OM        oral mucositis
OMAS       oral mucositis assessment scale 
ORN       ornithine 
OVS        oral viridans streptococci
PAMP       pathogen-associated molecular pattern 
PRR        pattern-recognition receptors 
SIRS        systemic inflammatory response syndrome
SNP        single nucleotide polymorphism 
TBI        total body irradiation
TLR        Toll-like receptor 
TNFα        tumor necrosis factor-alfa
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DANKWOORD
Ik heb dit promotietraject met zeer veel plezier doorlopen en dat is in belangrijke mate te 
danken aan alle direct en indirect betrokkenen, die ik graag allen hierbij hartelijk wil danken 
(ook al kan ik niet iedereen speciaal benoemen). 
PATIËNTEN
De onderzoeken die beschreven zijn, hadden nooit plaats kunnen vinden indien niet vele 
patiënten bereid waren geweest om hier aan mee te werken. Het was dan ook erg bijzonder 
om mee te mogen maken dat mensen die zelf al zo ziek zijn, veelal bereid zijn om (vooral door 
een extra bloedafname) te helpen de zorg in de toekomst nog beter te maken. Enkele van deze 
patiënten maken deel uit van mijn huidige praktijk in het Jeroen Bosch Ziekenhuis. Daarnaast 
zijn er ook velen patiënten uit deze praktijk geweest die steeds belangstellend informeerden 
naar mijn activiteiten in dit promotietraject. Hieruit heb ik veel energie geput en ben ik een 
ieder erg dankbaar voor.
COLLEGA’S 
 Radboud	universitair	medisch	centrum	(Radboudumc)		
Op de dinsdagen dat ik op het Radboudumc ben, kom ik altijd “in een warm bad” terecht. Ik heb 
een kamer waar mijn naam opstaat (iets wat mij in de nieuwe locatie van het Jeroen Bosch 
Ziekenhuis niet gegeven is) en voel mij altijd welkom. Dit gevoel komt voort uit de inspanningen 
van velen: het secretariaat, verpleegafdeling E00, het laboratorium hematologie, het datacen-
trum, wetenschappelijk onderzoekers, arts-assistenten interne, fellows hematologie en alle 
stafleden van de hematologie. Het heeft er mede toe bijgedragen dat ik het promotietraject 
heb afgerond. 
Omdat een aantal personen een belangrijke rol hebben vervuld in dit proefschrift, wil ik deze 
hieronder speciaal nog noemen: 
Mijn promotor Nicole	 Blijlevens heeft met haar enthousiasme en gedrevenheid ervoor 
gezorgd dat ik aan dit promotietraject ben begonnen. Samen met haar zijn alle onderzoeken 
in dit boekje bedacht. Ondanks al mijn perifere ambities heeft zij gedurende het gehele traject 
altijd naar mij toe aangegeven “het volste vertrouwen te hebben in de goede afloop ervan”. 
Dit heb ik enorm in haar gewaardeerd.
Peter	 Donnelly is als mijn copromotor altijd de meest stabiele persoon in de begeleiding 
geweest. Hij gaf goede tips en aanwijzingen en liet mij vervolgens vrij in hoe ik het wilde gaan 
aanpakken. Over de laatste jaren ben ik mij steeds meer gaan realiseren wat een enorm geluk 
ik heb met zo’n ervaren copromotor. Het komt dan ook recht uit mijn hart als ik zeg: “It has 
been an honor and pleasure to work with him.”
Walter	van	der	Velden is in 2013 copromotor geworden, maar was al veel eerder betrokken bij 
de onderzoeken in dit proefschrift. Hij is inhoudelijk kritisch en ziet de dingen scherp. Ik heb 
dit erg gewaardeerd.
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Dankwoord
Ton	Feuth was t/m 2012 bij alle onderzoeken als statisticus betrokken, nadien heeft Ton	de	
Haan dit van hem overgenomen. Met beiden had ik een prettige samenwerking en ze hebben 
mij erg geholpen bij alle statistiek. 
Theo	de	Witte is bij aanvang van het promotietraject mijn promotor geweest. Hij heeft mij 
ondersteund in mijn plannen om een deel van mijn opleiding tot hematoloog in een perifeer 
ziekenhuis te doen, in combinatie met academisch onderzoekswerk. Uiteindelijk is dit voor 
mij een perfecte combinatie gebleken. 
Met Ben	de	Pauw is het tweede hoofdstuk geschreven. Het is in een Amerikaans (leer)boek 
verschenen en zorgt er voor dat er op internationale congressen meermaals aan mij is 
gevraagd of ik misschien de auteur van dat hoofdstuk was. Ik ben er dan ook erg trots op en 
Ben dankbaar dat hij mij als fellow hematologie hiervoor destijds heeft benaderd. 
Lenneke	van	Groningen,	Roger	Brüggemann,	Michiel	Schaap en Mihai	Netea wil ik graag hartelijk 
danken voor hun bijdrage aan respectievelijk hoofdstuk 3, 5, 7 en 11. 
      
	 Jeroen	Bosch	Ziekenhuis
Vanuit het Jeroen Bosch Ziekenhuis is er vanuit verschillende gelederen, maar vooral het 
secretariaat, MOC, afdeling C5zuid, arts-assistenten interne en alle leden van de vakgroep 
interne/ MDL altijd veel interesse geweest voor mijn onderzoek. Ook het feit dat het woord 
mucositis regelmatig het ochtendrapport passeert, doet mij veel deugd.
FAMILIE EN VRIENDEN 
Een prettige thuissituatie is van groot belang voor alle energie die je aan je werk kan besteden. 
Ik prijs mij dan ook erg gelukkig met een fijne familie en vriendenclub. Mijn 2 paranimfen zijn 
mijn zusje Krysta Herbers en mijn beste vriendin Carolina Laumans. Ik ben erg trots dat zij op de 
dag van de promotie naast mij staan. Ook mijn ouders en schoonouders kunnen allen aanwezig 
zijn, iets waar ik heel erg blij om ben. Mijn ouders hebben mij altijd gestimuleerd om mijn 
dromen waar te maken en bij de totstandkoming van dit proefschrift heeft mijn vader geholpen 
door allerlei gegevens in te voeren, ik ben hen beiden daar erg dankbaar voor. Mijn lieve Rob 
heeft mij alle ruimte gegeven om dit proefschrift af te ronden en nu het bijna zo ver is… 
heb ik weer allerlei ideeën om deze ruimte weer in te vullen (werk en niet-werk gerelateerd)!
Hartelijke groeten en tot de 21e augustus! 
                   Alexandra  
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BIOGRAFIE
Alexandra Herbers studeerde geneeskunde aan de Universiteit Antwerpen, te Antwerpen in 
België. In 1996 werd ze kandidaat arts onder vermelding: “grote onderscheiding” (magna cum 
laude). In hetzelfde jaar verrichtte ze aan de Rijksuniversiteit Groningen, in het kader van een 
Erasmus-uitwisselingsprogramma, onderzoek naar een RT-PCR-techniek om uitzaaiingen van een 
melanoom vroegtijdig op te sporen (begeleiders: A. Calogero en Dr. G. Hospes). Haar eindwerk, 
waaraan ze van 1999 tot 2000 werkte, ging over palliatieve intrahepatische chemotherapie bij 
patiënten met levermetastasen van mamma- of colorectaal carcinoom (promotor: Prof. dr. J. B. 
Vermorken; copromotor: Dr. J. van den Brande). Na haar eindwerk voor een universitaire jury 
verdedigd te hebben, behaalde ze in 2000 haar diploma tot arts, eveneens met “grote onder-
scheiding”, en begon ze met haar opleiding tot internist in Nederland.
De 1e 4 jaar van haar opleiding vonden perifeer plaats in het St. Joseph Ziekenhuis in Veldhoven 
(opleider: dr. A. W. L van den Wall Bake). Nadien vervolgde zij haar opleiding in het Radboudumc 
in Nijmegen (opleiders: Prof. dr. P. M. J. Stuyt, Dr. J. de Graaf en Prof. dr. J. W. M. van der Meer). 
In 2006 werd Alexandra internist en rondde ze ook haar subspecialisatie tot medisch oncoloog 
af (opleider: Prof. dr. P. H. M. de Mulder). Aansluitend vond ook de subspecialisatie tot hema-
toloog plaats (opleider: Prof. dr. T. J. M. de Witte). In 2007 werkte ze hiervoor perifeer in het 
Maxima Medisch Centrum te Veldhoven en Eindhoven (opleider: Dr. G. C. Vreugdenhil).
In hetzelfde jaar startte zij met haar promotieonderzoek bij Prof. dr. T. J. M. de Witte, Dr. N. M. A. 
Blijlevens en Dr. J. P. Donnelly. Na het afscheid begin 2013 van Prof. dr. T. J. M. de Witte als 
hoogleraar hematologie van het Radboudumc, werd N. M. A. Blijlevens benoemd tot hoogleraar 
en Alexandra’s promotor en werd Dr. W. J. F. M. van der Velden toegevoegd als copromotor. 
De werkzaamheden in dit promotietraject hebben geleid tot het proefschrift, zoals dit nu voor 
u ligt.
Als internist-oncoloog-hematoloog werd Alexandra met ingang van 1 januari 2008 lid van de 
maatschap interne geneeskunde/ MDL van het Jeroen Bosch Ziekenhuis in ‘s-Hertogenbosch. Ze 
oefent de medische oncologie en hematologie in brede zin uit, maar speciale aandachtsgebieden 
zijn de supportieve zorg, chronische myeloproliferatieve aandoeningen en borstkankerzorg. 
Bovendien is zij, als lid van het opleidingsteam interne geneeskunde, opleider van de profiel-
stage hematologie en plaatsvervangend opleider voor coassistenten interne geneeskunde, 
intensief betrokken bij de opleiding voor coassistenten en arts-assistenten in het Jeroen Bosch 
Ziekenhuis. 
238
PUBLICATIES IN DE PERIODE VAN DIT 
PROMOTIETRAJECT
o  Herbers AH, Blijlevens NM, Donnelly JP, de Witte TJ. Bacteraemia coincides with low 
citrulline concentrations after high-dose melphalan in autologous HSCT recipients. Bone 
Marrow Transplant 2008; 42(5): 345-349.
o  Herbers AHE, Blijlevens NMA. Palifermine voor mucositis bij stamceltransplantatie 
patiënten. Ned Tijdschr Hematol 2008; 5: 110-115. 
o  Herbers AHE, Verbruggen B, Van de Veerdonk F, Van Kraaij M, Blijlevens NM, Novakova IR. 
Misleading one-stage coagulation factor assay during rFVIIa treatment in lupus patient. 
Haemophilia 2009; 15: 1164-1166.
o  van der Velden WJ, Herbers AHE, Blijlevens NM. Palifermin in allogeneic HSCT: many questions 
remain. Bone Marrow Transplant 2009; 43: 85-86.
o  ten Oever J, Herbers AHE, Verhoef LHM, Van den Wall Bake AWL. Streptococcus equi 
subspecies zooepidemicus bacteremia as first manifestation of hairy cell leukemia. Infect 
Dis Clin Prac 2009; 17: 407-408.
o  Herbers AHE, Feuth T, Donnelly JP, Blijlevens NM.  Citrulline-based assessment score: first 
choice for measuring and monitoring intestinal failure after high-dose chemotherapy. Ann 
Oncol 2010; 21: 1706-1711. 
o  Willemsen DJP, Bons E, Herbers AHE, Mackenzie MA, Van Spronsen DJ, Van der  Velden 
WJFM. Pneumocystis jirovecii-pneumonia in non-hodgkin lymphoma patients treated 
with R-CHOP. Tijdschr Infect 2010; 5(4): 152-156.
o  Velden WJFM, Herbers AHE, Feuth T, Schaap NPM, Donnelly JP, Blijlevens NMA. Intestinal 
damage determines the inflammatory response and early complications in patients receiving 
conditioning for a stem cell transplantation. PLoS One 2010; 5(12): e15156.
o  Herbers AHE, De Pauw P. Managing infections in patients with acute leukemia and febrile 
neutropenia. Managing Infections in Patients with Hematological Malignancies. Edited by 
Michael Kleinberg. New York, NY, United States: Humana Press - Springer New York. 2010.
o  Kerckhoffs APM, Herbers AHE, Pequeriaux NCV. A diagnosis on the basis of a blood smear. 
Neth J Med 2013; 71(9): 483, 487.
Appendices
239
o  van der Velden WJ, Herbers AH, Brüggemann RJ, Feuth T, Peter Donnelly J, Blijlevens NM. 
Citrulline and albumin as biomarkers for gastrointestinal mucositis in recipients of hemato-
poietic SCT. Bone Marrow Transplant 2013; 48: 977-981.
o  Herbers AH, van der Velden WJ, de Haan AF, Donnelly JP, Blijlevens NM. Impact of palifermin 
on intestinal mucositis of HSCT recipients after BEAM. Bone Marrow Transplant 2014; 49: 
8-10. 
o  Herbers AH, van der Velden WJ, de Haan AF, Donnelly JP, Blijlevens NM. Mucositis not 
neutropenia determines bacteraemia among haematopoietic stem cell transplant recipients. 
Transpl Infect Dis 2014; 16: 279-285.
o  van der Velden WJ, Herbers AH, Netea MG, Blijlevens NM. Mucosal barrier injury, fever and 
infection in neutropenic patients with cancer: introducing the paradigm febrile mucositis. 
Br J Haematol 2014; 167: 441-452.
 
 
Biografie & Publicatielijst

THE RO
LE O
F CITRULLIN
E IN
 PATIEN
TS FO
LLO
W
IN
G HEM
ATO
PO
IETIC STEM
 CELL TRAN
SPLAN
TATIO
N
         A.H.E. HERBERS
Hematopoietic stem cell transplantation (HSCT) provides effective treat-
ment of hematological malignancies and other disorders. However, the 
procedure temporarily compromises the immune system resulting in 
damage to the gastrointestinal (GI) tract, called mucosal barrier injury 
(MBI), and neutropenia. The GI tract is host to billions of micro-organisms 
that not only share our body space but are essential for health. These 
micro-organisms constitute the microbiome and seldom cause us harm. 
However infection can, and does, occur when the mucosal barrier of the 
gut is injured. Fortunately antimicrobial agents are employed to prevent 
and treat infectious complications.
Never the less, as this thesis shows, almost all HSCT recipients develop 
fever that is the result of inflammation induced by certain drugs employed 
to prepare for the transplant. Furthermore, measuring the blood concen-
trations of the amino acid citrulline provides a means of assessing MBI and 
indicates that MBI, rather than neutropenia, defines the period of risk of 
fever and bacteraemia following transplant. With the ready availability 
of blood, this simple and reliable test can help to explore ways of amelio-
rating MBI to reduce inflammation and fever which, in turn, would lead 
to a more tailored approach to antibiotic treatment. This can only be 
a good thing as it will help reduce the risk of antimicrobial resistance. 
Knowing the citrulline level could also help decide whether a patient 
needs to be admitted to hospital or can be treated safely at home.
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